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The nervous system is arguably the most complex organ system in vertebrates. It allows 
the organism to sense and integrate environmental information, control body posture and 
movement, regulate the internal organs and develop complex behaviour. Also, all higher 
cognitive functions are generated by the nervous system. Despite its complexity, the ner-
vous system consists of only two principal cell types: neurons and glial cells. Although 
neurons can adopt a bewildering variety of morphologies they elaborate from their soma 
two main structures: the dendrites and axons (see figure 1A). Axons are the ‘output’ struc-
ture of the neuron and they either contact other neurons or target organs such as muscle 
or gland. The neuron receives ‘input’ from multiple, up to thousands, of other neurons 
that form contacts, synapses, on the dendritic tree and soma. Glial cells were originally 
considered the connective or supporting tissue of the nervous system. The name for these 
cells, neuroglia, coined by Rudolph Virchow, the eminent 19th century cell biologist and 
pathologist, literally means ‘nerve glue’, a reflection of the modest role these cells were 
supposed to have. However, over the last decade it has become clear that glial cells are not 
mere structural cells but are in fact involved in every functional and structural aspect of 
neuronal shape and function1. This is particularly evident in the role myelin-forming glial 
cells have in shape and function, and thus the evolution, of complex nervous systems.
Communication between neurons and their targets relies on electrical impulses, called 
action potentials, which travel the length of the axon as a series of membrane depolarisa-
tions/repolarizations, very much like a wave moves along the surface of the ocean. The 
speed, with which the action potential is propagated, inversely correlates with the internal 
resistance of the axon, a property that largely depends on the diameter of the axon2. Thus, 
large calibre axons have higher conduction velocities than smaller calibre axons. The ac-
tion potential of the axon depend on the properties of the voltage-gated Na+/K+ channels 
and the Na+/K+ gradient over the axonal membrane that is maintained, at the expense of 
ATP, by the Na+-K+ pump3. The ATP expense associated with maintaining this gradient 
increases with the square of the radius of the axon. Therefore, the evolution of faster neu-
ronal circuits in larger animals cannot be solely based on increasing the diameter of axons, 
as an upper limit is quickly reached because of the exponential growth in energy costs as-
sociated with maintaining the Na+/K+ gradient over the axonal membrane. The evolution of 
compact nervous systems in larger animals has become possible through a novel structure 
produced and maintained by glial cells4. This structure is referred to as myelin. Myelin 
consists of specialized layers of cell membrane of dedicated glia cells that ensheath the 
axon. Two types of myelin forming glia cells exist: oligodendrocytes in the central division 
of the nervous system and Schwann cells in the peripheral division. An early drawing of a 
myelinated fibre is presented in figure 1B. 
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One functionally important consequence of myelin is that axonal depolarisation is restrict-
ed to the nodes of Ranvier, the space in between adjacent myelin sheaths, and that the 
capacitance of the axonal membrane under the myelin sheath is strongly reduced. Con-
sequently action potentials jump from node to node, a process referred to as saltatory 
conduction, with a speed that is ten to a hundred times faster than conduction velocities of 
non-myelinated axons of similar diameter.
With this evolutionary innovation also came new vulnerabilities, as evidenced by the many 
neurological diseases that are caused by instability or breakdown of the myelin sheath. 
Prime examples of such diseases are multiple sclerosis, Guillain-Barré syndrome and the 
Figure 1. (A) is a nerve cell (taken from ref 5). The (ax) in the drawing indicates the axon. The other fibers are the 
dendrites. (B) shows two myelinated axons. In the left axon (taken from ref 6) is (c) the cell body, (d) the dendrites, 
(ax) the axon, (col) the collaterals and (t) the terminals. In the right drawing is (n) the node of Ranvier and (k.Sch.) 
is the nucleus of the Schwann cell (taken from ref 7).
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hereditary motor and sensory neuropathies (HMSN) also referred to as Charcot-Marie-
Tooth (CMT) disease. In fact, CMT is the most common hereditary disease of the nervous 
system affecting 1 in 4000 individuals in North America8. No cure is available for these 
diseases and the therapeutic possibilities are very limited. The development of future treat-
ments for these diseases will be based on a detailed understanding of the basic biology of 
the myelin-forming cell and the pathogenic mechanisms involved in the etiology of the 
disease.
The work described in this thesis addresses a number of questions related to the process 
of myelin formation by Schwann cells in the peripheral nervous system. In particular, we 
have focused on the role the POU domain transcription factor Oct-6 (POU3f1, Tst-1, Scip) 
plays in the transcriptional program of myelination and on the natural mouse mutant claw 
paw (clp), which is characterized by congenital hypomyelination of its peripheral nervous 
system. In the first chapter we will briefly discuss the structure and function of myelin, the 
pathology of demyelinating diseases and the development of the Schwann cell lineage. 
The Oct-6 transcription factor is transiently expressed in the Schwann cell lineage and 
plays a critical role in the initiation of myelination. In the absence of Oct-6, Schwann 
cells stall for a prolonged time at the promyelin stage of differentiation resulting in a de-
layed onset of myelination. Oct-6 is strongly upregulated in response to unknown axonal 
signals. We have identified the cis-acting element within the Oct-6 locus through which 
these signals activate the gene. This element is called the Schwann cell enhancer or SCE 
and we demonstrate that it is sufficient and required to confer temporally and spatially 
correct expression of the gene (chapter 2). We further demonstrate that a second POU 
domain transcription factor, closely related to Oct-6 is expressed in Schwann cells. This 
factor, Brn-2, seems to be a redundant factor as in the absence of both Oct-6 and Brn-2 
the myelination program is even further delayed than in Oct-6 mutant Schwann cells alone 
(chapter 3). As it is anticipated that Oct-6 and Brn-2 interact with other nuclear factors 
to execute their function, we adopted a specific labelling approach to purify and identify 
such cooperating nuclear factors. As a first step we generated a generic mouse model that 
allows the specific labelling of transgenic protein in any tissue of the mouse. The results 
of these studies are described in chapter 4. The congenital hypomyelination observed in 
clp mice shares a number of characteristic features with the hypomyelination phenotype 
of Oct-6 mutant animals. These similarities suggested that the two genes might act in the 
same or in a non-redundant parallel pathway. In chapter 5 we describe our studies into the 
cell-autonomy of the clp mutation. Through a collaborative effort with the laboratory of 
Dr. John Bermingham Jr at the McLaughlin Research Institute in Great Falls, Montana, 
we have identified the genetic lesion underlying the clp phenotype.  We found that the clp 
mutation results in intracellular retention of a novel gene called Lgi4. This secreted protein 
is expressed in Schwann cells and is probably involved in direct Schwann cell-axon com-
munication. These studies are described in chapter 6. In the final chapter we summarize 






Structure and function of myelin
Schwann cells in the peripheral nervous system (PNS) and the oligodendrocytes and astro-
cytes in the central nervous system (CNS) are the myelin forming glia cells. The structure 
of myelin produced by these different cells is in essence identical, although important dif-
ferences exist and different sets of proteins are used to build myelin9,10. In addition, while 
Schwann cells produce one myelin sheath around an axon, an oligodendrocyte can serve 
several axons producing multiple myelin sheaths (figure 1). In the following paragraphs we 
will be focusing on myelin of the PNS.
Figure 1. In the CNS the oligodendrocytes can myelinate more than one axon at the same time, while in the PNS 
the Schwann cell can only myelinate one axon. Also the nodes of Ranvier are indicated in the PNS figure (taken 
from ref 11).
The myelin sheath was originally described as the oily substance that covers the inner axial 
fibre or axis cylinder and was thought to be the product of the axial fibre itself12. It was not 
until the introduction of the electron microscope in the middle of the 20th century and the 
development of suitable fixation and contrasting techniques that it was unequivocally dem-
onstrated that the myelin sheath is in fact a product of the Schwann cell. It was demonstrat-
ed that the myelin sheath is a specialization of the cell membrane that wraps around the 
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axon like a scroll around a rod. During development, Schwann cells will initially loosely 
wrap an axon but as progressively more wraps are added, cytoplasm is removed resulting 
in the apposition of the cytoplasmic faces of the membrane and compaction of the sheath. 
The larger the diameter of the axon the more myelin wraps will form13,14. In cross sections 
through the myelin sheath the apposition of the cytoplasmic side of the membrane will ap-
pear as thick electron dense lines referred to as the major dense line while the apposition of 
the outer surface of the membrane forms a thinner intraperiod line (see figure 2).
 
The myelin membrane differs from the cell membrane in that it is enriched in specific 
lipids and incorporates a specific set of proteins. The surface area of myelin membrane 
of a myelinating Schwann cell wrapping 40 rounds of myelin along a length of 500 µm 
axon (10 µm diameter) is around 700,000 µm2, 7000 times more then the surface area of 
Figure 2. (A) is an electromicrograph 
of a part of myelin surrounding the 
axon. The major dense line and the 
intraperiod line are clearly visible and 
outlined in (B) the enlargement of part 
of the photo. The electron micrograph 
(C) shows the paranodal loops of the 
myelin on the axon at the node of Ran-
vier. A more schematical view (D; taken 
from ref 11) of the node, paranode, jux-
taparanode and the internode is shown 
in the figure on the bottom right. (E) and 
(F) show enlargement of the protein-
complexes which are located between 
the myelin and the nodal parts. 
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for example a red blood cell, which is estimated at 100 µm2. The most abundant lipid in 
the myelin membrane is cholesterol (~25% of total lipid weigth) in addition to galacto-
cerebroside and its sulfatide, which account for 14-25% and 2-7% of lipids respectively9. 
The stability of these huge slabs of wrapped myelin membrane is a function of the myelin 
proteins. The bulk of myelin proteins fall into two classes: glycoproteins and basic pro-
teins. The most abundant protein (50-70% of myelin proteins) is myelin protein zero (mpz 
or P0) which is a single transmembrane glycoprotein with an extracellular domain that is 
structurally similar to an immunoglobulin-related cell adhesion domain. This extracellular 
domain is involved in homophilic interactions between two opposing myelin membranes 
and contributes to the intraperiod line4,15. In P0-/- mice the intraperiod line is not formed 
properly leading to instability of the myelin sheath, which results in a demyelinating neu-
ropathy in these mice16. Overexpression of P0 results in dysmyelination of the peripheral 
nerves17,18. Thus, the amount of P0 needs to be regulated carefully. Mutations in mpz are 
a major cause of peripheral neuropathies in humans underlying the clinical symptoms 
of CMT1B and Dejerine Sottas syndrome (see table 1). Many of these mutations inter-
fere with the proper processing of the protein resulting in reduced expression. Another 
important myelin glycoprotein is the tetraspanning protein peripheral myelin protein 22 
(PMP22)19. The carbohydrate moiety on the first extracellular loop of the protein may 
contribute to adhesive interaction similar to those of P04.  Also mutations in PMP22 are a 
major cause of demyelinating neuropathies in humans. In fact, duplication of the chromo-
somal region spanning this gene is the underlying cause of the most common hereditary 
peripheral neuropathy usually referred to as HMSN1 or CMT1A20-23.
At the margins of the myelin sheath, cytoplasm is not extruded and these loops fold down 
onto the axolemma where they form tight junctions with the axonal membrane (figure 2). 
The space between two adjacent myelin segments is referred to as the node of Ranvier. 
These so-called paranodal myelin loops are of functional importance as they regionalize 
the axonal membrane into a nodal, paranodal and juxtaparanodal segment. The nodal mem-
brane is highly enriched in voltage gated sodium channels (1200 of Na+ channels/µm2)24 
while the internodal axonal membrane (underlying the compact myelin sheath) is almost 
completely devoid of Na+ channels11. K+ channels are localized in the juxtaparanodal 
membrane and are separated from the Na+ channels by the septate-like junctions of the 
paranodal domain. This separation is functionally important, as loss of these junctions 
results in a shift of the K+ channels towards the node and altered electrophysiological 
properties of the nerve fibre25. The formation and stabilization of the septate-like junctions 
is governed by the adhesive properties of the cell adhesion molecules Caspr-1 and Neuro-
fascin. Caspr-1 interacts with contactin in cis26. This interaction is already established at 
the endoplasmatic reticulum and is necessary for Caspr-1 to be transported to the plasma 
membrane27. The complex is expressed at the membrane and the extracellular part of the 
complex interacts with NF-155, which is expressed on the membrane of the paranodal 
loop28. It is thought that this interaction of the Caspr-1/contactin complex with the NF-155 
is important for the tight attachment of the paranodal loop to the paranode. The paranode 
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is also thought to act as a barrier for the K+ channels that are located in the juxtaparanode 
and the Na+ channels located at the node11. Caspr-2, a molecule closely related to Caspr-1, 
is found at the juxtaparanode and interacts there with the K+ channels29. Caspr-2 also inter-
acts with the Tag1 glycoprotein which seems to be important in tethering the K+ channels 
at the juxtaparanode30,31. The function of the K+ channels at the juxtaparanode is thought to 
be the maintenance of the resting potential of the axonal membrane11. 
The paranodal loops are not the only regions of non-compact myelin. Spiral interrup-
tions of non-compact myelin occur in the internodal myelin membrane and are referred 
to as Schmidt-Lanterman incisures. The Schmidt-Lanterman incisures are thought to 
function in the transport of nutritional and signalling molecules from the outerme-
saxon to the innermesaxon and vice versa4. The transport of the molecules through the 
Schmidt-Lanterman incisures is faster and more energy efficient to transport molecules, 
because the cell is not forced to uncompact complete myelin membranes at the moment 
molecules need to pass. Connexin32 (Cx32), a gap junction molecule, has been shown to 
be localized at the Schmidt-Lanterman incisures in the Schwann cell32. Normally Cx32 
forms gap junctions between cells, but in the Schwann cell it appears to form gap junctions 
between the myelin layers in the Schmidt-Lanterman incisures33. These Cx32 forming gap 
junctions could be important for the Schwann cell because it could make a radial pathway 
for molecules with a size up to 1000 Da32. Using the radial pathway instead of the circum-
ferential pathway would be a 1000 fold shorter in a myelin sheath that is unrolled about 4 
mm long, but compacted just 4 µm32,34.
The nerve is protected by a nerve sheath
The peripheral nerves are protected by a layer of connective tissue called the nerve sheath. 
Axons lie in small groups together, surrounded by the endoneurium. Several of these small 
groups form a small bundle and are surrounded by the perineurium. Blood vessels lie be-
tween these small bundles and are separated by the perineurium from direct contact with 
the axons. Several of these small bundles form the nerve and the nerve is surrounded by 
the epineurium (figure 3).
Figure 3. The peripheral nerve 
has three layers that protect the 
nerve: an epineurium, a perineu-




The perineurium is formed from mesenchymal cells in the surrounding of the nerve bun-
dle. Initially they form an irregular layer and then go through a mesenchymal-epithelial 
transition in 2-3 weeks. After this transition a compact multilayer around the nerve is 
established. The epineurium and the endoneurium are then formed by large deposits of 
collagen, which also reinforces the nerve bundle36-40.
Experiments done by Parmantier and colleagues showed that Desert hedgehog (Dhh) pro-
tein is very important for the development of a normal epi-, peri- and endoneurium. Dhh 
mutant mice showed thinner layers of cells forming the perineurium. Also the cells did 
not form tight junctions with the other cells in the layer39. Normally the epi-, peri, and 
endoneurium protect the nerves from harmful effects like unwanted molecules and intrud-
ing cells. It was also shown with the same experiments that Dhh was derived from the 
Schwann cells. The natural mouse mutant clp does also have a thinner epineurium and was 
tested for Dhh levels. Clp mice showed significantly lower amounts of Dhh in developing 
nerves then wild type mice41.
Mutation affecting myelin function and/or stability
Mutations in a number of genes, most notably those encoding structural myelin proteins, 
cause hereditary motor and sensory neuropathies (HMSN) also called Charcot Marie-
Tooth (CMT) neuropathies in humans. CMT has several variants of which CMT1A with a 
prevalence of 1:2500 is the most common8. The CMT1A variant is caused by a duplication 
of a 1.5 Mb fragment on chromosome 17, which contains the PMP22 gene. This duplica-
tion causes PMP22 to be expressed at a higher level20-23. Dejerine-Sottas syndrome (DSS) 
is an even more severe form of CMT and is caused by four copies of the PMP22 gene42. 
In patients with hereditary neuropathy with pressure palsies (HNPP) there is a deletion of 
one of the alleles of PMP2243. In all three of the above mentioned neuropathies the nerve 
conduction velocity is slowed because there is a partial or complete loss of the myelin 
sheet. Nerve biopsies of patients with CMT1A also show ‘onion bulbs’, which are formed 
by layers of collagen and Schwann cell processes44. 
The severity of the disease in humans depends on the type of the mutation. Mouse models 
have been developed to study these mutations. Five mouse mutants are mainly studied: the 
Trembler (Tr) mouse, the Trembler J (TrJ) mouse, the PMP22+/-and the PMP22-/- mouse 
and also a mouse that over expresses PMP22 . The Tr  and the TrJ mutation are both point 
mutations in the PMP22 gene, G150D and L16P respectively23,45. Both mutations were 
originally discovered in mice and later shown to exists in patients46,47. Trembler mice are 
more severely affected by their point mutations than the PMP22 heterozygous mouse, 
because they have less myelin than PMP heterozygous mouse48. The PMP22 in the Tr and 
in the TrJ mice cannot reach the myelin membrane. The PMP22 protein seems to remain 
localized in the endoplasmatic reticulum (ER)46,49. In both heterozygous Tr and TrJ mice, 
wild type(wt)-PMP22 does not reach the plasma membrane. In TrJ mice it is shown that 
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this is because the wt-PMP22 forms heterodimers with the TrJ-PMP22. These heterodi-
mers are not able to go to the plasma membrane because of the TrJ-PMP22 which is not 
able to leave the ER46. 
The PMP22+/- mouse develops a demyelinating peripheral neuropathy which is reminis-
cent of patients with HNPP, while the PMP22-/- is even more severe50,51.
Mutation in P0 cause CMT1B which is a relatively mild variant, but can also cause DSS 
or congenital hypomyelination (CH)15 more severe forms of CMT. The P0-/- mouse is used 
as a model for studying DSS, while the heterozygous P0 mouse is used for the study of 
CMT1B. The variants that are caused by mutations in the myelin genes are not the only 
forms of CMT4. 
CMT2 are neuropathies that show an axonal or neuronal defect. Demyelination occurs in 
these forms, but is a secondary effect caused by degeneration of Schwann cells that lose 
contact with its axon4,52.
CMT also has variants that are caused by genes that are important for the Schwann cells 
and the myelination process but are not a part of the myelin layer itself. These genes are 
Cx32, Krox-20 and myotubularin-related protein-2 (MTMR-2)4.   
The variant CMT1X is caused by mutations in Cx32. Patients have an abnormal myelin 
compaction and a reduced nerve conduction velocity. The mutations found until now are 
evenly spread over the gene. Most mutations are missense mutations that cause single 
amino acid changes. Partial deletion and insertion causing frame shifts and premature stop 
codons are also found33,53-55. In most mutant forms the protein is still produced but is not 
able to leave the Golgi56.This could have a negative or even toxic effect on the cell and in 
this way disturbing normal myelination processes.
Another variant of CMT1 is caused by mutation in the Krox-20 gene4. Krox-20 is a very 
important gene for the onset of myelination, which will be discussed in the next section.
The forms of CMT that are categorized in CMT4 are the recessive forms of the disease. 
MTMR-2 is the cause of CMT4B. It is not exactly known what the function of MTMR-2 
is in the peripheral nerve, but it has been found that MTMR-2 is enriched in peripheral 
nerves and Schwann cells which starts already during embryonic development57,58. Nerve 
biopsies from patients with CMT4B show irregular folding of myelin and also redundant 
loops of myelin59.
CMT4F is caused by mutations in the periaxin gene. Periaxin is an important myelin pro-
tein which is mostly found on the outside of the myelin sheath and on the border with the 
node, so in the non-compact parts of the myelin. It is not quite clear yet how periaxin muta-
tions influence the onset of the neuropathy. Periaxin null mice show hypermyelination and 
demyelination at later stages of life62.
The Schwann cell lineage does develop from the neural crest. Before a Schwann cell adopts 
a myelinating or a non-myelinating phenotype the cell has to go through several transitions 




Development of the Schwann cell lineage
The neural crest is a transient embryonic population of cells that originate from the dorsal 
margin of the neural tube. These cells give rise to a wide variety of cell types63. The cells 
that are derived from the neural crest are all the neurons and glia of the sympathetic ner-
vous system, which include the satellite cells in the dorsal root ganglia and all the Schwann 
cells in the PNS64-66. The focus will be on the development of the Schwann cells from the 
neural crest.
Before a Schwann cell becomes a myelinating or a non-myelinating Schwann cell it has 
to go through several developmental stages. There are three major transitions during this 
process. The first one is the transition of the neural crest cell to the Schwann cell precur-
sor. The second transition is from the Schwann cell precursor to the immature Schwann 
cell and the final transition takes place when the immature Schwann cell proceeds to the 
non-myelinating or the myelinating Schwann cell phenotype67-69. Schwann cell precur-
sors can be found in developing embryonic nerves from embryonic day 12 to 13 (E12-13) 
of gestation. Immature Schwann cells are found from E15 to birth70,71. The myelinating 
Schwann cells will initially make their transition during the first postnatal week and the 
non-myelinating Schwann cells will follow in the second postnatal week72. During these 
transitions many processes take place in the cells, which involve many transcription fac-
tors and growth factors for the timing and regulations of these transitions. Until now sev-
eral transcription factors have been found to play a role in this process. The most impor-
tant transcription factors, involved in the transition of the immature Schwann cell to the 
myelinating Schwann cell, are Oct-673,74, Brn-275 and Krox-2061,76. Krox-24 is restricted to 
non-myelinating Schwann cells77. Other transcription factors, which are involved in the 
development of the neural crest cell to myelinating or non-myelinating Schwann cell are 



















Cx-32 Cx-32-/- 60 Mutations CMT-X
Krox-20 Krox-20-/- 61 Mutations CMT1
MTMR-2 Mutations CMT4B
Periaxin PRX -/- 62 Mutations CMT4F
Table 1: Overview of the various genes and available mouse models as well as the genetic human defects of the 
neuropathy they cause (for additional references see text).
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Sox10, Sox2, Pax-3 and AP-2. Next to the transcription factors there are also growth fac-
tors involved such as neuregulin (NRG) and Notch. The clp gene which has recently been 
identified as the Lgi-4 (leucine-rich, glioma inactivated) gene is also involved in nerve de-
velopment78. Clp mutant mice have delayed myelination, but it is not known yet how Lgi4 
is involved in the myelination program.
Oct-6 and Brn-2 are both POU domain transcription factors, which have two regulatory 
domains: the POU-specific domain and the POU homeodomain. The POU homeodomain 
is highly conserved in these transcription factors. Both POU domains are involved in 
binding DNA79. Oct-6 and Brn-2 also have almost the same expression pattern. Both are 
upregulated in the pro-myelinating stage of the myelinating Schwann cell and are down-
regulated when myelination proceeds. Brn-2 expression diminishes just before Oct-6 ex-
pression does75.
The expression of Oct-6 is regulated by a downstream regulatory sequence that is named 
the Schwann cell enhancer (SCE)80. In mice carrying a null allele for the SCE myelination 
is transiently blocked. But with a delay the nerves eventually become myelinated81. Experi-
ments have shown that Brn-2 is a possible candidate to take over the function of Oct-6 in 
these Oct-6 mutants, because in the absence of Oct-6 Brn-2 expression stays upregulated 
longer than in a wildtype mouse. Myelination will occur in almost the same rate as in wild 
type mice75.
Figure 4. (A) Expression patterns of several transcription factors and growth factors during the development of 
the Schwann cell lineage. (B) shows a non-myelinating Schwann cell, while in (C) the left cell is a pre-myelinating 
Schwann cell and the right cell a myelinated Schwann cell.
23
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Krox-20 expression follows Oct-6 expression. The regulatory element of Krox-20 has POU 
binding sites, which indicates that Oct-6 could bind to these regulatory sequences and ac-
tivate the expression of Krox-2082. The Krox-20 homozygous mutant has a complete block 
in myelination demonstrating that when Krox-20 is absent there is no other factor able to 
activate myelination. This makes Krox-20 very important for the myelination process61. 
Recently, it has been shown that Krox-20 regulates other genes and does so in a complex 
with Nab-1 and/or Nab-2. When a double Nab1-/-Nab2-/-  mutant was analysed it showed 
the same block in myelination as the Krox-20 mutant. Even when Krox-20 was overex-
pressed in these Nab mutant animals, myelination was still blocked. This indicated that 
Nab1 and Nab2 are required to mediate the effects of Krox-20 in myelinating cells83. Nab 
proteins control the transcriptional activity of the complex by repression or activation84,85. 
Other positive control transcription factors are Sox10 and Pax-3. Sox10 is expressed in the 
neural crest cell and expression continues throughout the Schwann cell lineage86. In Sox10 
mutant mice Schwann cell precursors and immature Schwann cells are completely absent. 
This indicates that Sox10 plays a crucial role in the development of the Schwann cell lin-
eage from the neural crest. Experiments have shown that Sox10 regulates the expression 
of the ErbB3 receptor, which is essential for NRG-1 signalling87 (discussed below). Thus 
when there is no Sox10 expression, ErbB3 expression is not upregulated and NRG-1 is not 
able to signal through this receptor. Sox10 has also been found to regulate the expression 
of P088.
Pax-3 is another positive regulator of Schwann cell development. Pax-3 mutant mice, 
splotch89 and splotch delayed90, show no Schwann cell lineage at all and a strongly reduced 
number of Schwann cells respectively91. Expression of Pax-3 starts at E12 in mice. Expres-
sion is high around birth when the Schwann cells make the decision to myelinate or to 
remain in a non-myelinating state92,93. It is thought that Pax-3 is involved in this decision. In 
an experiment where Pax-3 was injected into cultured Schwann cells, these Schwann cells 
showed a decline in myelin basic protein, which is a characteristic molecule of myelin, and 
an upregulation of markers for non-myelinating Schwann cells93. The function of Notch 
is not completely clear. Notch expression in neural crest cultures showed that there is a 
strong tendency of the cells to make the transition toward the Schwann cell precursor state, 
indicating that Notch is a strong positive regulator of Schwann cell development involved 
in the decision of a cell in becoming a Schwann cell precursor94.
Recently, two transcription factors have been shown to have a negative regulatory effect 
on the development of the Schwann cell lineage: Sox2 and AP-2. Sox2 is involved in the 
suppression of several myelination-related genes. It was shown that overexpression of Sox2 
in Schwann cell/neuron co-cultures inhibited myelination95.
The transcription factor AP-2 gene family consists of three members: AP-2α, AP-2β96-98 and 
AP-2γ99-101. Both AP-2α and AP-2γ are expressed in early embryonic nerves and expression 
peaks at E12/E13, when Schwann cell precursors are found in the developing nerve. When 
the transition of Schwann cell precursor to immature Schwann cell takes place, AP-2 is 
downregulated. Forced expression of AP-2α in Schwann cell precursor cultures showed 
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a delay in the transition of Schwann cell precursors to immature Schwann cells102. Thus 
AP-2α seems to be a negative regulator of Schwann cell development.
Growth factors and the initiation of myelination
Several growth factors have been implicated in the differentiation of Schwann cells, in 
particular in myelin formation.
For example, it has been demonstrated that the brain derived-neurotrophic factor (BDNF) 
stimulates myelination in Schwann cell/neuron co-cultures. In addition, sequestering 
BDNF with a soluble TrkB-Fc (BDNF binds to the TrkB and p75NTR receptors) fusion 
results in reduced myelination. Addition of the neurotrophin NT3 had the opposite effect 
in these cultures: Increased levels of NT3 inhibit myelination and sequestration of NT3 
with a soluble TrkC-Fc fusion protein promotes myelination.  Indeed, NT3 levels drop 
precipitously in actively myelinating cultures and developing nerves. These results were 
confirmed in vivo through injection of BDNF or NT3 in the vicinity of the sciatic nerve of 
newborn mice. Analysis of the myelination status of the sciatic nerve 48 hours after neuro-
trophin injection showed increased myelination in BDNF injected animals while myelina-
tion was reduced in NT3 injected animals103,104.
The positive effect of BDNF on myelination is most likely mediated through the p75NTR 
receptor and not through the TrkB receptor. In fact, Schwann cells express only the trun-
cated versions of the TrkB receptors that lack tyrosine kinase activity. It is suggested that 
these truncated TrkB isoforms negatively modulate myelination through sequestration of 
BDNF104. 
In a similar series of experiments, Chan and colleagues provided evidence for a posi-
tive role of the classical neurotrophic factor nerve growth factor (NGF) in myelination 
by Schwann cells. Surprisingly, NGF has the opposite effect on myelination by oligo-
dendrocytes. These data suggest that NGF affects the receptivity of axons to myelination 
and that different axonal signals control myelination in the peripheral and central nervous 
system105.
The injection of GDNF in peripheral nerves of mice showed an increase in the number of 
myelinated axons. This was probably caused by the proliferation of Schwann cells along 
the unmyelinated axons which then assume a 1:1 relationship with those axons and myelin-
ate these normally unmyelinated units106. Thus, a delicate balance of neurotrophic factors 
and their receptors modulate myelination in the developing nerve. 
Neuregulin-1 (NRG-1) is found to be crucial for the process of myelination. NRG-1 sig-
nals through the heterodimeric complex of the ErbB2/ErbB3 receptor107,108. The NRG-1, 
the ErbB2 and the ErbB3 mutants all show the same phenotype. The NRG-1 and ErbB3 
mutants have no Schwann cell precursors while in the ErbB2 mutant the Schwann cell pre-
cursors have lost the ability to migrate109-111. The axonally-derived NRG-1 is thought to be 
important for the selection of Schwann cells. Schwann cells that are not in contact with an 
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axon have no access to NRG. Schwann cells need NRG for their survival, so only Schwann 
cells that are in contact with the axon and have access to NRG are able to survive108. Next 
to the survival of the Schwann cell lineage, NRG-1 also seems to be important for the 
migration of Schwann cells along the axon, as was shown in zebrafish112. Taveggia and col-
leagues provided evidence that the membrane bound type III NRG-1 plays an important 
role in Schwann cell adhesion and initiation of myelination113. Another important function 
of NRG is the involvement of the protein in the regulation of myelin sheath thickness dur-
ing myelination114.
Regulation of myelination is a very complex process that is still not understood in detail. In 
the following chapters we provide experimental evidence that corroborates the notion that 
the POU domain transcription factors Oct-6 and Brn-2 play key roles in orchestrating the 
transcriptional program of myelination. In addition, we provide evidence that Lgi4, a novel 
Schwann cell-derived protein, plays a role in axonal sorting and myelin formation.
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The POU proteins Brn-2 and Oct-6 share
important functions in Schwann
cell development
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The genetic hierarchy that controls myelination of peripheral nerves by Schwann cells includes the POU
domain Oct-6/Scip/Tst-1 and the zinc-finger Krox-20/Egr2 transcription factors. These pivotal transcription
factors act to control the onset of myelination during development and tissue regeneration in adults following
damage. In this report we demonstrate the involvement of a third transcription factor, the POU domain factor
Brn-2. We show that Schwann cells express Brn-2 in a developmental profile similar to that of Oct-6 and that
Brn-2 gene activation does not depend on Oct-6. Overexpression of Brn-2 in Oct-6-deficient Schwann cells,
under control of the Oct-6 Schwann cell enhancer (SCE), results in partial rescue of the developmental delay
phenotype, whereas compound disruption of both Brn-2 and Oct-6 results in a much more severe phenotype.
Together these data strongly indicate that Brn-2 function largely overlaps with that of Oct-6 in driving the
transition from promyelinating to myelinating Schwann cells.
[Keywords: POU domain; myelin; Schwann cell; nerve development]
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The high conduction velocity of nerve fibers is a hall-
mark of the nervous system of higher vertebrates and
depends on structural and molecular specializations that
are elaborated during development. These specializa-
tions occur through intimate and continued interactions
between the neuron and its associated glial cells and re-
sult in the elaboration by glial cells of myelin, the im-
portant membranous structure that ensheaths and insu-
lates axons (Arroyo and Scherer 2000; Fields and Stevens-
Graham 2002; Mirsky et al. 2002). Two glial cell types
produce myelin: the oligodendrocyte in the central ner-
vous system (CNS) and the Schwann cell in the periph-
eral nervous system (PNS). Although very similarly or-
ganized, the molecular composition of CNS and PNS
myelin differs significantly, and oligodendrocytes and
Schwann cells have adopted different, but overlapping,
sets of transcriptional regulators to coordinate myelo-
genesis (Hudson 2001; Topilko and Meijer 2001). These
differences reflect their distinct embryonic origins.
Whereas oligodendrocytes originate from the neuroepi-
thelial precursors that line the lumen of the spinal cord
and ventricles of the brain, Schwann cells derive mainly
from the neural crest, a transient embryonic stem (ES)
cell population that generates a wide variety of cell types
including sensory and autonomic neurons and melano-
cytes (Le Douarin and Kalcheim 1999; Richardson 2001).
Schwann cell precursors populate the early outgrowing
nerve bundles, where they proliferate and segregate in-
dividual and groups of fibers until the number of
Schwann cells and fibers is eventually matched. During
the first few days of postnatal development, many
Schwann cells establish a 1:1 relationship with axons,
cease to proliferate, and initiate myelin formation such
that by the end of the first postnatal week of develop-
ment, all myelin-competent axons are actively being
myelinated. Schwann cells that remain associated with
groups of lower-caliber fibers will segregate these fibers
in cytoplasmic cuffs without myelinating them (Webster
1993). Although virtually nothing is known about the
molecular identity of the axon-associated signal(s) that
divert Schwann cells along either a myelinating or a non-
myelinating differentiation pathway, significant infor-
mation has accumulated in recent years about the tran-
scription factors involved in Schwann cell differentia-
tion and myelination.
To date, several transcription factors have been found
to be involved in the differentiation of Schwann cells and
include the zinc-finger protein Krox20 (Egr-2), the Sry
box protein Sox10, and the POU domain protein Pou3f1/
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Oct-6/Scip/Tst-1 (referred to here as Oct-6; Topilko and
Meijer 2001). Gene targeting experiments in mice have
revealed insight into the functional roles of each of these
factors and their possible order within a genetic hierar-
chy. Sox10 is required early in development for the es-
tablishment and/or maintenance of Schwann cell precur-
sors from the neural crest (Britsch et al. 2001). At later
stages of development, Oct-6 and Krox20 are both re-
quired for the differentiation of myelinating Schwann
cells at two respective progressive steps in the genetic
hierarchy (Topilko et al. 1994; Bermingham et al. 1996;
Jaegle et al. 1996; Ghislain et al. 2002). During fetal de-
velopment, Oct-6 gene expression is induced in imma-
ture Schwann cells and peaks in promyelinating and
early myelinating cells during the first week of postnatal
life (Scherer et al. 1994; Blanchard et al. 1996; Arroyo et
al. 1998). Consequently, Oct-6 regulates a set of down-
stream genes that includes Krox-20 (Blanchard et al.
1996; Ghislain et al. 2002). Krox-20 regulates an addi-
tional set of target genes including the major myelin
genes and those involved in lipid metabolism (Nagarajan
et al. 2001). In addition, Sox10 may continue to partici-
pate in these transcription programs, as it interacts with
both Oct-6 and Krox20 when bound to adjacent DNA-
binding sites (Kuhlbrodt et al. 1998b).
Schwann cell differentiation in nerves of Krox20 or
Oct-6-deficient mice is arrested at the promyelin stage
(Topilko et al. 1994; Bermingham et al. 1996; Jaegle et al.
1996). However, this differentiation block in Krox20−/−
mice is permanent, and is transient inOct-6mutant ani-
mals (Oct-6geo/geo). Thus,Oct-6geo/geo Schwann cells
do eventually activate Krox20 expression and commence
myelination, albeit with a delay of 7–10 d, thus suggest-
ing some functional redundancy in the genetic program
(Ghazvini et al. 2002). We previously proposed that the
transient nature of the differentiation block is the result
of an unknown Oct-6-like activity in Schwann cells,
with this putative factor acting at a later developmental
time than Oct-6 in the Schwann cell lineage (Jaegle and
Meijer 1998). Alternatively, the transient block could be
the result of a factor that regulates part or all of the
transcriptional targets of Oct-6, but does so less effi-
ciently. The most likely candidates for this Oct-6-like
activity are the other members of the POU domain tran-
scription factor family, of which there are 15 members in
mammals (Ryan and Rosenfeld 1997). Interestingly, two
POU domain transcription factors, Brn-1 and Brn-2, have
virtually identical DNA-binding characteristics com-
pared to Oct-6. Hence, to provide insight into the genetic
program acting alongside Oct-6 in promyelinating
Schwann cells, we examined the expression and function
of the candidate POU domain transcription factors dur-
ing development and in Oct-6-deficient mice.
In this report, we show that Schwann cells express
Brn-2 in a developmental profile similar to that of Oct-6.
We demonstrate that Brn-2 gene activation is indepen-
dent of Oct-6, but that Oct-6 negatively regulates Brn-2
expression levels. Higher expression levels of Brn-2 in
Oct-6 mutant Schwann cells result in a partial rescue of
the developmental delay phenotype, whereas homozy-
gous deletion of Brn-2 in Oct-6 mutant Schwann cells
results in a more severe phenotype. Together these data
strongly indicate that Brn-2 function largely overlaps
with that of Oct-6 in driving the transition from promy-
elinating to myelinating Schwann cells.
Results
Brn-2 is expressed and regulated in Schwann cells in a
manner similar to Oct-6
The transient nature of the Schwann cell defect in Oct-
6-deficient mice suggested some redundancy in tran-
scription factor function. Interestingly, previous work on
the expression of octamer binding factors Oct-6 and
Oct-1 in the developing chick sciatic nerve suggested the
presence of a novel octamer-binding activity and possi-
bly a homologous candidate factor involved in develop-
ing mouse sciatic nerves (Levavasseur et al. 1998).
Hence, to examine the developmental expression profile
of this novel binding activity, we performed electropho-
retic mobility shift assays (EMSAs) using whole sciatic
nerve extracts derived from chick embryos and young
chicks. Three complexes can be distinguished (Fig. 1A).
The largest complex contains Oct-1, a ubiquitous POU
factor, the levels of which are relatively constant at all
stages of nerve development (Blanchard et al. 1996). In
contrast, the smallest and fastest migrating Oct-6-con-
taining complex is strongly regulated during develop-
ment. Like in rodents, Oct-6 expression peaks in promy-
elinating and early myelinating cells (embryonic day 17
and 20; E17 and E20 in Fig. 1A) and is sharply down-
regulated at later stages of myelination (postnatal day 3;
P3). The third, intermediate complex (X) is regulated
similarly to Oct-6, but its expression is maintained at
reduced levels at later stages (P20 in Fig. 1A). Using dif-
ferent octamer-related DNA-binding sites, such as the
HSV1 TAATGARAT motif, and a mutated octamer mo-
tif, we found that this novel activity demonstrated bind-
ing site preferences very similar to those of Oct-6 (data
not shown).
To identify the protein in this complex, we performed
EMSA experiments in the presence of antisera against
several POU proteins closely related to Oct-6. Although
the mobility or intensity of the intermediate complex X
was not affected by antibodies against the chicken Oct-6
protein (Fig. 1B, middle lane), a Brn-2-specific goat anti-
serum strongly reduced the intensity of this complex,
thus identifying the protein in the intermediate complex
as Brn-2 (Fig. 1B, right lane).
Until recently, expression of Brn-2 in mammalian pe-
ripheral nerves had not been described and, paradoxi-
cally, only one octamer complex, in addition to Oct-1,
had been observed in cultured rat Schwann cells (Kuhn
et al. 1991; Sim et al. 2002). Therefore, we next examined
the presence of Brn-2-binding activity in the developing
sciatic nerve of the mouse at P4 by EMSA. In accordance
with previous data, only one prominent protein/DNA
complex, in addition to the Oct-1/DNA complex, was
observed (Fig. 1C, lane 1). However, in supershift assays
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using antibodies specific for Oct-6 and Brn-2, this band
was found to be composed of two complexes, a Brn-2/
DNA complex and an Oct-6/DNA complex (Fig. 1D,
lanes 2–4). Thus, Brn-2 protein is expressed in both the
developing chick and murine nerve.
Because sciatic nerve extracts are heterogeneous, it is
possible that Brn-2 is expressed exclusively in cell types
other than Schwann cells, such as endothelial or peri-
neural cells. We therefore examined expression of Brn-2
in pure differentiating primary rat Schwann cell cultures
using EMSA (Fig. 1D). These cells express high levels of
Oct-6 and moderate levels of Brn-2 (Fig. 1D, cf. lanes 2
and 3). Thus, Brn-2 is expressed in the Schwann cell lin-
eage and is therefore an attractive candidate for the pu-
tative Oct-6 like function.
Brn-2 is expressed in Oct-6-deficient Schwann cells
We next examined whether Brn-2 expression is affected
by loss of Oct-6 function in Schwann cells. As the vast
majority of full Oct-6 knockout animals (Oct-6geo/geo)
are not viable and die shortly after birth, thus precluding
studies at postnatal stages of development, we used in
this study animals that carry on one chromosome a full
knockout allele (geo) and on the other chromosome a
Schwann cell-specific Oct-6 strong hypomorphic allele
(SCE; Ghazvini et al. 2002). The Oct-6SCE allele was
generated through deletion of the Oct-6 Schwann
cell enhancer (SCE; Mandemakers et al. 2000). Both
Oct-6SCE/SCE and Oct-6geo/SCE mice are viable and
exhibit a peripheral nerve phenotype that is indistin-
guishable from that observed in nerves of Oct-6geo/geo
animals (Ghazvini et al. 2002).
Using EMSA and Western blotting, we analyzed Brn-2
expression in the developing nerve of Oct-6geo/SCE
mice (Fig. 2). In addition to the expected Oct-1 complex,
one abundant octamer complex is observed. Supershift
experiments using Oct-6- and Brn-2-specific antibodies
identify Brn-2 as the major protein component in this
complex (Fig. 2A, cf. lanes 2 and 3), with only very low
levels of Oct-6 protein detected, in agreement with pre-
vious data (Ghazvini et al. 2002). Both EMSA and West-
ern blot analyses demonstrate that Brn-2 protein levels
are increased in Oct-6geo/SCE nerves at P4 compared to
heterozygous or wild-type nerves (Fig. 2A,B). The higher
Brn-2 protein levels in Oct-6-deficient nerves result from
increased transcription of the Brn-2 gene (or increased
Brn-2 mRNA stability), as reverse transcriptase PCR
(RT–PCR) data for Brn-2 expression in P1 mice show that
steady-state levels of Brn-2 mRNA are increased in Oct-
6geo/SCE nerves compared to Oct-6SCE/+ nerves (Fig.
2C). Immunostaining of single nerve fibers shows that
within the nerve, Brn-2 is highly expressed in Schwann
cell nuclei (Fig. 2D).
Next we examined developmental regulation of Brn-2
protein expression in nerves of Oct-6SCE/+ and Oct-
6geo/SCE mice, using Western blotting (Fig. 2E). In het-
erozygous animals, Brn-2 expression is up-regulated in
the late embryonic nerve and peaks during the first post-
natal week of development. At later stages (P32), Brn-2
expression is extinguished. Thus, in both chick and
mouse, Oct-6 and Brn-2 are similarly regulated, although
Brn-2 down-regulation appears to be faster in mice. In
Oct-6 mutant nerves, Brn-2 expression appears to be af-
fected in two ways. First, overall Brn-2 expression levels
Figure 1. Brn-2 is expressed in chick and mouse sciatic nerves.
(A) Developmental expression of a novel octamer-binding com-
plex was examined by EMSA using freeze-thaw extracts from
chicken nerves at different stages of development [embryonal
stages E14, E17, and E20 and postnatal days 3 (P3) and 20 (P20)].
Whole-cell extracts of COS cells expressing chicken Oct-6 (Oct-
6) served as a control (Meijer et al. 1990). Free probe is not
shown, but all experiments were performed in probe excess. (B)
Using E17 chick embryonic nerve, extracts identify Brn-2 in
complex X, as antibodies directed against the C-terminal part of
mouse Brn-2 specifically affect complex X, whereas chicken
Oct-6 antibodies (-Oct-6) affect the Oct-6 complex but not
complex X. Preimmune serum (Pre) does not affect either com-
plex. (C) Brn-2 is expressed in mouse nerves. Incubation of Oct-
6-specific antibodies with P4 mouse whole-nerve extracts and
an octamer probe results in the formation of a ternary complex
(supershift Oct-6 complex; ssOct-6) and unmasks another com-
plex that is specifically supershifted (ssBrn-2) with mouse Brn-2
antibodies (-Brn-2). When both antibodies are added all com-
plexes are shifted, demonstrating that no other complexes comi-
grate with the Oct-6/DNA and Brn-2/DNA complexes. (D)
Brn-2 is expressed in the Schwann cell lineage. Whole-cell ex-
tracts from cultured rat Schwann cells grown in the presence of
20 µM forskolin for 36 h were incubated with the octamer probe
in presence of the indicated sera. As in C, Oct-6- and Brn-2-






are increased (see also Fig. 2A,B). Second, whereas up-
regulation of Brn-2 expression follows its normal course,
down-regulation of Brn-2 expression is protracted, with
significant levels of Brn-2 still present at P32. In both
Oct-6SCE/+ and Oct-6geo/SCE genetic backgrounds,
down-regulation of Brn-2 correlates with the build up of
P-zero immunoreactivity, indicating that a myelination-
associated signal, which is independent of Oct-6, extin-
guishes Brn-2 expression.
Together, these data demonstrate that the develop-
mental profile of Brn-2 expression in the nerve is regu-
lated through mechanisms independent of Oct-6, but
that Brn-2 expression levels are negatively attenuated by
Oct-6.
Role of Brn-2 in Schwann cell development
and myelination
Considering the findings that Brn-2 is expressed at rela-
tively high levels in Oct-6-deficient Schwann cells that
are transiently blocked in their differentiation, and that
Brn-2 DNA-binding characteristics are virtually identi-
cal to those of Oct-6, one can suggest several possible
roles for Brn-2 in Schwann cells. First, it is possible that
Brn-2 regulates the same repertoire of genes as Oct-6 but
does so less efficiently, possibly because of different af-
finities for Oct-6 interacting factors important in target
gene regulation. Second, it is possible that Brn-2 function
only partially overlaps with Oct-6 and/or that yet an-
other factor, which might be activated at a later devel-
opmental time, is responsible for the delayed activation
of the myelination program in the absence of Oct-6. It
was recently proposed that the POU homeodomain pro-
tein Brn-5, a class VI POU protein, might fulfill such a
role (Wu et al. 2001). This factor is activated at a later
developmental time than Oct-6 and Brn-2, and its acti-
vation does not depend on Oct-6. Third, it is possible
that Brn-2 negatively regulates Oct-6 targets, possibly
through its interaction with the homopolymeric gluta-
mine tract binding protein PQBP-1 (Waragai et al. 1999),
and that the balance between Oct-6 and Brn-2 governs
the progression of cells into the myelinating phase of
differentiation. In the absence of Oct-6 this balance
shifts to Brn-2, and cells are inhibited in their differen-
tiation. Thus, to begin to explore the possible roles of
Brn-2 and Brn-5 in Schwann cell differentiation, we per-
formed transgenic mouse experiments in which Brn-2 or
Brn-5 is overexpressed in the Schwann cell lineage.
To direct expression of Brn-2 or Brn-5 in Schwann
cells, we made use of the Oct-6 SCE (Fig. 3A). This ge-
netic element drives transgene expression from a generic
promoter in Schwann cells with a profile that is identical
to that of Oct-6 and very similar to that of Brn-2 but not
Brn-5 (Mandemakers et al. 2000). We previously showed
that a transgenic construct carrying the SCE and an HA-
tagged version of Oct-6 rescues the delay in development
of the peripheral nerve in Oct-6-deficient mice (Mande-
makers et al. 2000). To test whether Brn-2 or Brn-5 over-
expression can replace Oct-6 in this rescue, we generated
transgenic lines for the three constructs depicted in Fig-
ure 3A. These transgenes were subsequently crossed into
an Oct-6geo/SCE background, and nerve maturation at
P4 was studied by Western blotting and light microscopy
(Fig. 3B,C). Additionally, we counted the number of pro-
myelin and myelinating configurations in these nerves
and expressed the fraction of myelinating figures divided
Figure 2. Elevated and protracted expression of Brn-2
in nerves of Oct-6geo/SCE mice. (A) EMSA with
whole-cell extracts from sciatic nerves of P4Oct-6geo/SCE
mice and a radiolabeled octamer probe reveal a strong
complex that migrates at the same position as Brn-2
and Oct-6 DNA complexes. This complex is super-
shifted with antibodies against Brn-2, unmasking the
low residual expression of Oct-6 from the SCE allele.
Preimmune serum affects none of these complexes. (B)
Western blot analysis confirms that Brn-2 protein lev-
els are elevated in the nerves of Oct-6geo/SCE vs.
Oct-6SCE/+ nerves at P4. Tubulin served as a loading
control. (C) Semiquantitative RT–PCR using RNA ex-
tracted from newborn sciatic nerves shows the higher
Brn-2 mRNA steady-state levels inOct-6geo/SCEmice
than in Oct-6SCE/+ mice. Cyclophilin mRNA served
as a control. (D) Brn-2 is expressed in the nucleus of
Schwann cells in the nerves of P4 Oct-6geo/SCE mice.
Nerves were dissected and teased into single fibers and
incubated with antibodies against mouse Brn-2 (-Brn-2)
in green and Neurofilament medium chain (NFM) in
red. (E) Expression of Brn-2 and Oct-6 was examined in
developing nerves of Oct-6SCE/+ and Oct-6geo/SCE
animals at E17 and P1–P32. Amounts of nerve extract
loaded were normalized for acetylated -tubulin. The
build-up of P-zero immunoreactivity over time illus-
trates the progression of myelination in both genotypes.
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by the total number of myelinating and promyelin con-
figurations to obtain a quantitative measure of nerve
maturation (Fig. 3D). In the absence of Oct-6, all but a
few myelinating Schwann cells are stalled at the promy-
elin stage of differentiation [Fig. 3C (cf. panels a and b),
3D (50% and 0.5%)], and P-zero protein levels are very
low (Fig. 3B, cf. lanes 1 and 2) compared to heterozygous
or wild-type animals. Expression of the HA-Oct-6 trans-
gene results in a significant restoration of P-zero protein
levels in nerves of Oct-6geo/SCE mice (Fig. 3B, lane 3).
At the morphological level, this finding correlates with
increased numbers of myelinating Schwann cells, up to
60% of wild-type (Fig. 3C, panel c, 3D). Expression of the
HA-Brn-2 transgene also results in significant restora-
tion of P-zero protein levels (Fig. 3B, lane 4) and a strong
increase in the numbers of actively myelinating
Schwann cells (Fig. 3C, panel d, 3D). In contrast, the
HA-Brn-5 transgene is not capable of restoring P-zero
protein levels (Fig. 3B, lane 5) and accordingly, no in-
crease in the number of myelinating cells is observed
(Fig. 3C, panel e) despite relatively high levels of HA-
Brn-5 expression (Fig. 3B, lane 5). Thus, increased Brn-2
expression in early postnatal development results in a
significant increase in the number of actively myelinat-
ing Schwann cells in transgenic SCE Brn-2/Oct-6geo/SCE
nerves. This number approaches that observed in nerves
of transgenic SCE Oct-6/Oct-6geo/SCE animals (Fig.
3D). These results demonstrate that Brn-2 does not an-
Figure 3. HA-Oct-6 and HA-Brn-2, but not HA-Brn-5, can rescue the developmental delay phenotype of Oct-6geo/SCE mutant mice.
(A) Schematic representation of the constructs used to generate mice transgenic for HA-Oct-6 (SCE Oct-6), HA-Brn-2 (SCE Brn-2), and
HA-Brn-5 (SCE Brn-5). Two restriction sites used in the generation of these constructs are indicated [NotI (N) and SwaI (Sw)]. The SCE
is indicated as a gray box and the triple HA-tag as a yellow box. The intron-less Oct-6 gene is shown as a thick black line. The ORF
of Oct-6 is in light green, that of Brn-2 is in pink, and that of Brn-5 is in orange, with their POU-specific domain in dark blue and their
POU-homeodomain in light blue. (B) Oct-6geo/SCE mutant mice that express HA-Oct-6 or HA-Brn-2 show high levels of P-zero
protein expression in sciatic nerve. Western blot analysis of P4 sciatic nerve extracts from wild-type (wt; lane 1), Oct-6geo/SCE (lane
2), Oct-6geo/SCE/SCE Oct-6 (lane 3), Oct-6geo/SCE/SCE Brn-2 (lane 4), and Oct-6geo/SCE/SCE Brn-5 (lane 5) animals. Levels of
HA-tagged proteins are assessed with -HA antibodies. The amount of protein loaded per lane is estimated by the intensities of the
-tubulin immunoreactive band. (C) Comparison of the morphology of cross sections through P4 sciatic nerves of Oct-6SCE/+ (panel
a), Oct-6geo/SCE (panel b), Oct-6geo/SCE/SCE Oct-6 (panel c), Oct-6geo/SCE/SCE Brn-2 (panel d), and Oct-6geo/SCE/SCE Brn-5
(panel e) animals. Plastic-embedded osmicated nerves were sectioned at 1 µm and stained with ppd. Myelin is strongly stained by this
compound and appears as dark rings in cross sections. Bar, 20 µm. (D) Quantification of the promyelin–myelinating transition in nerves





tagonize Oct-6 function, but instead functionally substi-
tutes for Oct-6 in promoting the transition from promy-
elinating to myelinating Schwann cells. Furthermore,
our results suggest that Brn-2 levels are rate-limiting in
Schwann cells of Oct-6geo/SCE mice.
Schwann cell-specific deletion of Brn-2 does not affect
peripheral nerve development
The experimental results described above suggest that
Brn-2 and Oct-6 share many transcriptional targets, but
do not reveal whether Brn-2 has distinct (non-Oct-6)
regulatory targets. In addition, the above experiments do
not exclude that other, as yet unidentified transcription
factors, contribute to the delayed entry ofOct-6geo/SCE
Schwann cells into the myelinating phase of differentia-
tion. To address these questions we examined the effect
of loss of Brn-2 function in the Schwann cell lineage. A
full null allele of Brn-2 had been generated previously
and revealed a vital function for Brn-2 in the develop-
ment and survival of endocrine neurons in the hypo-
thalamus (Nakai et al. 1995; Schonemann et al. 1995). As
a consequence, the hypothalamic–pituitary axis is dis-
turbed and homozygous animals die before postnatal day
10. Therefore, we generated mice carrying a conditional
null allele of Brn-2 in which deletion of the LoxP-flanked
Brn-2 open reading frame (ORF; Fig. 4A) depends on ac-
tivity of the Cre recombinase in Schwann cells. The in-
troduction of LoxP sites at the Brn-2 locus, together with
a neomycin selection cassette and an eGFP reporter, did
not compromise Brn-2 gene function, as Brn-2flox/flox
animals are healthy and breed normally.
To achieve Schwann cell-specific deletion of the Brn-2
gene, we generated transgenic mouse lines in which the
Cre recombinase is expressed from Desert hedgehog
(Dhh) regulatory sequences (Fig. 4B). The Dhh gene is
prominently expressed in Schwann cell precursors of the
developing nerves and in Sertoli cells of the testis (Bit-
good and McMahon 1995). The cell-type specificity of
the recombination event was monitored in offspring of
crosses between the DhhCre transgenic mice and
ROSA26 LacZ reporter (Soriano 1999). Embryos were
isolated from these crosses at different developmental
stages and stained with Bluo-Gal for -galactosidase ac-
tivity. DhhCre activity was observed in the Schwann
cell lineage from E12, as evidenced by blue staining of
the peripheral nerves (Fig. 4B, panels a,b). DhhCre activ-
ity is also observed in the testis, another well docu-
mented site of Dhh gene expression. Outside the
Schwann cell lineage and testis, expression of Cre is ob-
Figure 4. (A) The targeting strategy to generate an
inducible deletion allele of Brn-2. The structure of
the wild-type Brn-2 locus is shown at the top. The
Brn-2 single exon gene is represented in olive green
with the POU domain in light green. The Southern
blot probes A and B are indicated as horizontal
black bars. The positions of restriction enzyme cut-
ting sites are shown for BamHI (B), HindIII (H),
EcoRI (E) and ScaI (S). In the targeting construct
(targeting vector), the neomycin (NEO) expression
cassette (purple box) is flanked by FRT sites (verti-
cal red bars) followed by a 3 LoxP site (blue tri-
angle) and an eGFP reporter gene (dark green box).
The orange box represents the counter-selection
cassette, containing the thymidine kinase gene
(TK). The targeted allele (the floxed allele) obtained
after homologous recombination is shown below
the targeting construct. Cre-mediated recombina-
tion removes Brn-2 sequences and generates the re-
combined allele (bottom). (B) Schwann cell-specific
recombination is achieved through expression of
the Cre recombinase under control of Dhh gene
regulatory sequences. The 19-kb construct contain-
ing the entire Dhh gene with its three exons (in
green) is shown. The Cre recombinase ORF (indi-
cated in red) is preceded by a nuclear localization
peptide sequence and cloned in-frame with theDhh
ORF. Restrictions sites for NotI (N) and BamHI (B)
are indicated. Expression of the Cre recombinase
was examined in crossing with the ROSA26lacz
(R26R) reporter mouse. (Panel a) Whole-mount
staining of E12.5 embryo reveals expression in the
PNS, the snout, and part of the vasculature. (Panel
b) Paraffin sections of a stained E14.5 embryo dem-
onstrate the strong expression in immature Schwann cells that populate the peripheral nerves. (Panel c) Strong expression is also
observed in the seminiferous tubules of the testis, where Dhh is expressed in the Sertoli cells.
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served in the skin of the snout, but not in the brain and
more specifically the hypothalamic region.
To explore the effect of loss of Brn-2 expression in the
Schwann cell lineage, we crossed the DhhCre transgene
into the Brn-2flox/flox background. Offspring from these
crosses were healthy and bred normally. Southern blot
analysis of DNA derived from sciatic nerves of adult
DhhCre/Brn-2flox/flox animals revealed that the majority
of cells had undergone recombination [cf. the ratio of the
14-kb band (recombined) and the 8.3-kb (not recombined)
band in Fig. 5A, lane 4]. The nonrecombined band de-
rives from non-Schwann cells in the nerve that do not
express the DhhCre transgene. Recombination within
the Schwann cell compartment of the nerve was com-
plete, as judged by the complete loss of Brn-2 expression
in nerves of transgenic DhhCre/Brn-2flox/flox pups using
EMSA (Fig. 5B, cf. lanes 1 and 2). Additionally, loss of
Brn-2 did not affect Oct-6 expression levels in these
nerves compared with age-matched Oct-6SCE/+ nerves
(Fig. 5B, cf. lanes 3 and 4). We next examined the effect of
complete loss of Brn-2 expression in Schwann cells on
nerve development. Light microscopic examination of
sciatic nerves of P8 transgenic DhhCre/Brn-2flox/flox ani-
mals did not reveal clear morphological abnormalities
(Fig. 5C). In both Brn-2flox/flox and DhhCre/Brn-2flox/flox
nerves, the majority of Schwann cells associated with
larger axons are actively myelinating. Thus, loss of Brn-2
expression in the Schwann cell lineage does not affect
the timing or progression of postnatal peripheral nerve
development.
Schwann cell-specific deletion of Brn-2 and Oct-6
results in a severe hypomyelinating phenotype
To study the role of Brn-2 in Schwann cells deficient for
Oct-6, we generated double homozygous mutants by in-
tercrossing transgenic DhhCre/Brn-2flox/flox/Oct-6SCE/SCE
and transgenic DhhCre/Brn-2flox/flox/Oct-6geo/+ mice.
The development of peripheral nerves was examined by
electron microscopy and quantified as described above.
In the absence of Oct-6 function, Schwann cell develop-
ment is transiently blocked at the promyelin stage (Ber-
mingham et al. 1996; Jaegle et al. 1996; Ghazvini et al.
2002). Whereas >90% of large-caliber axons in nerves of
wild-type (data not shown) and heterozygous Oct-
6CSE/+ animals are myelinated by the third postnatal
week (at P16), nerves ofOct-6geo/SCEmice still contain
many promyelin configurations (Fig. 6A, panels a,b, 6B,
∼60%). A dramatic increase in the severity of this phe-
notype is observed with the Schwann cell-specific dele-
tion of Brn-2 on the Oct-6geo/SCE genetic background.
As shown in Figure 6A, panel c, none of the ensheathing
Schwann cells has progressed beyond the promyelin
stage of differentiation. To determine whether these
cells are permanently blocked in their differentiation,
nerve morphology in young adult animals was examined
at P56 and P120. At these stages most, if not all, Oct-
6geo/SCE Schwann cells have gone on to myelinate their
associated axon [Fig. 6A (cf. panels d and e), 6B]. In con-
trast, nerves of double homozygous animals are abnor-
mal, with many promyelin configurations (∼55% at P56
to ∼25% at P120) and thinly myelinated axons (Fig. 6A,
panels f,i). This morphology resembles that of wild-type
nerves during the first week of postnatal development.
Therefore, deletion of both Oct-6 and Brn-2 results in
further delay in the promyelinating–myelinating transi-
tion relative to that observed in single Oct-6 mutants,
indicating that, in addition to Oct-6, Brn-2 plays a role in
the transition of promyelinating to myelinating
Schwann cells.
Discussion
In the present study we have shown that the class III
POU domain protein Brn-2 is regulated in parallel with
Oct-6 during Schwann cell differentiation. As the previ-
Figure 5. (A) The floxed Brn-2 locus is effectively recombined
by the Cre recombinase in peripheral nerve. DNAwas extracted
from adult sciatic nerve of wild-type (wt),Brn-2wt/flox,Brn-2flox/flox,
and Brn-2flox/floxCre (Brn-2flox/flox mice transgenic for the
DhhCre transgene) animals, digested with BamHI, and sub-
jected to Southern blot analysis with probe B. Probe B detects
fragments of 7.3 kb (wild-type allele), 8.3 kb (targeted allele), and
14 kb (recombined allele). The nonrecombined band present in
lane 4 results from DNA derived from cells that do not express
the DhhCre transgene, such as nerve sheath cells. (B) The re-
combination of the Brn-2 allele in Schwann cells is complete, as
Brn-2flox/floxCre nerves do not express Brn-2 atP4 (lanes 1,2).
Complete deletion of Brn-2 does not affect Oct-6 expression, as
Oct-6 expression levels are the same in nerves of Oct-6SCE/+
and Brn-2flox/floxCre animals (cf. lanes 3 and 4). (C) Deletion of
Brn-2 in Schwann cells does not affect the morphological matu-
ration of the nerve. The overall morphology appears very similar
in cross sections of nerves from both genotypes. Resin sec-
tions (1 µm) of P4 sciatic nerves of Brn-2flox/flox (panel
a) and Brn-2flox/flox/Cre (panel b) animals were stained with ppd.





ous data on the delayed myelination phenotype of Oct-
6-deficient mice suggested a redundant activity, we
show here that Brn-2 acts as that novel factor. Our ge-
netic evidence, arising from the overexpression of Brn-2
in Oct-6-deficient mice and moreover, the double defi-
ciency of Brn-2 and Oct-6, demonstrates that these POU
domain transcription factors share roles as positive regu-
lators of the promyelinating–myelinating transition in
Schwann cell development. Considering the importance
of peripheral nerve myelination, the activity of both
these transcription factors most likely assures the pro-
gression of this process.
Regulation of Brn-2 expression in the Schwann
cell lineage
Our studies on chick and mouse sciatic nerve at different
embryonic and post-hatching or postnatal stages show-
ing that Oct-6 and Brn-2 are regulated similarly during
nerve development provided a strong suggestion that
Brn-2 plays a role in the onset of myelination. Both genes
are activated around the time that most Schwann cells
have adopted an immature promyelinating phenotype
(E14 in the chick and E17 in the mouse). Expression of
both genes peaks in promyelinating Schwann cells and is
down-regulated in actively myelinating cells. Using cul-
tured rat Schwann cells as a convenient in vitro system,
we found that both Brn-2 and Oct-6 expression is in-
creased upon addition of forskolin (an agent that elevates
intracellular cAMP concentration through the reversible
activation of adenylyl cyclase; Fig. 1D). Similarly, during
nerve regeneration, Sim and colleagues (2002) showed
the parallel expression of Brn-2 and Oct-6. Our present
studies of Oct-6- and Brn-2-deficient mice demonstrate
that the activation of these genes is not interdependent,
thus providing a safeguard for myelination in the devel-
oping organism.
Intracellular signaling pathways that regulate Oct-6
expression in Schwann cells converge on the SCE, an
enhancer element that has been identified in both the
mouse and human Oct-6 locus. A first attempt to iden-
tify such an enhancer within the Brn-2 locus on the basis
of sequence homology has failed thus far. DNaseI hyper-
sensitivity mapping of the Brn-2 locus in Schwann cells
should suggest the position of relevant enhancer se-
quences and facilitate the identification of relevant bind-
ing sites within the enhancers of Oct-6 and Brn-2, so as
to determine whether the activation of these genes is by
means of a similar signaling pathway. One signaling
Figure 6. Schwann cell-specific deletion of Brn-2 in an
Oct-6geo/SCE background results in a severe hypomyelin-
ation phenotype. (A) Representative sections (1 µm; ppd-
stained) are shown from sciatic nerves at three develop-
mental time points (P16, P56, and P120). In Oct-6SCE/+
mice, most myelin-competent axons are actively being
myelinated by P16 (panel a). At P56 and P120, these nerves
are fully matured (panel d). This pattern contrasts with
that observed in Oct-6geo/SCE animals, which exhibit a
strong delay in the differentiation of Schwann cells (Ber-
mingham et al. 1996; Jaegle et al. 1996; Ghazvini et al.
2002). At P16, a majority of Schwann cells is arrested at the
promyelin stage, with only the largest axons myelinating
(panel b). By P56, most if not all myelinating Schwann cells
have elaborated a myelin sheath (panels e,h; P120). Dele-
tion of Brn-2 in this genetic background results in a dra-
matic increase in the severity of the phenotype. At P16,
essentially all myelinating Schwann cells are arrested at
the promyelin stage of differentiation (panel c). Even at P56
and P120, myelination is largely abnormal, with large
numbers of cells at the promyelin stage (panel f). Those
axons that are myelinated have very thin myelin sheaths.
Bar: panels a–f, 20 µm. (B) Quantification of delayed my-
elination in genotypes presented in A.
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pathway that is of particular interest in this respect is
the NFB pathway, as Nickols and colleagues (2003) re-
cently provided evidence of its involvement in periph-
eral nerve myelination and Oct-6 regulation in Schwann
cells.
Although Oct-6 and Brn-2 are activated independently,
Brn-2 expression levels are attenuated by Oct-6. Brn-2
expression levels are increased (two- to threefold) in Oct-
6-deficient Schwann cells compared to wild-type (Figs.
1C, 2A,B). It is at present not known by what mechanism
Brn-2 levels are regulated by Oct-6, although our semi-
quantitative RT–PCR data suggest involvement of tran-
scriptional or posttranscriptional mechanisms rather
than translational or posttranslational mechanisms.
Brn-2 expression is extinguished through an Oct-6-inde-
pendent pathway, as Brn-2 expression is down-regulated
at later stages of postnatal development, even in the ab-
sence of Oct-6 (Fig. 2E).
Role of Brn-2 in Schwann cell development
The coordinated expression of Brn-2 and Oct-6 prompted
our in vivo studies of Brn-2 as the additional overlapping
activating factor in the Schwann cell developmental pro-
gram. We found that overexpression of Brn-2 under con-
trol of the Oct-6 SCE in Oct-6-deficient Schwann cells
results in an increase in the number of Schwann cells
that enter the myelinating phase on schedule. Schwann
cell-specific deletion of Brn-2 in an Oct-6-deficient back-
ground results in a phenotype that is much more severe
than that observed in Oct-6 single mutant animals, with
Schwann cells arrested at the promyelin stage up to 120
d after birth. These results strongly suggest that Brn-2
shares a role with Oct-6 in Schwann cell development as
a positive regulator of the promyelinating–myelinating
transition, and identify Brn-2 as the proposed Oct-6 like
function in Oct-6 mutant animals (Jaegle and Meijer
1998).
Functional overlap, as demonstrated here for Brn-2 and
Oct-6, is a common phenomenon among members of the
same transcription factor family and has been described
for, among others, members of the Gata and Sp1 family.
Within the POU family of transcription factors, overlap-
ping roles have been described for the closely related
Brn-1 and Brn-2 genes in cortical neuron development
(McEvilly et al. 2002; Sugitani et al. 2002). Functional
overlap has also been described between Oct-6 and the
more distantly related Skn-1a/i POU gene, which are
both required for proper differentiation of epidermal ke-
ratinocytes (Andersen et al. 1997). In our system, we
tested whether the more divergent POU domain gene
Brn-5 could functionally complement Oct-6. The choice
of Brn-5 was motivated by the work of Wu and col-
leagues (2001), who demonstrated that Brn-5 is expressed
in myelinating Schwann cells and is regulated indepen-
dently of Oct-6. High levels of Brn-5 expression did not
ameliorate the developmental delay phenotype of nerves
in Oct-6-deficient animals. This is not due to a possible
inhibitory function of Brn-5, as SCE-Brn-5/Oct-6SCE/+
nerves were normally myelinated (data not shown).
Analysis of Brn-2 expression in Oct-6 mutant animals
and Brn-2 overexpression studies led us to the conclu-
sion that quantitatively higher levels of Brn-2 protein are
required to initiate myelination on schedule. These data,
together with the fact that Brn-2 and Oct-6 have very
similar DNA-binding preferences, suggest that the dif-
ferences in biological function between Brn-2 and Oct-6
result mainly from differences in the affinities for inter-
acting factors and/or the repertoire of interacting part-
ners.
POU domain proteins are known to interact with
members of the Sry box (Sox) transcription factor family.
For example, the activation of the Fgf4 enhancer in ES
cells depends on the synergistic interaction between
Sox2 and Oct4 proteins (Ambrosetti et al. 1997). In glial
cells it has been shown that Sox10 interacts synergisti-
cally with Oct-6, but not Brn-1 or Brn-2, to activate tran-
scription when both proteins are bound to adjacent bind-
ing sites in an artificial enhancer (Kuhlbrodt et al.
1998a). Synergistic activation required the N-terminal
region of Oct-6 and Sox10 (Kuhlbrodt et al. 1998b). Simi-
larly, the oligodendrocyte-enriched Sox11 protein syner-
gizes with Brn2 and Brn-1, but not with Oct-6. Taken
together, these data suggest that a specific POU/Sox code
exists and postulates that specific POU proteins require
specific Sox proteins to exhibit cooperative effects (Kuhl-
brodt et al. 1998a,b). If indeed important target genes of
Oct-6 in glial cells are regulated through interaction
with Sox10, and the pair Brn-2/Sox11 is equivalent to
Oct-6/Sox10, the developmental defect in Oct-6-defi-
cient Schwann cells but not in oligodendrocytes (Ber-
mingham et al. 1996) could be explained as follows: Oli-
godendrocytes express Brn-2/Sox11 in addition to Oct-6/
Sox10, whereas Schwann cells express Oct-6/Sox10 and
Brn-2 but not Sox11. Further experiments are required to
test this hypothesis.
Our data demonstrate that the promyelin-to-myelina-
ting transition is regulated by Oct-6/Brn-2 function, but
even in the absence of these POU factors, Schwann cells
eventually do enter the myelinating phase of cell differ-
entiation. This is not due to accumulation of Oct-6 pro-
tein expressed from the hypomorphic SCE allele (Fig.
2E). Also, as Brn-2 deletion in the Schwann cell lineage is
complete, mosaicism of Brn-2 expression cannot explain
this delayed myelination (Fig. 5). Two observations are
particularly important in understanding the roles of
Oct-6 and Brn-2 in Schwann cell differentiation and why
even in their absence myelination occurs. First, in the
absence of Oct-6, entry into the myelinating phase is
delayed and the kinetics of this transition are changed
(Fig. 6B). Whereas >80% of wild-type Schwann cells have
entered the myelinating phase by P8, in the absence of
Oct-6 it takes several weeks for the same number of
Schwann cells to make this transition into the myelina-
ting phase. In the absence of both Oct-6 and Brn-2, this
transition is even further protracted. Second, kinetics of
this transition are Oct-6/Brn-2 dosage-dependent. In
terms of transcriptional regulation, this suggests that
Oct-6 greatly increases the chance that its target genes





Oct-6 and Brn-2 this chance is not zero indicates that
these target genes are activated, albeit less effectively,
through other transcription factors, possibly including
the ubiquitous POU factor Oct-1.
Notwithstanding, the identification and characteriza-
tion of Brn-2 and its in vivo role in Schwann cells have
provided insight into the transcriptional network of my-
elination. These results will ultimately lead to a bio-
chemical explanation of the different, yet overlapping
roles of Oct-6 and Brn-2 in Schwann cell development
and possible intervention strategies to promote myelina-
tion in clinical therapeutic settings.
Materials and methods
Gene targeting
A 10.5-kb HindIII fragment of Brn-2 genomic sequences was
isolated from a 129ola ES cell-genomic phage library. Two re-
strictions sites (HindIII and AgeI) were generated by PCR at the
ATG and used to insert a 5 loxP site. A second clone was
generated containing the neomycin gene driven by a thymidine
kinase (Pytk) promoter flanked by FRT sites. Next to the 3FRT
site we inserted a 3 loxP sequence and an eGFP reporter gene.
A 1.9-kb fragment containing FRT-Pytk-neomycin-FRT-loxP-
eGFP was isolated as a BglII fragment and cloned in a unique
BamHI site in the Brn-2 3 untranslated region. We positioned a
negative-selection marker gene, a thymidine kinase gene driven
by the phosphoglycerate kinase-1 promoter (PGK-tk), down-
stream from the 3 homology region.
SpeI-linearized DNA (15 µg) was electroporated into E14 ES
cells followed by selection with G418 (200 µg/mL) and 2 µM
gancyclovir. Individual clones were screened for homologous
recombination by Southern-blot analysis of BamHI and HindIII-
digested genomic DNA with 5 and 3 external probes (probes A
and B). One correctly targeted ES cell clone with a correct karyo-
type was isolated and injected into C57Bl/6 blastocysts. Male
chimeric mice were mated with FVB/N females to transmit the
modified Brn-2 allele to the germ cells (Brn-2wt/flox). Heterozy-
gous offspring were back-crossed to generate homozygous mu-
tant Brn-2flox/flox mice. The different Brn-2 alleles were geno-
typed either by Southern blotting or by PCR with the following
primers: 5-GCGCGGCTCCTTTAACCAGAGCGCC-3 and
5-CTGGTGAGCGTGGCTGAGCGGGTGC-3. The wild-
type allele will yield a 210-bp PCR product, and Brn-2flox/flox
will yield a 250-bp PCR product.
Transgenic mice
For the generation of Cre recombinase-expressing mice, we used
an 18-kb NotI Dhh genomic clone encompassing the Dhh pro-
moter, exons 1, 2, and 3 (gift from Dr. Andy MacMahon, Har-
vard). The Cre gene was extended at its N terminus with a
nuclear localization peptide sequence and cloned in exon 1 on
the start codon ofDhh. The 19-kb transgene construct was sepa-
rated from vector sequences and microinjected into fertilized
FVB/N oocytes. Founder lines were crossed back to FVB/N
mice. The genotype of the mice was determined by PCR analy-
sis of genomic DNA isolated from mouse tails. Cre-specific
primers 5-ACCCTGTTACGTATAGCCGA-3 and 5-CTCC
GGTATTGAAACTCCAG-3 were used to amplify a 300-bp
fragment from the DhhCre construct.
The HA-tag expression cassette was generated by subcloning
a 2.3-kb NotI/HindIII fragment containing the HA-taggedOct-6
fusion gene described before (Mandemakers et al. 2000) into
pBluescript (pHA-Oct-6). A BglII/SpeI/NcoI synthetic polylinker
was inserted as a blunt/NcoI fragment into MscI/NcoI-digested
pHA-Oct-6, placing the linker just behind the triple HA tag and
removing most of the Oct-6 coding sequences (HA-tag cloning
vector). A 2-kb BamHI fragment containing the Brn-2 coding
sequence, isolated from pCMV-Brn-2, was subcloned into the
HA-tag cloning vector linearized with BglII (HA-Brn-2). A 0.9-kb
BamHI/XbaI fragment containing Brn-5 coding sequences, iso-
lated from pCMV-Brn-5, was cloned into the HA-tag cloning
vector digested with BglII/SpeI (HA-Brn-5). The NotI/SwaI frag-
ments from HA-Brn-2 and HA-Brn-5 were then ligated into
NotI/SwaI-digested R3HAOct-6-SCE vector, creating con-
structs SCE-HABrn-2 and SCE-HABrn-5. EcoRI restriction frag-
ments containing the transgene construct were isolated and mi-
croinjected into fertilized FVB/N oocytes. Transgenic lines were
crossed into an Oct-6SCE/SCE background.
Electron microscopy
Electron microscopy on sciatic nerves was performed as de-
scribed (Jaegle et al. 1996). Mice were anesthetized with Nem-
butal and transcardially perfused with PBS followed by 3% para-
formaldehyde (PFA) and 1% glutaraldehyde in 0.1 M sodium
cacodylate buffer at pH 7.5. Sciatic nerves were isolated and
placed in fresh fixative overnight at 4°C. The sciatic nerves
were washed in 0.2 M cacodylate buffer overnight at 4°C before
being postfixed in 1% OsO4 for 3 h, dehydrated, and embedded
in Epon. Semithin sections were stained with para-phenylene-
diamine (ppd; Estable-Puig et al. 1965) and viewed under an
Olympus microscope. Ultrathin sections were stained with ura-
nyl acetate and lead citrate, and analyzed with a Philips CM100
electron microscope. For quantification, five random nonover-
lapping electron micrographs were produced for every nerve at a
final magnification of 2600×. Myelinating and promyelin figures
were counted (250–450 fibers per nerve).
Whole-mount X-gal staining
Embryos were isolated and fixed by immersion for 1 h at room
temperature in 2% formaldehyde, 0.2% glutaraldehyde, 2 mM
MgCl2, 5 mM EGTA at pH 8, and 0.02%NP-40 in PBS. Embryos
were washed three times for 10 min in PBS with 0.02% NP-40
and stained overnight at room temperature in PBS containing 1
mg/mL Bluo-gal, 5 mM K3Fe(CN)6, 5mM K4Fe(CN)6, 2 mM
MgCl2, 0.01% SDS, and 0.02% NP-40. Subsequently, the
stained embryos were washed twice in PBS with 0.02% NP40,
postfixed overnight in 4% formaldehyde, and embedded into
paraffin. Sections (8 µm) were cut, counterstained with eosin,
and viewed under the microscope. Images were collected using
an Olympus DP50 digital camera.
Antibodies and immunohistochemistry
Rabbit polyclonal antibodies were raised against the N terminus
of Brn-2 protein (amino acids 155–271). Animals were immu-
nized with His-tagged fused protein expressed in Escherichia
coli and purified on Ni2+-NTA-agarose beads (QIAGEN). Speci-
ficity of the Brn-2 antiserum was confirmed by EMSA (data not
shown). Antibodies raised against the N-terminal portion of the
Oct-6 protein have been described (Ilia et al. 2002).
Sciatic nerves were isolated, teased into single fibers, and
fixed for 30 min with 4% PFA at room temperature. The tissue
was blocked in 1% BSA, 0.05% Tween-20 in Tris-buffered sa-
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line (TBS). Rabbit anti-Brn-2 antibodies and mouse anti-Neuro-
filament (hybridoma 2H3, Developmental Studies Hybridoma
Bank) antibodies, both diluted 1:200, were incubated simulta-
neously in TBS/0.05% Tween-20 overnight at room tempera-
ture. Oregon Green-conjugated goat anti-rabbit IgGs (Molecular
Probes) and Texas Red-conjugated goat anti-mouse IgGs (Mo-
lecular Probes) were subsequently used as secondary antibodies.
The tissue was viewed using a Leica fluorescence microscope.
Western blotting
Sciatic nerves were isolated and directly lysed in loading buffer,
followed by sonication and heating in a boiling water bath.
Western blotting was performed as described (Ghazvini et al.
2002). Primary antibodies include anti-HA (rabbit polyclonal
Y-11; Santa Cruz Biotechnology; used at dilution 1:2000), anti-
Brn-2 (goat polyclonal C-20; Santa Cruz Biotechnology; used at
1:100), anti-Oct-6 (rabbit polyclonal; 1:1000), anti-P-zero
(mouse monoclonal, hybridoma clone P07; 1:1000 (Archelos et
al. 1993), and acetylated -Tubulin (mouse monoclonal Sigma
T-6793; 1:10,000). Secondary antibodies were either conjugated
with alkaline phosphatase (Dako) or horseradish peroxidase
(Dako) for the detection of primary antibodies.
Electrophoretic mobility shift assay
Sciatic nerve and Schwann cell extracts were prepared by plac-
ing the tissue or cells in 5–10 tissue volumes of 20 mM Hepes-
KOH at pH 7.9, 400 mM KCl, 1 mM EDTA, 10 mM DTT, 10%
glycerol supplemented with 1 mM PMSF, and 1× protease in-
hibitor cocktail (Sigma; Meijer et al. 1992). The tissue was dis-
rupted by four cycles of snap-freezing in liquid nitrogen and
thawing on ice. Cellular debris was removed by centrifugation
at 14000g for 5 min at 4°C. The supernatant was snap-frozen
and stored in aliquots at −80°C. Equal amounts of extract were
used in a bandshift assay using 10 fmole of a 32P end-labeled
double-strand oligonucleotide probe (GAGAGGAATTTG
CATTTCCACCGACCTTCC). Probe and protein were incu-
bated on ice, in the absence or presence of antiserum, for 20 min
in 20 mM Hepes-KOH at pH 7.9, 1 mM EDTA, 1 mM EGTA,
4% Ficoll in a total volume of 20 µL. Complexed and free probe
were separated on a 4% polyacrylamide gel in 0.25× TBE elec-
trophoresis buffer at room temperature. Gels were fixed in 10%
methanol/10% acetic acid, dried, and exposed to a Phosphor-
Imager screen (Molecular Dynamics). Relative band intensities
were calculated using the ImageQuant 5.2 software.
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Abstract
The remarkable high affinity (Kd � 10)15 M) of avidin/streptavidin for biotin has been extensively
exploited in purification methodologies. Recently a small peptide sequence (Avi-tag) has been defined that
can be specifically and efficiently biotinylated by the bacterial BirA biotin ligase. Fusion of this small peptide
sequence to a protein of interest and co-expression with the BirA gene in mammalian cells allowed purifi-
cation of the biotinylated protein together with its associated proteins and other molecules. Ideally, one
would like to apply these technologies to purify tagged proteins directly from mouse tissues. To make this
approach feasible for a large variety of proteins we developed a mouse strain that expresses the BirA gene
ubiquitously by inserting it in the ROSA26 locus. We demonstrate that the BirA protein is indeed expressed
in all tissues tested. In order to demonstrate functionality we show that it biotinylates the transgene-encoded
Avi-tagged Gata1 and Oct6 transcription factors in erythroid cells of the foetal liver and Schwann cells of the
peripheral nerve respectively. Therefore, this mouse can be crossed to any transgenic mouse to obtain
efficient biotinylation of an Avi-tagged protein for the purpose of protein (complex) purification.
Introduction
Many different affinity purification techniques
have been developed to study protein complexes
and identify individual molecules interacting with-
in these complexes. One important experimental
strategy is to fuse a protein of interest with a tag
for which specific high affinity reagents are readily
available. Examples of such tags include the
maltose binding protein, the haemagglutinin
(HA)-tag, the TAP-tag, the FLAG-tag, the Histi-
dine-tag and the Avi-tag (Rigaut et al., 1999;
Terpe, 2003). Of particular interest is the
Avi-tag. This short (15aa) peptide sequence
contains a central Lysine residue that can be
biotinylated at the epsilon nitrogen by the bacte-
rial BirA biotin ligase. Co-expression of a tagged
protein and the BirA gene in cells results in a
highly specific, quantative biotinylation of the
tagged protein (Beckett et al., 1999). Proteins thus
biotinylated can be purified from complex sources,
such as mammalian cell extracts, in a simple single
step procedure that takes advantage of the very
high affinity of the biotin moiety for avidin or
streptavidin (Cull & Schatz, 2000). The extraordi-
nary power of this approach has been demon-
strated in a number of recent publications
(Beckett et al., 1999; Chapman-Smith & Cronan,
1999; Cull & Schatz, 2000; de Boer et al., 2003). As
future applications of this technology will include
the study of complex protein interactions in
*Author for correspondence
E-mail: d.meijer@erasmusmc.nl




developing and adult mouse tissues it is advanta-
geous to develop a mouse strain that will express
the bacterial BirA gene in all cell types of the body
at all developmental stages. This mouse would
then serve as a generic strain that can be crossed
with any transgenic mouse expressing an Avi-
tagged protein, resulting in biotinylation of that
protein.
In the studies presented here, we have gener-
ated a transgenic mouse expressing BirA from the
ROSA26 locus. We show the ubiquitous expres-
sion of BirA and present proof for principle of in
vivo biotinylation of the Avi-tagged Gata1 and
Oct6 transcription factors in compound transgenic
foetal liver cells and postnatal Schwann cells,
respectively.
Results and discussion
We chose to introduce the BirA gene in the
ROSA26 transcription unit, as this gene is active
in all cells at all stages of development
(Zambrowicz et al., 1997). Furthermore, disrup-
tion of the ROSA26 gene does not result in any
cellular defect in the heterozygous or homozygous
state (Zambrowicz et al., 1997). To reprogram the
ROSA26 gene we first introduced the BirA gene in
the third exon of the rabbit b-globin gene. We
then excised the whole exon, containing the BirA
ORF, splice acceptor and transcription termina-
tion sequences, and introduced it together with a
LoxP flanked puromycin selection cassette, into
the first intron of the ROSA26 construct (target-
ing construct in Figure 1(a)). Homologous recom-
bination into the ROSA26 gene will result in a
chimaeric gene in which transcripts are initiated
from the ROSA26 promoter and the ROSA26 first
exon splices to the b-globin third exon.
Transcription is terminated downstream of the
b-globin exon and the primary transcripts are
cleaved and polyadenylated resulting in a short
chimaeric stable mRNA encoding the BirA protein
(data not shown).
The targeting construct was transfected into ES
cells and puromycin resistant clones were selected.
Homologous recombinants were identified by
Southern blot analysis of EcoRI digested DNA
probed with probe1 and probe2 (Figure 1(b)).
Results for two independent clones are presented
in Figure 1(B). Approximately 50% of puromycin
resistant clones resulted from correct homologous
recombination events.
We next checked whether the BirA protein is
expressed in these correctly targeted clones. As
BirA was extended at the amino-terminal portion
with a triple HA-tag, we could detect the protein
using a HA antibody. In preliminary experiments
we had determined that the presence of the triple
HA-tag does not abolish the biotin ligase activity
of the BirA protein (data not shown). As shown in
Figure 1(c) a protein of correct size (�39 kD) is
expressed in the correctly targeted ES cell lines.
From these cell lines mouse strains were estab-
lished. These mice were crossed with a Cre deleter
mouse to remove the puromycin selection cassette
(see Figure 1(a)) and were examined for expression
of the BirA protein. Tissues were dissected from
mouse pups at postnatal day 8 and subjected to
Western analysis. As shown in Figure 1(d), BirA is
expressed in all tissues examined. Although BirA is
expressed in all tissues, expression levels vary from
tissue to tissue as has been reported for the
ROSA26 transcripts (Zambrowicz et al., 1997).
Next we wished to establish whether the
expression level of BirA is sufficient to biotinylate
a tagged protein in a mouse tissue. We chose two
different Avi-tagged transcription factor genes
expressed in different tissues to establish the
feasibility of our approach. One is an Avi-tagged
Gata1 transgene expressed in the erythroid lineage
(Elefanty et al., 1996). The second is an Avi-tagged
Oct6 allele (Oct6Avi) that has been generated by
gene targeting and is expressed in the Schwann
cells of the developing peripheral nervous system.
Breedings were initiated between heterozygous
BirA (ROSA26HABirA/+) and heterozygous AviG-
ata1 (tg[AviGata1/+]) mice or heterozygous
Oct6Avi/+ to obtain compound heterozygous mice
(Figure 2(a)). Since the Gata1 transgene is highly
expressed in proerythrocytes in foetal liver of the
mouse (Ohneda & Yamamoto, 2002), we recov-
ered embryos at day 13.5 of gestation and
prepared single cell smears from foetal livers.
AviGata1 and endogenous Gata1 expression in
both AviGata1 and AviGata1:BirA cells was
detected using a monoclonal antibody against the
Gata1 protein (Figure 2(b), panels a and c). The
AviGata1 protein could not be detected in foetal
liver cells of single transgenic AviGata1 mice using
fluorescein conjugated Avidin indicating that the
Avi-tag is not a target for endogenous biotin
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ligases (Figure 2(b), panel b). Furthermore, endog-
enous biotinylated proteins, such as carboxylases,
are not detected by the fluorescein-Avidin under
the conditions used here. In contrast, biotinylated
AviGata1 protein could readily be detected in
foetal liver cells of compound AviGata1:BirA mice
using fluorescein conjugated Avidin (Figure 2(b),
panel d). The fluorescein signal overlaps with the
Gata1 signal (Cy5 signal, panel c) indicating that
indeed AviGata1 is biotinylated and not another
endogenous target protein.
To further demonstrate biotinylation of Gata1
and to examine the extent of this biotinylation,
we performed electrophoretic mobility shift
assays (EMSA) using foetal liver extracts of
transgenic mice and a 32P labelled double
stranded oligonucleotide containing a Gata1
binding site (Figure 2(c)). Foetal liver cells of
transgenic AviGata1 mice express one specific
complex containing Gata1 and AviGata1 that can
be shifted to a higher position in the gel using a
Gata1 specific antibody (Figure 2(c), lanes 1 and
2). As expected, the Gata1 complex is not shifted
in the presence of streptavidin indicating that
AviGata1 is not biotinylated (Figure 2(c), lane 3).
Furthermore, this result illustrates the fact that
the Avi-tag is not a target for endogenous biotin
ligases. Next, we similarly examined foetal liver
Figure 1. (a) Schematic representation of the targeting strategy. The ROSA26 locus contains the ROSA26 gene that generates two
transcripts through alternative splicing of exon 2 and 3 and one anti-sense uncharacterised four-exon gene. The 3xHABirA gene
was cloned into the EcoRI (R) and BglII (B) site of the rabbit b-globin third exon including the splice acceptor sequences (450 bp)
and termination/polyadenylation sequences. At the 3¢ end a LoxP site flanked PGK puromycin selection cassette was introduced.
The resulting fragment was cloned into the unique NheI (Nh) site of the ROSA26 targeting cassette that covers 13 kb of ROSA26
homologous DNA from the NotI (N) site to the NsiI (Ns) site. Homologous recombination results in introduction of the HABirA
encoding exon and the selection cassette in the first intron of the ROSA26 gene. Subsequent removal of the LoxP flanked puromy-
cin selection cassette results in the situation depicted in Figure 1(a): B, BamHI; C, ClaI; S, SalI. (b) Homologous recombinants
were selected by Southern blot analysis of EcoRI digested DNA using probe1 and probe 2. The length of the expected restriction
fragments is indicated in Figure 1(a). The targeting efficiency was around 50%. Two correctly targeted ES cell clones that were in-
jected into mouse blastocyst embryos and implanted into a foster mouse are presented here. (c) Western blot analysis of targeted
ES cell clones. In correctly targeted ES cells, transcription from the ROSA26 promoter will result in a chimaeric mRNA encoding
the HABirA protein. The HA antibody detects a protein of expected size, 39 kD, in cell extracts of clone 13 and 28 but not in ex-
tracts of non-targeted ES cells (ES). (d) Western blot analysis of HABirA expression in tissues of ROSA26HABirA/+ mice. Protein
extracts (12.5 lg) from tissues dissected from postnatal day 8 mice were size separated on a 10% SDS-polyacrylamide gel and blot-
ted onto nitrocellulose paper. The HA antibody recognises a 39 kD protein in all tissues tested.
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extracts from AviGata1:BirA compound trans-
genic embryos. Addition of the Gata1 antibody
to the EMSA reaction results in one extra lower
mobility complex (Figure 2(c), lanes 4 and 5). It
appears that most of the AviGata1 protein
present is biotinylated as most of the AviGata1
protein is shifted to a higher mobility by incor-
poration of streptavidin in the complex (Fig-
ure 2(c), lane 6). The remaining Gata1 complex
represents endogenous Gata1 protein that does
not contain an Avi-tag and therefore does not
interact with streptavidin.
In a second set of experiments we analysed the
biotinylation of Avi-tagged Oct6 protein expressed
from the endogenous Oct6 locus. As Oct6 is
expressed in postnatal Schwann cells we isolated
sciatic nerves from mouse pups at postnatal day 4
(Scherer et al., 1994) and analysed biotinylation of
Avi-Oct6 by Western blotting and purification
(Figure 2(d) and (e)). Using Avidin-HRP as a
probe we detect a 55 kD band corresponding to
biotinylated Oct6 protein (Oct6bio in Figure 2(d))
in nerves of compound heterozygous mice
(Oct6Avi/+: ROSA26HABirA/+ but not in single
Oct6Avi/+, ROSA26HABirA/+ or wildtype mice
(Figure 2(d)). Expression of BirA in sciatic nerve
is detected using an HA antibody. Expression of
the BirA and Oct6Avi transgenes do not affect
peripheral nerve development as judged by the
normal high level expression of the major periph-
eral Myelin Protein Zero (MPZ in Figure 2(d)).
Furthermore, biotinylated Oct6 could be readily
purified from nerve extracts of compound hetero-
zygous animals (Figure 2(e)).
From these experiments we conclude that the
BirA mouse strain is an excellent generic strain to
obtain biotinylation of an Avi-tagged transgenic
protein or endogenous protein that is extended
with an Avi-tag through gene targeting. As such,
this mouse might prove very useful in a wide
range of studies in which complex interactions
need to be studied in the developing or adult
animal. One potential drawback of this particular
mouse strain is that proteins that are translated
on the endoplasmic reticulum bound ribosomes
and are entering the secretory pathway, will not
be efficiently biotinylated by the BirA protein
which is located largely in the cytoplasm. Parrot
and Barry (2001) have recently shown that
proteins in the secretory pathway can be effi-
ciently biotinylated provided that the BirA pro-
tein itself is extended with a signal peptide that
will direct the protein into the secretory pathway.
The generation of such a mouse following the
same strategy described here is under way and
will allow future studies on proteins or protein
domains that function outside the cell or within
the secretory pathway itself.
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Figure 2. (a) Crossing scheme: Male ROSA26HABirA/+
mice were crossed with female tg[AviGata1] or Oct6Avi/+ mice
to obtain the genotypes depicted. (b) Foetal liver cells were
prepared from E13,5 embryos of the genotype indicated and
prepared for immunohistochemistry. A monoclonal antibody
against Gata1detects the Gata1 protein in the nucleus of ery-
throid cells (panels a and c). The transgenic AviGata1 protein
can be detected with fluorescein conjugated avidin when co-
expressed with BirA (d) but not when BirA is not expressed
(b). (c) Electrophoretic mobility shift assay. Gata1/DNA com-
plexes were resolved on a 4% native polyacrylamide gel and
visualised. Inclusion of a Gata1 specific antibody results in a
ternary complex that migrates slower through the gel (Gata1/
ab SS in lane 2 and 5). Inclusion of streptavidin results in a
ternary complex with reduced mobility (Gata1/S.avidin SS) in
foetal liver extracts of compound AviGata1:BirA embryos
(lane 6). This complex is not formed in transgenic animals
that do not express the HABirA protein (lane 3). The Gata1
complex in lane 6 represents endogenous Gata1 protein that
does not contain an Avi-tag. (d) Biotinylation of Avi-tagged
Oct6 in Schwann cells of the sciatic nerve at postnatal day 4.
Sciatic nerves were dissected from mice with the indicated
genotype and directly extracted in loading buffer. Proteins
were size separated on a 10% SDS-polyacrylamide gel and
transferred to nitrocellulose by electroblotting. Expression of
BirA is detected using an HA antibody. Biotinylated Oct6 is
detected using Avidin coupled to HRP and myelin P-zero is
detected using the mouse monoclonal antibody P07 (Archelos
et al., 1993). (e) Sciatic nerves of ROSA26HABirA/+:Oct6Avi/+
compound heterozygous animals were extracted in a buffer
(20 mM Hepes-KOH, pH 7.6, 400 mM KCl, 1 mM DTT,
10% glycerol) by three freeze-thaw cycles. Biotinylated pro-
teins were purified from this extract using magnetic streptavi-
din beads (Dynal), size separated on a 10% SDS-
polyacrylamide gel and transferred to nitrocellulose. Biotiny-
lated Oct6 is detected by Avidin coupled HRP in the bound
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Abstract
Mice homozygous for the autosomal recessive mutation claw paw (clp) are characterized by limb posture abnormalities and congenital
hypomyelination, with delayed onset of myelination of the peripheral nervous system but not the central nervous system. Although this
combination of limb and peripheral nerve abnormalities in clp/clp mice might suggest a common neurogenic origin of the syndrome, it is not
clear whether the clp gene acts primarily in the neurone, the Schwann cell or both. In the work described here, we address this question of cell
autonomy of the clp mutation through reciprocal nerve grafting experiments between wild-type and clp/clp animals. Our results demonstrate
that the clp mutation affects the Schwann cell compartment and possibly also the neuronal compartment. These data suggest that the clp gene
product is expressed in Schwann cells as well as neurones and is likely to be involved in direct axon–Schwann cell interactions. Within the
Schwann cell, clp affects a myelin-related signaling pathway that regulates periaxin and Krox-20 expression, but not Oct-6.
D 2004 Elsevier Inc. All rights reserved.
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Introduction
Congenital limb posture abnormalities in humans and
other vertebrates occur under a variety of circumstances and
clinically manifest as a singular abnormality or as part of a
syndrome. In clinical practice, such abnormalities are de-
scribed as arthrogryposis multiplex congenita (AMC;
arthron = ‘‘joint’’ and gryposis = ‘‘bent’’). It is generally
accepted that any condition resulting in reduced fetal
movement will lead to joint contractures in newborns
(Drachman, 1971; Hageman and Willemse, 1983; Hall,
1997). In principle, such conditions could be extrinsic or
intrinsic to the developing fetus. An example of the former
is provided by experiments in which chick or rat embryos
were paralyzed by injection with curare, causing limb
posture abnormalities at birth (Del Torto et al., 1983;
Drachman and Coulombre, 1962; Moessinger, 1983). Ad-
ditionally, maternal antibodies that functionally inhibit the
fetal acetylcholine receptor cause arthrogryposis in human
fetuses (Jacobson et al., 1999; Matthews et al., 2002; Polizzi
et al., 2000).
Intrinsic causes of reduced fetal movement can be classi-
fied as either myogenic and/or neurogenic in origin. In
several clinical cases, AMC was found associated with
congenital hypomyelination of the peripheral nerves suggest-
ing a common aetiology (Boylan et al., 1992; Charnas et al.,
1988; Seitz et al., 1986). In the peripheral nervous system,
myelin formation and maintenance of the peripheral nervous
system by Schwann cells is dependent on continuous recip-
rocal interactions between the axon and Schwann cell (Fields
and Stevens-Graham, 2002). Mutations that affect this dia-
logue by disabling function in the Schwann cell, the axon or
in both result in dys- or demyelinating neuropathies as in the
human hereditary motor and sensory neuropathies (Suter and
Scherer, 2003). Limb posture abnormalities, mostly pes
cavus, and distal muscle wasting frequently develop in these
patients as consequence of axonal loss.
Congenital limb posture abnormalities are observed in
mice homozygous for the murine autosomal recessive
mutation claw paw (clp) (Henry et al., 1991). In affected
0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2004.05.017
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animals, the forelimbs are flexed at one or more of the joints
(shoulder, wrist or digital joints) but extended at the elbow,
resulting in the forelimbs pointing in the direction of the
hindlimbs. These abnormalities are visible within 2 days of
birth. More severely affected animals also show involve-
ment of one or both hindlimbs. Pathological examination of
affected animals demonstrates severe congenital hypomye-
lination with delayed onset of myelination of the peripheral
nerves with central nerves unaffected. Persistently blocked
myelination is observed in a fraction of the smaller axons
(Henry et al., 1991). Additionally, it was found that the
mean internodal length is greatly reduced for all axonal size
classes in clp/clp nerves when compared to heterozygous or
wild-type animals (Koszowski et al., 1998). The clp gene
has not been identified yet, although mapping studies have
placed the gene close to the Gpi locus on mouse chromo-
some 7 (Henry et al., 1991). No mutations were found in the
myelin-associated glycoprotein (MAG) gene, close to the
Gpi locus, excluding this gene as a clp candidate (Niemann
et al., 1998). The pathology of the clp/clp mouse is
strikingly similar to the clinically described cases of AMC
mentioned above. Hence, clp/clp mice provide an opportu-
nity to study the basis of the relationship between arthrog-
ryposis and hypomyelination.
It has been hypothesized that the clp gene is part of the
neurone–glia signaling system that governs myelination
initiation during development. However, it is not known
what cellular and molecular components of this signaling
system are affected by the clp mutation. To further charac-
terize this mutant mouse, we set out to determine whether
the gene acts in the neurone, the Schwann cell or both,
through reciprocal nerve graft experiments. Additionally, we
studied the interaction of the clp gene with many known
Schwann cell autonomous regulatory genes involved in
myelination including the transcription factors Oct-6 and
Krox-20 (Topilko and Meijer, 2001). Our results indicate
that clp function is required within the Schwann cell as well
as in the neurone. Upregulation of the promyelin transcrip-
tion factor Oct-6 is not affected by clp, while the subsequent
Krox-20 activation is delayed. Additionally, embryonic
periaxin expression is absent or reduced in clp/clp Schwann
cells and postnatal expression is delayed. Taken together,
these results suggest that clp is involved in neurone–glia
interactions and furthermore that, within the Schwann cell,
clp is involved in a pathway that regulates periaxin and
Krox-20 expression. This clp-dependent pathway is parallel




Nerve crush experiments were performed on young adult
F2 animals from a C57BL6J/Balbc-clp heterozygous inter-
cross. Affected and non-affected mice were anesthetized by
inhalation of halothane and placed on a heating pad. The left
sciatic nerve was exposed and crushed for two times 15 s at
mid-femoral level using No.5 Biology forceps. Mice were
sacrificed 4 weeks after the operation through trans-cardiac
perfusion with a solution of 1% gluteraldehyde/3% parafor-
maldehyde in 100 mM cacodylate (pH 7.4). The operated
and contralateral nerve was isolated for light and electron
microscopic analysis.
Transplantation experiment
Reciprocal nerve grafting experiments were performed
between wild type and wild type (wt:wt), wild type and
clp/clp (wt:clp), clp/clp and wild type (clp:wt) and between
clp/clp and clp/clp (clp:clp). All animals were of C57BL6J
background, obviating the use of immune-suppressants to
prevent graft rejection. Operations were performed on two
animals at a time, both animals serving as nerve donor and
recipient. Two mice of appropriate genotype were anesthe-
tized through inhalation of halothane and placed on a
heating pad. The left sciatic nerve was exposed in both
animals. Approximately 7.5 –10 mm of nerve was excised
and placed in the same orientation in the host animal. Nerve
and muscle tissue were kept wet by regular application of a
drop of sterile phosphate-buffered saline (PBS). The nerves
were sutured at both the proximal and distal anastomosis site
with two 10-0 black filament sutures. The retracted muscles
were placed back in position and the skin was sutured. All
surgical manipulations were done under a microscope.
Animals were transferred to a clean cage and allowed to
recover under a heating lamp. Animals were carefully
monitored for wound healing on a daily basis. Four weeks
after transplantation, animals were sacrificed.
Perineurium permeability
A 1% Evans Blue (Sigma) solution in 5% bovine serum
albumin (fraction V)/PBS (pH 7.4) was dialyzed overnight
in PBS. The sciatic nerves of an adult claw paw animal and
a wild-type littermate were dissected out and placed imme-
diately in 4 ml of Evans blue albumin (EBA) solution at
room temperature. After a 30- or 60-min incubation period,
nerves were briefly washed in PBS and fixed in 4%
paraformaldehyde for 2 h. Nerves were cryoprotected in
30% sucrose/PBS, frozen and sectioned at 24 Am. Sections
were mounted in VectashieldR (Vector laboratories) and
viewed immediately under a fluorescence microscope.
Quantitative RT-PCR
Total RNAwas extracted from sciatic nerves using RNA-
Bee (Tel Test Inc.). First-strand cDNA was generated using
Superscript II (Invitrogen) reverse transcriptase and oligo-
dT as primer. The following primers were used to amplify
dhh and cyclophilin transcripts: dhh forward, CATGTGGC-
A. Darbas et al. / Developmental Biology 272 (2004) 470–482
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CCGGAGTACGCC; dhh reverse, CGCTGCATCAGCG-
GCCAGTA; cyclophilin forward, GGTCAACCCCAC-
CGTGTTCTTCGACAT; cyclophilin reverse, GGACAA-
GATGCCAGGACCTGTATGCT. Annealing temperature
for dhh primers: 60jC, annealing temperature for cyclo-
philin primers 68jC. Aliquots were taken from the reaction
with two cycle intervals and amplification products were
analyzed on a 1.8% agarose gel.
Light/electron microscopy
Anesthetized animals were sacrificed through transcar-
dial perfusion with PBS (pH 7.4) for 3 min followed by
fixative [3% PFA (Sigma); 1% glutaraldehyde (Sigma) in
100 mM cacodylate buffer, pH 7.2] for 10 min. Sciatic
nerves were isolated, fixed overnight in the same fixative at
4jC. The next day, nerves were rinsed with 0.2 M cacody-
late buffer, osmicated in 1% osmium tetroxide solution and
embedded in Epon. Sections (1 Am) of Epon-embedded
sciatic nerves were mounted on glass slides and stained with
methylene blue. Ultra-thin cross sections from nerve grafts
at mid-graft level were cut and uranyl acetate and lead
citrate stained for electron microscopic analysis (Philips
CM100).
Nerve conduction velocities
Nerve conduction velocities were measured on the tail
nerve of anesthetized animals. Animals were placed on a
thermo-comfort heating pad at 38jC. Recording and stim-
ulation electrodes were made of 300-Am tungsten needles
with a 10-Am tip. The stimulus frequency and stimulation
period was 1 Hz and 0.1 ms, respectively. Impedance of the
recording electrode was 100 and 25 kV/kHz for the stim-
ulation electrode.
Immunohistochemistry
Rabbit polyclonal antibodies used in this study are direct-
ed against Oct-6 (Jaegle et al., 2003), Periaxin (Scherer et al.,
1995) andKrox-20 (1:400). The Krox-20 antibodywas raised
against the unique amino-terminal portion of the protein
(amino acids 1–180). Animals were immunized with
6xHis-tagged Krox-201–180 protein expressed in E. coli
(M15 strain) and purified on Ni2+-NTA-agarose beads (QIA-
GEN). Mouse monoclonal antibodies used were against P-
zero (1:1000) (Archelos et al., 1993) and neurofilament
medium chain (1:200, hybridoma 2H3, Developmental Stud-
ies Hybridoma Bank).
Embryos and tissues were isolated, fixed in a mixture of
methanol, acetone, acetic acid and water (35:35:5:25) for 1
h at 4jC, embedded in paraffin and sectioned at 7 Am. After
dewaxing, tissue sections were hydrated and blocked in 1%
BSA, 0.05% Tween-20 in PBS. Rabbit antibodies and
mouse monoclonal antibodies were incubated simultaneous-
ly in PBS/0.05% Tween-20 overnight at room temperature.
Oregon Green-conjugated goat anti-rabbit IgGs (Molecular
Probes) and Texas Red-conjugated goat anti-mouse IgGs
(Molecular Probes) were subsequently used as secondary
antibodies. The tissue was viewed using a Leica fluores-
cence microscope.
Results
Morphological examination of clp nerves and comparison
with Oct-6 mutant nerves
Our interest in the clp mouse mutant was initially raised
by the similarities in peripheral nerve phenotypes between
claw paw mice and Oct-6 transcription factor mutant mice
(Bermingham et al., 1996; Henry et al., 1991; Jaegle et al.,
1996). Both mice are characterized by delayed initiation of
myelination of their peripheral nerves. The similarities
between these phenotypes suggested several possible inter-
actions between the Oct-6 and clp genes. For example, it is
possible that the clp gene product is involved in those
signaling pathways that activate Oct-6 or, clp could be a
major regulatory target of Oct-6. Alternatively, clp could act
in a non-redundant pathway parallel to Oct-6. To begin to
answer these questions, we first compared nerve morpho-
logy in both mutant and wild-type mice at several postnatal
stages of development. Previously, nerve morphology in
clp/clp animals has been described only from postnatal day
14 (P14) onwards (Henry et al., 1991). Therefore, we
extended this analysis to include earlier stages of nerve
development. Fig. 1 shows a comparison of representative
transverse sections through the sciatic nerve of animals of
different genetic background at different stages of postnatal
development.
The sorting of prospectively myelinated axonal fibers by
Schwann cells during late fetal development culminates in
the promyelin stage of cell differentiation in which a
Schwann cell has established a one to one relationship with
its axon. These cells will exit the cell cycle, elaborate a basal
lamina and initiate myelination. The majority of myelin-
competent cells transit through this stage during the first
week of postnatal life. This is evident in transverse section
of the wild-type sciatic nerve at birth, in which many
promyelin cells can be observed with some cells already
actively myelinating (Fig. 1A, panel a). By P8, a majority of
cells is actively myelinating and at P16 almost all myelin-
competent cells are in an advanced stage of myelination
(Fig. 1A, panels d and g). In contrast to wild-type, clp/clp
Schwann cells are still at a very immature sorting stage at
birth (Fig. 1, panel b). Most Schwann cells are found at the
periphery of naked axon bundles, with cellular extensions
pioneering into the bundles. This configuration of Schwann
cells and naked axon bundles is typically observed in
embryonic nerves around mouse embryonic day 17 (E17)
(Feltri et al., 2002). To illustrate this developmental stage of
clp/clp Schwann cells more graphically, we traced the
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outline of several cells in a P1 nerve highlighting the
cytoplasmic extensions of the sorting Schwann cell (Fig.
1B). One week later, these axon bundles are sorted out and a
majority of Schwann cells have acquired a promyelin
configuration (Fig. 1, panel e). Over the next week, many
promyelin cells initiate myelination, such that by P16, a
large number of myelin figures are observed. However, a
substantial number of Schwann cells are still at the promye-
lin stage of cell differentiation, suggesting that this transition
occurs at a lower rate in clp/clp Schwann cells than in wild-
type Schwann cells (Fig. 1, panel h). By P32, the majority of
clp/clp Schwann cells are actively meylinating with only
few cells remaining in the promyelin configuration (data not
shown and Henry et al., 1991). In contrast to clp/clp
Schwann cells, Oct-6 mutant Schwann cells transit through
the sorting stage of development normally, but then stall at
the promyelin stage for several days before initiating myeli-
nation (Fig. 1A, panels c, f and i). Thus, clp/clp Schwann
cells appear strongly inhibited in the sorting stage of nerve
development and to a lesser extent in the promyelinating to
myelinating transition.
One other remarkable difference between clp/clp nerves
and Oct-6 mutant nerves (and wild-type nerves) is the
extensive fasciculation of the former. Division of the endo-
neurium by flattened, perineurial-like cells is already appar-
ent at P8 in clp/clp nerves (Fig. 1A, panel e). As illustrated
in Fig. 2A, these cells contain, like perineurial sheath cells,
many caveolae and secrete a basal lamina (arrows and
arrowheads, respectively, in Fig. 2A, panel a). The number
of cell layers that make up the perineurium and the mor-
phology of the perineurial cells appear normal in clp/clp
nerves at P16 and adult (Fig. 2A, panel b, and data not
shown). The hyper-fasciculation phenotype observed in clp/
clp peripheral nerves is reminiscent of that observed in dhh
mutant animals (Parmantier et al., 1999). Therefore, it is
possible that this particular aspect of the claw paw pheno-
type results from a failure to express dhh in the developing
nerve. We therefore examined expression of dhh mRNA in
clp/clp and wild-type nerves at P12 using quantitative PCR
normalized to cyclophilin expression. We found that dhh is
expressed in P12 clp/clp nerves, albeit at reduced levels
(Fig. 2B). It is therefore possible that the extensive subdi-
vision of clp/clp nerves by perineurial sheath cells is a
consequence of reduced dhh expression. It has been hy-
pothesized that the hyperfasciculation of dhh mutant nerves
results from a functionally defective perineurium (Parmant-
ier et al., 1999). A major function of the perineurium is to
prevent the invasion of cells and macromolecules from the
surrounding tissue into the endoneurium (Thomas et al.,
1993). This nerve–tissue barrier function of the perineurium
is compromised in dhh mutant animals as evidenced by the
penetration of dye loaded serum albumin into the endoneu-
Fig. 1. Abnormal development of peripheral nerves in clp/clp and Oct-6 mutant mice. (A) Shown are representative micrographs of transverse sections of
sciatic nerves from wild-type, clp/clp (claw paw) and Oct-6 mutant (Oct-6hgeo/hgeo) animals at P1 (a, b and c), P8 (d, e and f ) and P16 (g, h and i). At P1,
axonal sorting is well advanced in wild-type nerves, with many axons in a 1:1 relationship with Schwann cells and few in an early myelinating stage (a). In
contrast, axonal sorting in clp/clp nerves is in a very early stage with large groups of unsorted axons (b). Sorting in Oct-6 mutant nerves is well advanced with
most cells in a late sorting and promyelin stage (c). At P8, the majority of myelin-competent Schwann cells in wild-type nerves are actively engaged in
myelination (d), while in clp/clp nerves Schwann cells have now adopted a promyelin configuration (e). At this time, most Oct-6 mutant Schwann cells are
still at the promyelin stage of differentiation (f ). At P16, myelination is well advanced in wild-type nerves (g). In contrast, only a fraction of clp/clp, and Oct-6
mutant, Schwann cells have progressed to the myelinating stage of differentiation with many cells still at the promyelin stage (h and i). Scale bar: (a–c) 1.6
Am; (d– f ) 2.8 Am; (g– i) 5 Am. (B) Axonal sorting is delayed in nerves of clp/clp (claw paw) mice. In this representative micrograph, clp/clp Schwann cells
are just beginning to send out processes in the axon bundles. The outline of sorting Schwann cells is traced with a colored pencil. Each color represents an
individual Schwann cell. Scale bar: 2 Am.
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rium (Parmantier et al., 1999). We similarly tested the
integrity of the tissue–nerve barrier in claw paw nerves.
After 1 h exposure to a Evans blue albumin solution ex
vivo, nerves were processed for fluorescence microscopy.
No dye complex had penetrated the endoneurium of wild-
type or claw paw nerves (Fig. 2C, panels a and b, respec-
tively) demonstrating that, in contrast with dhh mutant
nerves, the nerve–tissue barrier in claw paw mice is intact.
Thus, clp/clp nerves resemble dhh mutant nerves in their
extensive subdivision into smaller fascicles by perineurial
sheath cells but have, unlike dhh mutant nerves, a function-
ally intact perineurium.
Activation of Oct-6 expression in clp/clp nerves
As previous work has demonstrated that the transcription
factors Oct-6 and Krox20 are major cell-autonomous regu-
lators of the Schwann cell myelination program, it is
possible that the delayed myelination phenotype in clp/clp
nerves can in part be explained by a failure to activate Oct-6
and subsequently Krox-20, in clp/clp animals (Ghislain et
al., 2002). We therefore examined expression of Oct-6,
Krox-20 and the myelin proteins P-zero and periaxin in
clp/clp animals at P8 and P16 by immunohistochemistry and
compared it with the expression of these proteins in wild-
type and Oct-6 mutant Schwann cells (Fig. 3). At P8, most
clp/clp Schwann cells are, like most Oct-6 mutant cells, at
the promyelin stage of cell differentiation (see Fig. 1) and
will commence myelination in the course of the next 2
weeks. As shown in Fig. 3A, Oct-6 is expressed in Schwann
cells of clp/clp animals at P8. This is in agreement with
previous mRNA expression data (Bermingham et al., 2002).
As reported earlier, Oct-6 is an upstream regulator of Krox-
20 and hence, Oct-6 mutant Schwann cells do not express
Krox-20 (Ghazvini et al., 2002; Ghislain et al., 2002).
Despite the expression of Oct-6 in clp/clp Schwann cells,
Krox-20 is not expressed at P8, but eventually is activated in
clp/clp nerves (and Oct-6 mutant nerves) when myelination
proceeds (Ghazvini et al., 2002 and Fig. 3B, panel a). As
expected, P-zero expression is very low in both mutant
mouse strains at P8, as the majority of Schwann cells have
not yet produced compact myelin (Fig. 3A, panels h and i).
However, at P16, clp/clp nerves show strong P-zero immu-
noreactivity in myelin-forming Schwann cells (Fig. 3B,
panel b). Interestingly, the myelin protein periaxin appears
reduced or misexpressed in clp/clp Schwann cells at P8.
This is in contrast to promyelin-arrested Oct-6 mutant
Schwann cells in which periaxin is expressed at near normal
levels (panels j, k and j). However, once clp/clp cells form
compact myelin, high levels of periaxin are observed in
these cells (Fig. 3B, panel c). Thus, in contrast to Oct-6
mutant Schwann cells, periaxin protein does not accumulate
in promyelin-arrested clp/clp Schwann cells suggesting that
the clp mutation affects activation of periaxin expression or
subcellular localization and/or processing.
To distinguish between these possibilities, we further
examined periaxin expression at late fetal stages of deve-
lopment in clp/clp and wild-type animals. Periaxin is first
expressed in the nuclei of embryonic Schwann cells at E14.
By E17, periaxin expression shifts to the cell membrane and
by E18, periaxin is no longer found in the nucleus (Sherman
and Brophy, 2000). We examined periaxin expression in
clp/clp Schwann cells of embryonic nerves at E17, the stage
at which claw paw animals can first be recognized. No
periaxin is detected in clp/clp nerves at this stage (Fig. 4A,
panel d). In contrast, wild-type Schwann cells express
periaxin in the nucleus and/or in the cytoplasm (Fig. 4A,
panel c). Thus, the clp mutation affects onset of periaxin
expression at this embryonic stage and subsequently, also
the subcellular localization of the periaxin protein.
Fig. 2. Morphological and functional characterization of the perineurium of claw paw nerves. (A) Perineurial-like cells subdivide the endoneurium of claw paw
nerves (panel a). This electron micrograph shows the typical flattened extensions of perineurial-like cells studded with numerous caveolae (arrows) and the
basal lamina produced by these cells (arrowheads). Schwann cells (Sc) and the nucleus of a perineurial cell (P) are indicated. The number of cellular layers and
the morphology of the perineurial cells appear normal in the developing perineurium of claw paw nerves (panel b). The epineurium is poorly defined at this
stage and later stages. Scale bar: 500 nm. (B) dhh mRNA expression is reduced in claw paw nerves. Expression levels of dhh were estimated using quantitative
RT-PCR during the exponential phase of the reaction and normalized against cyclophilin (cyclo), a housekeeping gene expressed at rather constant levels.
Samples were taken with two-cycle intervals. It is estimated that dhh mRNA levels are 4- to 16-fold lower in claw paw nerves at P12. (C) The nerve– tissue
barrier function of the perineurium is intact in claw paw nerves. Following submersion of dissected sciatic nerve of wild-type (panel a) or claw paw nerve
(panel b) for 1 h in EBA solution, EBA is found associated with the epi- and perineurial sheath of the nerve (arrows). EBA did not penetrate the endoneurium
of wild-type or claw paw nerves (asterisk). However, strong EBA staining is seen within muscle tissue lying next to the nerve (arrowhead).


























We next examined whether Oct-6 is also delayed in its
onset of expression. Oct-6 protein normally starts to accu-
mulate in the nuclei of immature Schwann cells of the
sciatic nerve at late fetal stages and reaches maximum levels
in promyelin cells during the first postnatal week of deve-
lopment. As clp/clp Schwann cells at P1 morphologically
resemble Schwann cells in E16–E17 wild-type embryonic
nerves, we examined Oct-6 expression in P1 clp/clp nerves.
At this stage, we found that clp/clp Schwann cells already
express appreciable levels of Oct-6 (Fig. 4B, panel b),
demonstrating that the clp gene product does not affect
activation of Oct-6 expression. In contrast to wild-type Oct-
6-positive Schwann cells, Oct-6-positive clp/clp Schwann
cells do not express appreciable levels of P-zero protein
(Fig. 4B, panels c and d).
Taken together, these data demonstrate that the clp
mutation affects nerve maturation through a pathway that
includes activation of periaxin, but not Oct-6, and thus
strongly suggest that during Schwann cell differentiation,
periaxin and Oct-6 are regulated through distinct signaling
pathways.
Nerve conduction velocities of clp nerves are reduced
The delayed maturation of peripheral nerves in clp/clp
animals results in reduced internodal lengths for all diameter
classes and thus, in the absence of axonal loss, increased
Schwann cell numbers. In addition, myelin thickness is
reduced in some, but not all, clp/clp animals and no decrease
in mean axon diameter was reported (Henry et al., 1991;
Fig. 3. Developmental expression of Oct-6, Krox-20, P-zero and periaxin in clp/clp and Oct-6mutant nerves. (A) Transverse sections of sciatic nerves of clp/clp
(claw paw), Oct-6 mutant (Oct-6DSCE/DSCE) and control (wild-type) mice at P8 were stained for Oct-6 (a–c), Krox-20 (d–e), P-zero (g– i) and periaxin (j – l). In
the control nerve, myelinating Schwann cells express Oct-6, Krox-20 and the myelin proteins P-zero and periaxin (a, d, g and j). At P8, most clp/clp Schwann
cells have adopted a promyelin configuration and express Oct-6 (b) but not the myelination-associated transcription factor Krox-20 (f ). Some cells express
appreciable levels of P-zero. These cells are probably in an advanced promyelin stage as there is no evidence of compact myelin yet at this stage (h). Very low
cytoplasmic periaxin expression is observed in many, but not all, cells (k). Few cells exhibit high level of periaxin expression. No nuclear periaxin staining is
observed at this stage. Like clp/clp Schwann cells, Oct-6 mutant Schwann cells do not express Oct-6 or Krox-20 at this stage (c and e). The few cells that have
initiated myelin formation are strongly positive for P-zero (i). In strong contrast to clp/clp Schwann cells (k), Oct-6 mutant cells express already high levels of
periaxin at this stage (l). Magnification �40. (B) Myelin formation is evident in clp/clp nerves at P16. An appreciable number of Schwann cells have initiated
myelination and express Krox-20 (a). High levels of P-zero and periaxin are present in Schwann cells that have formed compact myelin (b and c).
Magnification �40.
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Koszowski et al., 1998). The mean internodal length in
every axonal diameter class in clp/clp animals is approxi-
mately half of that of wild-type animals. Intuitively, and on
theoretical considerations, it is to be expected that propaga-
tion of action potentials will be slowed when the mean
internodal length drops well below its optimum (Brill et al.,
1977; Goldman and Albus, 1968; Rushton, 1951). To assess
nerve conduction velocity (NCV) in clp and wild-type
animals, we measured compound action potentials (CAP)
of the tail nerve (Fig. 5A). The mean NCV in wild-type and
heterozygous mice was 35.3 m/s (SD 1.8). In contrast, the
mean NCV in clp/clp mice was 23.9 m/s (SD 2.2), a
reduction of 35% (Fig. 5B). A similarly reduced conduction
velocity was observed for motor nerves within the sciatic
nerve of clp/clp animals as compared to wild type (data not
shown). Reduced NCV in the tail nerve of claw paw mice
shows little variance, and this variance does not correlate
with age or severity of the behavioral phenotype. Thus, it is
possible that the reduction in NCV in clp/clp animals can be
accounted for, at least in part, by the reduction in mean
internodal length.
Response to nerve injury
Although the claw paw phenotype has been described as
a developmental abnormality, it is not clear from these
observations whether the phenotype results from an intrinsic
defect in one or more components of the developing nerve
or through defects in other organs of the developing fetus.
Studying the damage response of the nerve in the adult
animal allows examination of Schwann cell–axon interac-
Fig. 5. Nerve conduction velocities are reduced in clp/clp nerves. (A)
Representative recordings of compound action potentials of the tail nerve of
wild-type (wt) and clp/clp (claw paw) animals. Arrows indicate the
stimulation artefact. (B) Mean conduction velocity for wild-type (wt) and
clp/clp (claw paw) nerves. The number (n) of animals from which
recordings were obtained in each group is indicated. The error bar
represents standard deviation. The difference in mean NCV between clp/clp
and wild-type animals is significant (P < 0.00001, Student’s t test).
Fig. 4. Expression of periaxin and Oct-6 in clp/clp Schwann cells. (A) Embryonic sciatic nerve is visualized by expression of the neurofilament medium chain
in the axonal fibers (Nfm; a and b). Embryonic Schwann cells within the nerve express periaxin in their cytoplasm or nucleus (c). In contrast, no periaxin
expression is observed in nerves of claw paw embryos at this stage of development (d). (B) Oct-6 is expressed in all Schwann cells in newborn wild-type sciatic
nerves (a). Also, Schwann cells in sciatic nerves of clp/clp animals express Oct-6 (b). Other than wild-type Schwann cells, clp/clp Schwann cells uniformly
express high levels of Oct-6. In wild-type nerves, many Schwann cells are at the promyelin configuration and some have initiated myelination and thus express
high levels of P-zero (c). In contrast, clp/clp Schwann cells appear at an early sorting stage at P1 (see Fig. 1) and do not express detectable levels of P-zero
protein (d).




















































tions that are largely a reiteration of developmental events
(Scherer and Salzer, 1996). Following nerve transection,
axons and myelin in the distal nerve segment disintegrate in
a process called Wallerian degeneration. Schwann cells
revert back to an immature pre-myelinating phenotype,
proliferate and participate with macrophages in the removal
of myelin and axonal debris. These reactive Schwann cells
create an environment that stimulates axonal regeneration of
the transected neurones. Upon restoration of axonal contact,
Schwann cells differentiate into myelin or non-myelin
forming cells (Scherer and Salzer, 1996). Therefore, if the
clp defect resides within the nerve tissue, it is likely that at
least part of the defect will be recapitulated during nerve
regeneration following nerve axotomy in an adult animal.
On the other hand, if the clp defect is strictly developmental
and not intrinsic to the nerve tissue, it is expected that
regeneration will be relatively normal.
To examine the effect of the clp mutation on Schwann
cell–axon interaction during regeneration, the sciatic nerve
of adult clp/clp and wild-type mice were crushed and
studied morphologically 4 weeks later (Fig. 6). The nerves
were sectioned at two levels distal to the injury, 3 and 6 mm,
respectively, representing two successive stages of regener-
ation. In wild-type animals, regeneration is well advanced,
with only few remnants of myelin remaining (arrows in Fig.
6A, panel b) and most axons associated with compact
myelin. Regeneration of clp/clp nerves differs significantly
from wild-type nerves in some aspects. First, most large-
caliber axons are ensheathed by a single Schwann cell, but
only a few of these are associated with a thin compact
myelin sheath (Fig. 6A, panels e and f). Second, supernu-
merary Schwann cells surround large axon–Schwann cell
units and are associated with numerous thin axons (Fig. 6B).
These structures are enclosed by the original basal lamina
(arrows in Fig. 6B), indicating excessive sprouting of the
regenerating axon. Third, excessive fasciculation results in a
further subdivision of the clp nerve (Fig. 6A, panels e and f).
Thus, while clp axons do grow back into the distal nerve
stump, regeneration is clearly disturbed. Some of these
regeneration abnormalities, such as delayed myelination
and hyper-fasciculation, are also observed during develop-
ment suggesting that the clp defects are caused by a nerve
intrinsic defect in one or more components within the
developing or regenerating nerve.
Nerve grafting
To distinguish between a Schwann cell and neuronal
defect in the regeneration of clp/clp nerves, we performed
nerve grafting experiments. Nerve transplantation experi-
ments create a situation in which Schwann cells, genetically
distinct from the host, differentiate in association with host-
derived neurons (Aguayo et al., 1977; de Waegh and Brady,
1991; Scaravilli and Jacobs, 1981). We performed nerve
transplantation operations in which a wild-type host was
engrafted with a segment of a wild-type (wt:wt) or clp/clp
(clp:wt) sciatic nerve segment. Also, the converse set of
transplantations was performed in which a clp/clp host was
engrafted with a wild-type (wt:clp) or clp/clp (clp:clp)
sciatic nerve segment. The poorly developed epineurium
of clp/clp nerves as compared to that of wild-type nerves
made the grafting of the segments particularly demanding
on the technical level. Four weeks after the operation, the
transplanted nerves were isolated and examined microscop-
ically. Each nerve was serially sectioned and examined at
250-Am intervals. Representative sections from the middle
of the graft and proximal and distal to the anastomosis site
are shown in Fig. 7. In the wt:wt transplantation, regenerat-
Fig. 6. Abnormal response to nerve injury in clp/clp mice. (A) Light micrographs of cross sections of sciatic nerves of young adult wild-type and clp/clp (claw
paw) animals 4 weeks after nerve crush. The myelin sheath in clp/clp nerves is thinner than in wild-type nerves, as described earlier (a and d). In wild-type
nerves, regeneration is well advanced, both at 3 and 6 mm distal of the nerve crush (b and c), with only little myelin debris remaining (arrows in panel b). All
regenerated axons are myelinated. Regeneration in clp/clp nerves is delayed with only few regenerated axons myelinated. This is even more pronounced at 6
mm distal to the lesion, corresponding to a later time point in regeneration (f ). Excessive fasciculation is evident in the regenerating nerve. A layer of epineural
cells enclosing a group of regenerating fibers is indicated with arrows (e). Scale bar: 10 Am. (B) In this electron micrograph of a regenerating clp/clp nerve,
supernumerary Schwann cells are associated with regenerating axons. In addition to the large central axon, excessive numbers of axon sprouts (red asterisks)
are observed within the regenerating unit that is enclosed by one basal lamina (arrows). The cross section is through three Schwann cells. Scale bar: 2 Am.
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ing axons have grown through the graft and entered the
distal nerve stump. Wild-type Schwann cells in the graft and
distal nerve stump have formed compact myelin around
regenerated axons (Fig. 7, panels b and c). Schwann cell
tubes (reactive Schwann cells within their basal lamina:
bands of Bunger) that were not re-innervated still contain
some myelin debris (arrows in panel b). In the clp:wt
transplantation, wild-type axons do regenerate through a
clp/clp nerve graft into the distal nerve stump (Fig. 7, panels
e and f ). Moreover, in contrast to wild-type Schwann cells,
clp/clp Schwann cells have only myelinated the larger axons
in the graft and many axons are still in an early ensheathing
Fig. 7. Nerve grafting experiments reveal Schwann cell and neuronal expression of the clp defect. Light micrographs of semi-thin cross sections of sciatic nerve
at three different levels of the engrafted nerve 4 weeks after the operation. The position of the sections relative to the engrafted segment is schematically
depicted in the diagram above the micrographs. At the level of the engrafted segment and distal to this segment, three different configurations are expected:
regenerated axons myelinated by graft-derived Schwann cells (blue in diagram); Schwann cell tubes (blue) that do not get re-innervated by host neurones and
host axons that do not enter the nerve graft and are associated with host-derived Schwann cells (gray in diagram) that migrate with the regenerating axons.
Donor and recipient genotypes (donor/recipient) are listed to the left. Non-innervated Schwann cell tubes with myelin debris are indicated with arrows in panel
b. Thinly myelinated axons that have re-innervated the distal nerve segment of the wild-type host are indicated in panel f with arrows. Arrows in panel h also
point to regenerating wild-type axons that are myelinated by clp/clp Schwann cells. For further details, see text. Scale bar: 10 Am.
A. Darbas et al. / Developmental Biology 272 (2004) 470–482
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or promyelin configuration (panel e). Smaller axons that
have navigated through the graft and have entered the distal
nerve stump are normally myelinated (arrows in panel f ).
These observations suggest that at least part of the delayed
myelination phenotype in clp/clp animals is Schwann cell
autonomous.
Transplantations of wild-type nerve segments into clp/
clp hosts were less successful as ligations to the distal
nerve stump did not hold. Nevertheless, clp/clp axons did
enter the wild-type nerve graft and were myelinated by the
wild-type Schwann cells within the graft (Fig. 7, panel h).
Also smaller-caliber claw paw axons were myelinated
(arrows in panel h). Distal to the second anastomosis site,
regrowing axons did not enter the distal nerve stump, but
were found associated with a large blood vessel (not
shown). Most likely, graft-derived perineural cells and
Schwann cells accompany these axons (panel i). Notwith-
standing, these data suggest that wild-type Schwann cells
receive appropriate signals from clp/clp neurones to mye-
linate them. Finally, the clp:clp transplantations show that
clp/clp axons do grow through the grafted segment into the
distal nerve stump. Consistent with the results in the clp/clp
nerve crush experiment (Fig. 6), regenerating clp/clp axons
are associated with supernumerary Schwann cells and only
few axons are thinly myelinated (Fig. 7, panels k and l).
We also observe a further increase in the extent of
fasciculation. This increased fasciculation was less pro-
nounced in the clp:wt and in wt:clp transplantations.
Therefore, this specific aspect of the claw paw phenotype
arises mainly from interaction of clp/clp axons with the clp/
clp endoneurium. This is also true for the delayed myeli-
nation phenotype, as it is much more severe in the clp:clp
transplantation than in the clp:wt and wt:clp transplanta-
tions. Thus, while the former two grafting experiments
(wt:clp and clp:wt) suggest a Schwann cell autonomous
effect of the clp mutation on myelination, the nerve crush
and clp:clp transplantation suggest that there is also an
important Schwann cell non-autonomous, most likely neu-
ronal, aspect to the clp mutation.
Discussion
We have studied the cellular and molecular basis of the
congenital limb abnormality manifested by claw paw mutant
mice. Our findings demonstrate that the clp mutation affects
both the axonal and endoneural/Schwann cell compartment,
resulting in axonal sorting and myelination defects. At the
molecular level, clp affects a signaling pathway that is
parallel and non-redundant to the Oct-6-dependent pathway,
suggesting that axonal signals that drive Schwann cell
differentiation and myelination are transduced through mul-
tiple parallel pathways. These findings suggest several
possible roles for the clp gene and, additionally, define a
set of requirements for clp candidate genes, to be identified
in the ongoing positional cloning effort.
What process in nerve development is affected by the clp
mutation?
The development of peripheral nerve tissue can be
conveniently thought of as an ordered series of cellular
transitions that result from several complex interactions
between Schwann cells, axons, mesenchymal cells and
extracellular components (Jessen and Mirsky, 1999; Web-
ster, 1993). The first transition occurs when migrating neural
crest cells associate with outgrowing axon bundles and
acquire Schwann cell precursor characteristics (Jessen and
Mirsky, 1991; Jessen et al., 1994). These cells proliferate,
migrate with the growing axons and, in a second transition,
differentiate into immature Schwann cells that invade the
axon bundles and start the process of radial sorting of nerve
fibers. This process culminates in larger axons singled out
by individual Schwann cells (promyelin stage) which, in a
third transition, will go on to myelinate their axon and
multiple smaller axons associated with Schwann cells to
form the so-called Remak fibers of non-myelinated axons.
During this last phase, immature Schwann cells exit the cell
cycle and elaborate an extracellular matrix. The peri- and
epineural layers that surround and protect the nerve differ-
entiate from the surrounding mesenchyme in a process that
requires Schwann cell-derived desert hedgehog signaling
(Bunge et al., 1989; Du Plessis et al., 1996; Parmantier et al.,
1999).
The major defects in the developing and adult peripheral
nerves of claw paw mutant mice were originally described as
a general delay of myelination initiation and the persistence
of promyelin fibers in adult animals (Henry et al., 1991). On
the basis of these morphological observations, Henry et al.
hypothesized that the clp defect affects the complex signal-
ing between axon, Schwann cell and extracellular compo-
nents that control the transition of promyelin Schwann cells
into myelinating cells. Molecular studies have shown that
this transition is mediated by the activity of the transcription
factors Oct-6 and Krox-20 acting consecutively in the
Schwann cells (Ghislain et al., 2002). Our finding that clp
does not affect activation of Oct-6 expression but that Krox-
20 activation is delayed suggests that clp acts either down-
stream of Oct-6 or in a second non-redundant pathway.
Several observations presented here argue in favor of the
second possibility. Morphological examination of nerves of
newborn claw paw animals revealed that Schwann cells are
still at an early sorting stage of development while wild-type
and Oct-6 mutant Schwann cells are at the end of the sorting
stage. This early sorting stage observed in P1 clp/clp nerves
would be appropriate for embryonic nerves in E16–E18
wild-type embryos. Sorting and ensheathment of axons by
Schwann cells critically depends on rearrangements of the
Schwann cell cytoskeleton. Deletion of the h1 integrin or
the laminin g1 gene in Schwann cells results in impaired
sorting of axon bundles, suggesting that these rearrange-
ments are mediated through interactions between the extra-
cellular matrix laminins and their integrin receptors (Chen
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and Strickland, 2003; Feltri et al., 2002; Saito et al., 2003).
The similarity in ultrastructural abnormalities observed in
newborn clp/clp, h1 integrin and laminin g1 mutant nerves,
suggests that clp acts in these pathways. In contrast to
laminin g1 null Schwann cells, clp/clp Schwann cells are
not permanently blocked at the sorting stage. It is therefore
likely that a clp redundant function exists or that the clp
allele is a hypomorph.
In addition, clp/clp nerves exhibit hyperfasciculation, a
phenotype resembling that observed in dhh mutant mice,
suggesting the possibility that this specific aspect of the claw
paw mutant phenotype results from downregulation of dhh
expression. In agreement with this suggestion, we found that
dhhmRNA is expressed at reduced levels in clp/clp nerves (at
P12). However, in contrast to dhhmutant animals, the nerve–
tissue barrier function of the perineurium in claw paw animals
is not affected (Fig. 2). As the biological effects of hedgehog
proteins are known to be dose-dependent, it is tempting to
speculate that the differences in phenotype between dhh
mutant and clp/clp nerves reflect differences in dhh expression
levels in the developing nerves of these two mutant animals.
Nuclear periaxin expression in embryonic Schwann cells,
and the later accumulation of periaxin in promyelin cells at
P8, is not observed in claw paw nerves at these stages (Figs.
2 and 3), although periaxin does eventually accumulate in
Oct-6 and Krox-20 expressing myelinating clp/clp Schwann
cells (Fig. 2). It has recently been suggested that a dual
mechanism of periaxin regulation exists in which Krox-20
amplifies an earlier Krox-20 independent activation of the
periaxin gene (Parkinson et al., 2003). Our results suggest
further that the early Krox-20 independent activation of
periaxin is regulated through a clp-dependent pathway.
Alternatively, it is possible that clp Schwann cells at E17
represent an earlier differentiation stage at which periaxin is
not expressed yet (they will have to be very early Schwann
cell precursors, as E14 Schwann cell precursors express
periaxin in their nuclei, (Sherman and Brophy, 2000). It is
unlikely that the absence of detectable levels of periaxin in
clp Schwann cells contributes significantly to the peripheral
nerve phenotype in claw paw mice, as peripheral nerve
development is morphologically normal in periaxin null
mice (Gillespie et al., 2000).
Thus, in contrast to what has been suggested earlier, the
clp mutation affects nerve development at a stage well
before the promyelin-myelinating transition. The particular
defects suggest that clp is involved in axon–Schwann cell
interactions that drive the invasion and sorting of immature
Schwann cells and the subsequent elaboration of a basal
lamina and myelination initiation.
On the nature of the claw paw mutation
In the absence of knowledge about the mutation under-
lying the claw paw phenotype, we do not know what
mechanism could account for the peripheral nerve develop-
mental defect and the behavioral defect in claw paw
animals. However, on the basis of the observed develop-
mental defects, the recessive nature of the clp mutation and
in particular the results of regeneration and nerve transplan-
tation experiments, we can speculate on possible scenarios.
Although the morphological abnormalities observed in the
nerve of claw paw animals suggest that the clp mutation
affects primarily Schwann cells, the transplantation and
nerve regeneration experiments suggest that clp function
might also be required in the neurone and possibly the
endoneurial fibroblasts. It is therefore likely that the clp
gene product is expressed and functioning in both Schwann
cells and neurones and that the clp mutation is not a gain of
function mutation. These suggestions are compatible with
clp functioning in, or regulating, homo- or heterophilic
interactions between axons and Schwann cells. For exam-
ple, it is possible that the claw paw protein is involved in
bringing adhesion molecules to the cell surface or that claw
paw itself is a cell surface protein directly involved in cell–
cell interactions. Alternatively, it is possible that the clp
mutation is a regulatory mutation affecting expression of
genes involved in the abovementioned interactions. These
impaired axon Schwann cell interactions at an early stage
could have repercussions for nerve activity during fetal
stages and affect the normal spontaneous movement of the
fetus, important for proper posture development.
In summary, we have provided evidence that the mouse
clp mutation affects the Schwann cell compartment and
possibly the neuronal compartment of the regenerating and,
by extension, the developing nerve, suggesting that the clp
gene is expressed in Schwann cells and neurones and is
involved in direct axon–Schwann cell interactions. Further-
more, the clp mutation affects early activation of periaxin
expression and Krox20 expression in Schwann cells, but
does not affect the signaling pathway that activates Oct-6
expression, suggesting that axonal signals that initiate
myelination are transduced through multiple parallel, non-
redundant pathways.
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The claw paw mutation reveals a role for Lgi4 in
peripheral nerve development
John R Bermingham Jr1, Harold Shearin1, Jamie Pennington1, Jill O’Moore1, Martine Jaegle2, Siska Driegen2,
Arend van Zon2, Aysel Darbas2, Ekim O¨zkaynak2, Elizabeth J Ryu3,4, Jeffrey Milbrandt3 & Dies Meijer2
Peripheral nerve development results from multiple cellular interactions between axons, Schwann cells and the surrounding
mesenchymal tissue. The delayed axonal sorting and hypomyelination throughout the peripheral nervous system of claw paw (clp)
mutant mice suggest that the clp gene product is critical for these interactions. Here we identify the clp mutation as a 225-bp
insertion in the Lgi4 gene. Lgi4 encodes a secreted and glycosylated leucine-rich repeat protein and is expressed in Schwann
cells. The clp mutation affects Lgi4 mRNA splicing, resulting in a mutant protein that is retained in the cell. Additionally,
siRNA-mediated downregulation of Lgi4 in wild-type neuron–Schwann cell cocultures inhibits myelination, whereas exogenous
Lgi4 restores myelination in clp/clp cultures. Thus, the abnormalities observed in clp mice are attributable to the loss of
Lgi4 function, and they identify Lgi4 as a new component of Schwann cell signaling pathway(s) that controls axon segregation
and myelin formation.
In the peripheral nervous system (PNS), Schwann cells synthesize
myelin sheaths, which permit the rapid, saltatory conduction of
nerve impulses. The debilitating effects of diseases that disrupt myelin
emphasize the importance of understanding the mechanisms that
control its synthesis. The development of peripheral nerve tissue results
from a series of coordinated interactions between neurons and
Schwann cells (reviewed in refs. 1 and 2). Schwann cell precursors
originate from the neural crest and migrate along embryonic nerve
trunks, proliferating in response to axonal cues and subdividing the
nerve into smaller groups of fibers; ultimately, they differentiate into
myelinating or non-myelinating Schwann cells. Several signaling pro-
teins that regulate Schwann cell development andmyelin formation are
known. Axonal membrane–bound neuregulin-1 (NRG1) isoform III,
signaling through the ErbB2-ErbB3 receptor on Schwann cells, is
required for Schwann cell survival, proliferation and myelination3–6.
The competing effects of neurotrophin-3 (NT3) and brain-derived
neurotrophic factor (BDNF) modulate Schwann cell myelination7, and
nerve growth factor (NGF) seems to stimulate Schwann cell myelina-
tion indirectly through binding to the TrkA receptor on dorsal root
ganglion (DRG) axons8. In parallel, neuronal activity triggers axonal
release of ATP that inhibits Schwann cell proliferation and myelination
(reviewed in ref. 9). Nevertheless, many important aspects of axon–
Schwann cell signaling are not yet understood. In addition to axonal
contact, the sorting of nerve fibers and Schwann cell myelination also
require the synthesis of a basal lamina (reviewed in ref. 1).
Axon–Schwann cell and Schwann cell–basal lamina interactions
activate multiple signaling pathways that converge onto the nucleus
to regulate the transcriptional programs for myelinating or non-
myelinating fates1,10,11. Critical roles in Schwann cell proliferation,
differentiation and myelination have been established for the transcrip-
tion factors Sox10, Sox2, Jun, NFkB, Oct6 (the product of the Pou3f1
gene) and Krox-20 (the product of the Egr2 gene) (reviewed in refs. 12
and 13). In particular, the cessation of Schwann cell proliferation and
the initiation of myelin formation require the downregulation of Sox2
and the upregulation of Pou3f1/Oct6 to induce Egr2/Krox-20, which in
turn—together with Sox10—activates the myelination program14–17.
Sox10 is also required in Schwann cell precursors for their survival,
where its actions are mediated at least in part through the regulation of
the neuregulin receptor ErbB3 gene18.
The clp mouse is a particularly interesting model for the study of
Schwann cell development in vivo. These mice are characterized by limb
posture abnormalities and peripheral hypomyelination, with no sign of
dysmyelination in the CNS19–21. The clp mutation, which arose
spontaneously in C57BL/6-ob mice at the Jackson Laboratory, is
recessive and has been mapped to proximal mouse chromosome
7 (ref. 19). The similarities in delayed myelination observed in
Pou3f1/Oct6 mutant mice and in clp mice suggest an interaction
between the two genes. We have shown previously that perinatal
Pou3f1/Oct6 upregulation is not affected by the clp mutation, but
that downstream effectors, such as Egr2/Krox-20, are activated with
delayed kinetics21,22. Additionally, the radial sorting of nerve fibers
is delayed in clp animals, and nerve-grafting experiments demonstrate
that clp gene function is required in Schwann cells and possibly in
neurons21. Taken together, these data demonstrate that clp function
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is required for peripheral nerve development and that, in Schwann
cells, clp functions in a myelination pathway that is distinct from
Pou3f1/Oct6 activation.
To understand the molecular basis of the claw paw phenotype, we
identified the genetic defect by positional cloning. Here we show that
the clp mutation is caused by a repetitive element insertion that
precludes splicing of exon 4 of Lgi4, one of four members of the
leucine-rich glioma-inactivated (Lgi) family of genes that encode
putative secreted proteins23. Lgi4 is dynamically expressed in Schwann
cells and restricted populations of neurons. The clpmutation results in
the production of Lgi4 protein with an interstitial deletion that fuses
two of its leucine-rich repeats (LRRs). We demonstrate that, although
Lgi4 is glycosylated and secreted, Lgi4clp is retained within the cell.
Moreover, we show that siRNA-mediated downregulation of Lgi4 in
sensory neuron–Schwann cell cocultures inhibits myelination, whereas
the addition of Lgi4 to clp/clp neuron–Schwann cell cocultures sig-
nificantly restores myelination. Thus, our data indicate that the claw
paw phenotype results from a loss of Lgi4 and identify Lgi4 as an
important signaling molecule that controls axon sorting and gene
expression in peripheral nerve myelination.
RESULTS
The clp mutation produces an arthrogryposis-like phenotype that
affects the forelimbs (Fig. 1a,b) and, in severe cases, also the hind
limbs. The growth of clp/clp pups is often delayed, and many of the
most severely affected individuals die before weaning. Notwithstanding
the variability of the limb posture abnormality, all peripheral nerves in
clp mice are hypotrophic (Fig. 1c,d; refs. 19 and 21).
Positional cloning of the clp gene
The initial backcross involving the clp locus revealed that it resides on
proximal chromosome 7 (ref. 19). As a first step toward the identifica-
tion of the clp gene, we localized it more precisely using clp/+ C57BL/6J
� BALB/c intercrosses and clp/+ C57BL/6J� CAST backcrosses. These
genetic mapping studies (Supplementary Figs. 1 and 2 online) resulted
in the definition of a clp candidate region that spanned approximately
150 kilobase (kb) from microsatellite marker D7MRI6 to D7MIT155
and contained at least eight genes (Fig. 2).
To identify the clpmutation, we analyzed the clp candidate region for
exons and putative regulatory sequences. Each of these sequences was
amplified using the polymerase chain reaction (PCR) from clp/+ and
clp/clp DNA, and sequenced. PCR products from primers that flanked
exon 4 of the Lgi4 gene consistently produced a larger than expected
product from clp/clpmice. The sequencing of this product revealed that
4 base pairs (bp), CTCT, located six nucleotides 5¢ to exon 4 were
replaced with a 225-bp repetitive sequence. This repetitive sequence
was 100% homologous to a repeat element located 797 bp upstream,
but in the reverse orientation (Fig. 3a,b). To confirm the presence of the
insertion in clp/clpmice, we performed exon 4 PCR on clp/clpmice that
were congenic with BALB/cmice (data not shown) and, using Southern
hybridization, we examined DNA from clp/clpmice and wild-type mice
for the clp restriction fragment length polymorphism (RFLP, Fig. 3c).
In each case, a larger fragment segregated with the claw paw phenotype,
and therefore it is likely that this insertion allele is the clp mutation.
Formally, clp is an allele of Lgi4 (Lgi4clp), but for simplicity we will
continue to call it clp.
The identification of an insertion associated with the clp mutation
facilitated genetic complementation studies with wild-type DNA from
the clp candidate region. We generated a transgenic mouse line with a
bacterial artificial chromosome (BAC), 75-D7, containing wild-type
mouse genomic DNA that spanned the clp candidate region (Fig. 2b).
To confirm that the clp locus resides within the candidate region, we
crossed mice that were heterozygous for clp to mice that were hetero-
zygous for clp and carried the BAC 75-D7 transgene (Supplementary
Fig. 3 online summarizes the genotyping of these mice and Table 1
details the offspring from such a complementation cross). We observed
no clp/clp transgene-positive mice with the claw paw phenotype,
whereas all clp/clp homozygous mice without the transgene were
phenotypically claw pawed. To confirm the rescue of the claw paw
phenotype, we performed direct microscopic examination of the
sciatic nerves from clp/+ and clp/clp offspring carrying the 75-D7
BAC transgene (Fig. 3c and 3d, respectively). These sciatic nerves
appeared healthy and myelinated, and in marked contrast to nerves
from clp/clp mice (Fig. 1c), were indistinguishable from the nerves of
wild-type mice (Fig. 1d). Thus, we concluded that the 75-D7 BAC
transgene complements the clp mutation. Because the Lgi4 insertion
was the only polymorphism identified in this region that segregated
with the clp mutation, the Lgi4 insertion is the most probable cause of
the claw paw phenotype.
Expression of the Lgi4 gene in the PNS
Previously we showed that clp gene function is required by Schwann









Figure 1 The claw paw phenotype. (a,b) P0 (a) and P15 (b) wild-type and
clp/clp mutant mice on a C57BL/6 genetic background. Arrowheads highlight
the forelimb defect in these mice. (c,d) Sciatic nerves from the mice shown
in b. For clarity, a 30-gauge needle has been inserted behind the nerves.
Note hypotrophy of the clp/clp sciatic nerve (arrows).
















Figure 2 The clp candidate region (NCBI build 33.1) consists of eight genes:
Fxyd5, Fxyd7, Fxyd1, Lgi4, Fxyd3, Hepsin, Scn1b and D7Bwg0611e.
The clp candidate region as defined by 27R and 187R backcross mice
(Supplementary Fig. 2) is shown as a thick bar; below it, CAST BAC
75-D7 is shown as a thinner bar.







































Lgi4 in peripheral nerve development
87
pattern of Lgi4 in the embryonic and early postnatal PNS of wild-type
mice and compared it to the expression of the closely related Lgi1, Lgi2
and Lgi3 genes. On embryonic day 14 (E14), Lgi4 was expressed in
developing peripheral nerves. Lgi4 was strongly expressed in the
trigeminal nerve and ganglion, and was particularly abundant in the
boundary cap cells (Fig. 4a,b)—a transient population of cells that
contributes to the Schwann cell population of the dorsal root nerve24.
The pattern of Lgi4 expression at E14 was distinct from those of Lgi1,
Lgi2 and Lgi3 (data not shown). Moderate Lgi4 expression was
observed in the DRG (Fig. 4c), and in the intestine in a pattern
consistent with its expression in the developing enteric nervous system
(Fig. 4d). Together, these observations demonstrate that Lgi4 is
expressed in the entire PNS at E14. Although it was clear that Lgi4 is
expressed in the Schwann cells of the embryonic nerve, it was not clear,
from in situ hybridization to embryonic DRG, whether Lgi4 expression
is in sensory neurons, satellite glia or both.
To determine whether Lgi4 is also expressed in postnatal Schwann
cells and whether its expression is altered by the absence of Oct6, we
performed in situ hybridization on sciatic nerves from wild-type and
Pou3f1–/– (Oct6-null) mice. Previous data suggest that in postnatal
nerve development, Lgi4 acts downstream of Oct6 or in parallel with
it21,22. We found that Lgi4 was expressed independently of Oct6
(Fig. 4e). Thus, Lgi4 and Oct6 function in independent pathways in
myelinating Schwann cells.
To further define the effects of the clp mutation, we examined the
expression of Lgi4 and additional genes in clp/clp mice (Fig. 4f). In
clp/clp sciatic nerves on postnatal day 4 (P4), Lgi4 expression was
upregulated, most probably reflecting the temporal delay in Schwann
cell differentiation. Egr2/Krox-20 mRNA expression was strongly
downregulated in clp/clp mice, demonstrating that the reduction
of Krox-20 protein in these mice21 occurs as a result of reduced
Egr2/Krox-20 transcription. To determine whether the reduction in
wild-type Lgi4 activity was compensated for by the upregulation of
other members of the Lgi family, we examined the expression of Lgi1,
Lgi2 and Lgi3 in sciatic nerves from P4 wild-type and clp/clp mice. In
nerves from wild-type mice, we observed modest expression of Lgi1
(Fig. 4f) and no expression of Lgi2 or Lgi3 (data not shown). In nerves
from P4 clp/clp mice, we observed no expression of Lgi1 (Fig. 4f), Lgi2
or Lgi3 (data not shown). These observations revealed a potential role
for Lgi1 in mature Schwann cells and indicated that compensation for
the Lgi4clp mutation by Lgi1, Lgi2 and Lgi3 was unlikely.
To determine if Lgi4 and the other Lgi genes were expressed in
sensory neurons during postnatal development, we examined their
expression in P4 DRGs by in situ hybridization. Lgi1 was expressed at
very low levels throughout the DRG (Fig. 4g), presumably reflecting its
low expression in Schwann cells (Fig. 4g). Lgi2 and Lgi3 were expressed
abundantly in a pattern that corresponded to the position of sensory
neurons in the DRG. In contrast, Lgi4 was expressed at moderate levels
uniformly throughout the DRG, probably by intraganglionic Schwann
cells. A comparison of these patterns of expression with the embryonic
data suggests that, during development, early Lgi4 expression in DRG is
supplanted postnatally by Lgi2 and Lgi3 in sensory neurons. To
determine whether Lgi4 is expressed by peripheral motor neurons,
we hybridized adjacent transverse sections of P4 spinal cord with
probes for Lgi4 and, as a control, the proteolipid protein gene (Plp1;
Fig. 4h). Plp1 expression was observed in white matter tracts, as
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Table 1 Rescue of the claw paw phenotype by BAC 75-D7
Lgi4 alleles BAC 75-D7 transgene Number of mice Phenotype
FVB/FVB no 4 normal
clp/FVB no 14 normal
clp/clp no 7 claw paw
FVB/FVB yes 10 normal
clp/FVB yes 18 normal
clp/clp yes 17 normal
To determine whether homozygous clp/clp mice that carry the BAC 75-D7 transgene are
phenotypically claw paw, clp/+ C57BL/6J � FVB TgN(BAC75-D7) mice were mated to generate
F1 clp/+ TgN(BAC75-D7) and clp/+ mice. These F1 mice possess a wild-type Lgi4 allele on
an FVB chromosome and a clp allele on a C57BL/6 chromosome. This makes it possible to
unambiguously genotype alleles at the endogenous Lgi4 locus in the presence of the wild-type
Lgi4 locus on the BAC75-D7 transgene, by using C57BL/6 and FVB-specific markers that are
linked to Lgi4 but are not present on BAC 75-D7. Genotype analysis of the F1 mice clp/+ no.
108 and clp/+ TgN(BAC75-D7) no. 93 are shown in Supplementary Figure 3. These mice were
mated to obtain the F2 progeny that are listed in the table. No clp/clp transgene–positive mice
that were phenotypically claw paw were observed, eliminating the hypothesis that the transgene
has no effect on the claw paw phenotype. This result indicates that the sequences within BAC
75-D7 complement the clp mutation. A statistically significant excess of transgene carrying mice
was observed, likely as a result of segregation of two independent insertion sites of the transgene
in mouse no. 93. Southern blot and quantitative RT-PCR analysis (data not shown) indicate that
transgene-positive mice possess two or three copies of BAC 75-D7.
Figure 3 The clp mutation is an insertion in Lgi4. (a) The structure of the
wild-type Lgi4 gene is shown, with a repetitive element in intron 3 shown in
red. This repetitive element has been duplicated and inserted in the opposite
orientation adjacent to exon 4 in the clp allele of the Lgi4 gene (Lgi4clp).
(b) Partial sequence of wild-type Lgi4 and Lgi4clp. Exon 4 is shown in blue,
the four bases that are replaced by the clp insertion are shown in red and a
sequence with strong homology to the branchpoint consensus49 is shown in
bold italics. The CAG sequence for a potential 3¢ splice site in the clp/clp
sequence is underlined. (c) Southern blot of genomic DNA from wild-type
and Lgi4clp mice depicting the RFLP that results from the clp insertion.
(d,e) BAC transgene complementation of the clp mutation. Two F2 FVB-
Tg75-D7 � C57BL/6J-clp mice, (d) no. 145 and (e) no. 148 (e), showing
that presence of the 75-D7 transgene permits development of normal
sciatic nerves in clp/clp mice (compare with Fig. 1d). Genotyping of
these mice is depicted in Supplementary Figure 3.









































expected. Although Lgi4 expression was observed in dorsal and
ventral roots, it was not observed in motor columns. Thus, Lgi4 does
not seem to be expressed in postnatal motor neurons. Together, these
data demonstrate that in the PNS, it is primarily Schwann cells that
express Lgi4.
The clp mutation alters splicing of Lgi4*
The proximity of the clp insertion to Lgi4 exon 4 suggested that it could
alter Lgi4 splicing in three possible ways: (i) the insert could disrupt
exon 4 splicing by interrupting the polypyrimidine tract of the adjacent
3¢ splice site and shifting a putative branchpoint 221 bp away; (ii) it
could introduce a new 3¢ splice site that would enlarge exon 4 and
prematurely terminate Lgi4 translation; or (iii) the clp insertion and the
oppositely oriented repeat (located 797 bp away in intron 3; Fig. 5a)
could form a pre-mRNA stem-loop structure that occludes the third
intron 3¢ splice site. To distinguish between these possibilities, we
performed reverse transcriptase PCR (RT-PCR) on RNA from the
brain and sciatic nerves of clp/+ and clp/clp animals, using primers
mapping to exons 2 and 5. A shorter DNA fragment was amplified
from clp/clp brain and nerve samples than from clp/+ cDNA samples
(Fig. 5b). We cloned and sequenced these DNA fragments and found
that the clp-derived cDNAs lacked exon 4. To assess whether stem-loop
formation blocked the use of the 3¢ splice site on exon 4 in Lgi4clp pre-
mRNAs, we generated minigenes that spanned exons 2 through 6 and
contained the clp insertion, but with the nearby oppositely oriented
repeat sequence either removed or inverted (Supplementary Fig. 4
online). The expression of these minigenes in COS1 cells and the
sequencing of the resulting cDNAs demonstrated that Lgi4 exon 3 was
spliced to exon 5, regardless of the presence or orientation of the
additional cognate repeat. Thus, we concluded that the insertion of the
repeat element in the clp allele disrupted the third intron 3¢ splice site,
which resulted in the skipping of exon 4. As exon 4 is 72 nucleotides
long, we predict that the Lgi4 protein encoded by the clp allele has a
24–amino acid interstitial deletion.
Cellular processing of Lgi4 and Lgi4clp
Lgi4 shares common protein structural domains with the other three
members of the Lgi family: an N-terminal signal sequence, LRRs and a
C-terminal epilepsy-associated repeat (EAR) or epitempin domain25,26.
The predicted domain organization of Lgi4 and Lgi4clp (Fig. 5c), based
on the wild-type amino acid sequence (Fig. 5d), revealed a putative
signal sequence; the presence of this sequence suggested that Lgi4 enters
the secretory pathway and may be secreted. In support of this, the LRR
repeats of Lgi4 and the Lgi1, Lgi2 and Lgi3 proteins were flanked by
cysteine-rich sequences (LRRNT and LRRCT in Fig. 5d) that typified
extracellular LRR proteins27,28. In addition, one potential glycosylation
site (Asn177) was present in the LRRCTof Lgi4.
To determine whether Lgi4 and Lgi4clp are indeed secreted proteins,
we stably expressed a Myc-epitope- and 6�Histidine-tagged Lgi4 or
Lgi4clp in CHO cells. Using an antibody to Myc, we observed Lgi4
protein expression in a reticular pattern that largely overlapped with
the ER of the cell, suggesting that it enters the secretory pathway
(Fig. 6a). To check whether Lgi4 and Lgi4clp were secreted into the
medium, we purified the recombinant proteins from cell extracts and
medium on NiNTA-agarose beads. In this analysis, we included CHO
cells expressing V5- and 6�Histidine-tagged Lgi1 as a positive control
and Oct6-expressing cells as a negative control. Lgi4 and Lgi1 could be
purified from the culture medium, whereas Lgi4clp and Oct6 could not
(Fig. 6b). Thus, in contrast to the readily secreted wild-type Lgi4 and
Lgi1 proteins, Lgi4clp was retained within the cell.
We next checked whether Lgi4 and Lgi4clp proteins are glycosylated








































Figure 4 Embryonic expression of Lgi4. (a–d) At embryonic day 14, Lgi4 is expressed in peripheral nerves,
presumably by Schwann cell precursors and immature Schwann cells. (a) Trigeminal nerve. Arrowheads
denote cranial nerves in a and boundary cap cells in a higher-magnification micrograph (b). Lgi4 is
expressed in DRGs (c) and in the putative enteric nervous system (d). (e) Expression of Lgi4 in P0 sciatic
nerve of wild-type and Pou3f1 mice. Lgi4 is normally expressed in Schwann cells of Pou3f1–/– mutant
animals. Pou3f1–/– animals carry a LacZ insertion in the Pou3f1 gene and thus express LacZ RNA in the
Schwann cells. (f) In P4 clp/clp sciatic nerve, Lgi4 expression is upregulated, whereas Egr2 (which
encodes Krox-20) is downregulated. Lgi1 is modestly expressed in P4 wild-type sciatic nerve but not in
clp/clp nerve. (g,h) Lgi4 does not appear to be expressed in postnatal PNS neurons. (g) In P4 DRGs, Lgi4
is expressed by intraganglionic Schwann cells and not by sensory neurons or satellite glia. In contrast,
Lgi2 and Lgi3 are expressed in sensory neurons but not in glia. (h) Lgi4 is not expressed in motor neurons
in the spinal cord.
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N-glycosidase F (PNGaseF). EndoH cleaves the high-mannose struc-
tures that are found in ER resident proteins, whereas PNGaseF cleaves
both the high-mannose structures and the complex oligosaccharides
present on mature glycosylated proteins. We observed that secreted
Lgi4 was not cleaved by EndoH but was cleaved by PNGaseF—as was
apparent from the downward shift in molecular weight (Fig. 6c). Thus,
secreted Lgi4 carries complex oligosaccharides. Lgi4 purified from cell
extracts was largely EndoH sensitive, indicating that the proteins were
rapidly secreted after maturation in the Golgi compartment. Lgi4clp
also was largely EndoH sensitive, demonstrating that the interstitial
deletion in Lgi4clp did not inhibit glycosylation per se. The observation
that little mature glycosylated Lgi4clp accumulated in the cell suggested
that the protein was retained within the ER. These data suggested that
Lgi4 functions extracellularly and that the claw paw phenotype results
from loss of Lgi4 function. An alternative possibility, that Lgi4clp
retention exerts a dominant-negative effect on Schwann cells, is
unlikely because the claw paw phenotype is largely recessive and is
complemented by wild-type Lgi4 genes.
Lgi4 controls myelination in neuron–Schwann cell cocultures
If the loss of Lgi4 function caused the claw paw phenotype, then the
downregulation of Lgi4 by means of siRNA should phenocopy the clp
defect. We established myelinating neuron–Schwann cell cocultures
from dissociated DRGs derived from clp/+ and clp/clp E13 mouse
embryos. clp/clp cultures did not myelinate, whereas clp/+ cultures
exhibited robust myelination (Fig. 7a). A lentivirus that expressed
Lgi4-specific siRNA was constructed and shown to suppress Lgi4
mRNA expression in cultured rat Schwann cells by approximately
80% (Fig. 7b). The transduction of neuron–Schwann cell cocultures
with the Lgi4 siRNA lentivirus resulted in reduced numbers of myelin
internodes as compared to cultures transduced with a control lentivirus
(Fig. 7a,c). Quantification of these results showed that the expression
of Lgi4 siRNA resulted in a decrease of myelin internodes by approxi-
mately 70% (Fig. 7c). These experiments strongly suggested that the
myelination defect in clp mice and in clp DRG explant cultures results
from a loss of Lgi4 function.
The data presented above suggested that Lgi4 acts extracellularly.
Therefore, we anticipated that the addition of Lgi4 to clp/clp neuron–
Schwann cell cocultures would restore their myelination defect
(Fig. 7a). We treated clp/clp DRG cultures with medium conditioned
by either CHO cells expressing Lgi4 or, as a control, non-recombinant
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Figure 5 Skipping of Lgi4clp exon 4 generates a protein with an internal
deletion. (a) Diagram of Lgi4 splicing patterns in wild-type and clp/clp mice,
showing skipping of exon 4 in Lgi4clp transcripts. (b) PCR of cDNA from clp/+
brain and nerve and clp/clp nerve, showing absence of exon 4 in clp/clp
transcripts. (c) Structure of mouse wild-type Lgi4 and Lgi4clp proteins.
SS, signal sequence that is predicted to be cleaved between amino acids 19
and 20 (SignalP3.0; ref. 46); LRRNT, leucine-rich N-terminal domain; LRR,
leucine-rich repeat; LRRCT, leucine-rich C-terminal repeat; EPTP, epitempin
repeat. Colored or shaded domains are recognized by the SMART database.
The red LRR has a lower E value (probability with which the sequence would
appear at random) than the orange LRR domains, and the dark gray
epitempin domain has a lower E value than the light gray domain. White
domains are not recognized by the SMART or CDART databases. A branched
structure depicts a putative glycosylation site within the LRRCT (blue).
The part of the protein that is encoded by exon 4 is overshadowed in green.
513AA Lgi4clp is shown below wild-type Lgi4, with the third and fourth
putative leucine-rich repeats fused. (d) Mouse Lgi4 protein sequence.
Signal sequence is depicted in italics. A putative N-linked glycosylation
site (Asn177 or NXS/T)50 in the LRRCT domain is shown in bold italics,
and conserved amino acids in leucine-rich repeats are shown in bold. Amino
acids encoded by exon 4 are highlighted in green. Leucine-rich domains and
conserved epitempin domains depicted in a are underlined. The sequence
is derived from mouse Lgi4 cDNA NM_144556.1.
Figure 6 The clp mutation affects processing and sorting of Lgi4. (a) Myc-
tagged Lgi4 protein expressed in CHO cells is detected with an antibody to
Myc (a-Myc) in a pattern that largely overlaps (overlay) with that of the GRP-
94 antigen, present on the ER resident protein GRP-94. (b) Lgi4 and Lgi1
protein can both be purified from cell lysates (cell) and culture medium
(medium) of stably transfected CHO cells. Lgi4clp is present in cell extracts
but not in medium. The nuclear protein Oct6 can be purified only from the
cell extract, demonstrating that there is very little contamination of the
medium fraction with the cellular fraction. Lgi4 is detected with a Myc
antibody, Lgi1 with a V5 antibody and Oct6 with an Oct6 antibody. (c) Lgi4
purified from medium is resistant to cleavage by EndoH but sensitive to
PNGaseF as judged by the shift in electrophoretic mobility (indicated with
arrows labeled ‘a’ and ‘b’). Lgi4 protein isolated from cell lysates (cell) is
largely EndoH sensitive (below).









































and myelination in these cultures by immunocytochemistry and
western blotting (Fig. 7d,e). No myelin internodes were observed in
clp/clp Schwann cell cocultures grown in the presence of medium
conditioned by non-recombinant CHO cells (CHO-CM; Fig. 7d), and
very little of the myelin-associated protein Mpz was expressed in these
clp/clp cultures (Fig. 7e). In contrast, clp/clpDRG cultures grown in the
presence of medium conditioned by Lgi4-expressing CHO cells (CHO/
Lgi4-CM) showed myelination, as demonstrated by the strong Mpz
staining of several internodes (Fig. 7d) and elevated Mpz protein
expression (Fig. 7e). High Oct6 expression marks immature and
premyelinating Schwann cells. We observed many Oct6-positive
Schwann cells in the CHO-Lgi4-CM cultures, but not in the CHO-
CM cultures (Fig. 7d). This was corroborated by increased Oct6
protein expression in the CHO/Lgi4-CM clp/clp cultures as compared
to CHO-CM clp/clp cultures (Fig. 7e).
Taken together, these experiments demonstrated that exogenous
Lgi4 can restore the myelination defect in clp/clp neuron–Schwann
cell cocultures, suggesting that Lgi4 can indeed function extracellularly.
DISCUSSION
Through genetic and cell biological studies of clpmutant mice, we have
identified the secreted protein Lgi4 as an essential molecule in PNS
development. The clp mutation results in intracellular retention of
mutant Lgi4. Downregulation of Lgi4 in wild-type neuron–Schwann
cell cocultures inhibits myelination, whereas exogenous Lgi4 restores
myelination in clp/clp cocultures. Thus, Lgi4 is involved in Schwann cell
signaling pathways that control axonal ensheathment and myelination.
Lgi4 protein
The Lgi4 protein belongs to a small family of proteins that are
characterized by the presence of a signal peptide and two putative
protein interaction domains: an LRR domain and an epitempin or EAR
domain. The function of these proteins is unknown, although their
structural characteristics suggest that they function extracellularly and
are involved in multiple molecular interactions.
LRR domains provide a versatile protein interaction interface that is
found in many proteins from phylogenetically diverse organisms27,28.
The LRR domain of Lgi4 has highest homology to the Drosophila Slit
D3 LRR. Slit proteins are extracellular guidance molecules for both
neurons and some non-neuronal cells, and function by binding to the
transmembrane Roundabout (Robo) receptors (reviewed in ref. 29)—
an interaction that is mediated through the LRR domain of Slit30. Also,
the C-terminal half of the Lgi proteins is potentially involved in direct
molecular interactions. This domain is predicted to adopt a b-sheath
structure and may represent a version of the seven-bladed b-propeller
fold, a structural element involved in protein-protein interactions. For
example, this structural motif is also found in the semaphorins, a family
of proteins involved in axon guidance (reviewed in ref. 31), and in the
integrins, a major family of basal lamina receptors. The epitempin
domain is shared by the four members of the Lgi family, by C21orf29
(TSPEAR) and by the extracellular domain of the G protein–coupled
receptor MASS1 (also known as VLGR). Two of these proteins are
altered in epilepsy: LGI1 mutations have been found in patients with
autosomal-dominant partial epilepsy with auditory features
(ADPEAF), whereas the MASS1 (or VLGR) gene is mutated in Frings
audiogenic seizure mice32 and in humans with audiogenic seizures33. In
humans with ADPEAF, point mutations in LGI1 have been found in
both the LRR and epitempin domains34–37. The human LGI4 gene
resides in 19q13, a region linked to benign familial infantile convulsions
(BFIC; OMIM 601764), and LGI4 polymorphisms are associated with
childhood absence epilepsy38. Thus far, however, no mutations in LGI4
have been detected in patients with either type of epilepsy.
The interstitial deletion of 24 amino acids within the LRR domain of
Lgi4 results in intracellular retention of the mutant protein, most
probably within the ER. The unique peptide junction in Lgi4clp does
not resemble any known ER retention signal and thus refutes a simple
gain-of-function mechanism. A stringent quality control regime within
the ER eliminates improperly folded or assembled proteins39. In the
peripheral nerve, the association of contactin-associated protein
(Caspr) and contactin within the ER is required for maturation and
Figure 7 Inhibition of Lgi4 results in reduced
myelination in DRG cultures and exogenous Lgi4
restores myelination in clp/clp DRG cultures.
(a) Anti-Mpz immunostaining of dissociated clp/+
or clp/clp DRG cultures 12 d after addition of
ascorbic acid to induce myelination (top panels).
Immunostaining by antibodies to Mbp of sensory
neuron–Schwann cell cocultures infected with
lentivirus expressing Lgi4 siRNA (siLgi4) or non-
recombinant lentivirus (control) after ascorbic
acid treatment. (b) Quantitative RT-PCR of Lgi4
and Mpz RNA expression levels in Schwann
cells infected with siLgi4 or control lentivirus.
(c) Quantification of myelin profiles in control
and siLgi4 panels. Percent myelination value is
calculated from three independent experiments.
Error bars represent s.e.m. (d) Mpz (red) and Oct6
(green) immunostaining of dissociated clp/clp
DRG cultures 12 d after addition of ascorbic acid
to induce myelination. Nuclei are blue (DAPI).
Cultures were grown in the presence of 50% non-
recombinant CHO cell–conditioned medium
(CHO-CM) or Lgi4-expressing CHO cell–
conditioned medium (CHO/Lgi4-CM). Myelin
internodes are recognized by their strong Mpz
staining. (e) Expression of Oct6 and Mpz in dissociated DRG cultures 12 d after addition of ascorbic acid was assessed on immunoblots. Acetylated a-tubulin
(Tub), which is highly enriched in neurites, was used as a protein loading control. DRG cultures derived from heterozygous (clp/+) or clp-homozygous (clp/clp)
embryos were grown in standard medium (M) or standard medium supplemented (1:1) with CHO-CM (–) or CHO/Lgi4-CM (+).
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surface expression of the Caspr-contactin complex40. Perhaps the
altered protein-interaction characteristics of the mutant LRR domain
of Lgi4 inhibit its incorporation into a complex destined for transport
to the cell surface. Alternatively, possibly Lgi4clp is recognized as a
misfolded protein, retained within the ER and eliminated through
proteasome-mediated decay. Notably, a variety of ADPEAF-associated
mutations in Lgi1 all result in intracellular retention of the protein
when overexpressed in 293T cells, whereas the wild-type Lgi1 protein is
normally secreted by these cells41.
Possible roles for Lgi4 in peripheral nerve development
The transplantation of wild-type sciatic nerve segments fromwild-type
mice into nerves of clp/clpmice and vice versa suggested both Schwann
cell–autonomous and Schwann cell–non-autonomous functions for
the clp gene product21. We found that Lgi4 is expressed primarily by
Schwann cells in the PNS, implicating it in Schwann cell–axon inter-
actions. The embryonic and postnatal secretion of Lgi4 by Schwann
cells suggests several potential roles for this protein in nerve develop-
ment. First, it is possible that Schwann cells signal axons through Lgi4
to stimulate axon growth, reduce axon-axon adhesiveness or trigger
axonal signaling back to Schwann cells. Lgi4 could bind directly to an
axonal receptor or it could bind to an extracellular ligand. Second, Lgi4
could modulate an axonal signal to Schwann cells. Third, the axonal
sorting defect in clp nerves resembles the defects observed in several
different mice that possess laminin or integrin mutations21. Similarly,
in neuron–Schwann cell cocultures treated with a low concentration of
cyochalasin D that only subtly affects the actin cytoskeleton, Schwann
cells project processes into fascicles of axons but fail to segregate them
completely42. These similarities raise the possibility that Lgi4modulates
basal lamina signaling through integrins, thereby triggering the cyto-
skeletal rearrangements that are required for elaboration of Schwann
cell processes and subsequent axon segregation.
clp/clp mice have a forelimb phenotype (Fig. 1) that is uncommon
among peripheral dysmyelinatingmutants. Abnormal forelimb posture
at birth is also observed in Sox10 and cysteine-rich domain–NRG1
knockout mice; however, in these mice, it is associated with paralysis
resulting from significant motor and sensory neuron cell death as a
consequence of the loss of Schwann cells18,43. clpmice are not paralyzed
and do not show excessive Schwann cell death or loss of sensory and
motor neurons19,21. In fact, it is possible that this particular aspect of
the phenotype is not associated with loss of Lgi4 expression in Schwann
cells. Lgi4 is expressed in restricted regions of the CNS (refs. 41,44 and
data not shown), and therefore the limb defect could be related to the
CNS. Purkinje cells in the adult cerebellum express Lgi4, but the
appearance of the limb defect precedes Purkinje cell maturation45,
suggesting that their involvement is unlikely. Identification of the
etiology of the limb defect in clp mutant mice will be facilitated by
the generation of tissue-specific deletions of Lgi4.
In summary, the identification and characterization of the clp muta-
tion presented here demonstrates that the loss of Lgi4 expression under-
lies the claw paw phenotype and implicates the Lgi4 protein in Schwann
cell differentiation and peripheral nerve development. Identification of
Lgi4-interacting proteins will be instrumental in uncovering the signal-
ing pathways in which Lgi4 participates and, additionally, may elucidate
the functions of other Lgi proteins in oncogenesis and epileptogenesis.
As a secreted protein that is required for Schwann cell development, Lgi4
is a promising target for therapies to stimulate myelination.
METHODS
Mice.We obtained C57BL/6J clp/+ mice from the Jackson Laboratory, and FVB
and CAST mice from the McLaughlin Research Institute breeding colony.
Animal experiments were performed according to protocols that had been
approved by the Institutional Animal Care and Use Committee at the
McLaughlin Research Institute and the Institutional Animal Experimentation
Committee at Erasmus University. Procedures for mapping of the clp mutation
are presented in Supplementary Methods online.
Genotyping of Lgi4clp mutant mice. Mice were genotyped by PCR using two
primers that flank the clp insertion (5¢-CTTGACAATGACCAGAGAGC
CAAGAC-3¢ and 5¢-TGGCACCCTCGGATGACAGC-3¢) and a third primer
that covers the 3¢ junction of the repeat insert (5¢-CCATTCCCAGCAC
CACAGCTTCA-3¢).
cDNA amplification. We isolated RNA from adult C57BL/6 Lgi4+/+ and clp/+
mouse sciatic nerves using Trizol (Invitrogen) and then carried out cDNA
synthesis using Superscript II (Invitrogen) and a Clontech Advantage kit (BD
Biosciences and Clontech). The Lgi4 open reading frame was amplified from
this cDNA using the primers 5¢-AAACTCGAGGAGCAACATGGGAGG
GGCGGGCATCTTG-3¢ and 5¢-GGGTCTTTCCCGGTACCCGGCACTGAG
ATCCAATTCATGGTG-3¢ to improve the Kozak consensus around the ATG
start site and to remove the stop codon. We cloned the 1,645-bp PCR product
into pCRII+ (Invitrogen), sequenced it and subsequently cloned it into
pcDNA3.1/Myc-His(–)C (Invitrogen) as an EcoRI-KpnI fragment.
In situ hybridization. We anesthetized and perfused mice with formalin.
Hindquarters were dissected to expose the sciatic nerve and stored at 4 1C in
formalin. Tissues were frozen in a 1:1 mixture of OCT and Aquamount, and
sectioned at 20 mm. We performed in situ hybridization as described22 and
prepared single-stranded 35S-labeled antisense transcripts from the clones
described above. Emulsion-dipped sections were exposed for 7–21 d, counter-
stained in 0.001% bisbenzimide (Sigma) and photographed using dark-field
optics and Kodak Ektachrome 160T film.
Transgenic complementation of the clp mutation. BACs were identified from
the CAST/Ei BAC library at the Children’s Hospital of Oakland Research
Institute, by hybridizing filters with radiolabeled Fxyd3 cDNA according to the
manufacturer’s protocol. BAC transgenic mice were made by pronuclear
injection of 75-D7 BAC DNA that was purified using the Qiagen large construct
kit (Qiagen), purified by density centrifugation in a CsCl gradient and dialyzed
against 10 mM Tris (pH 8.0), 0.1 mM EDTA using Slide-A Lyzer 10K dialysis
cassettes (Pierce). We identified BAC transgenic mice by PCR amplification of a
350-bp sequence from the pTARBAC 2.1 plasmid backbone using the primers
5¢-CGCAGGTAAATGTGTCAAAATCTG-3¢ and 5¢-GCCGTTCGCTAACTCAG
CATC-3¢. We analyzed FVB and C57BL/6 chromosome-7 sequences using MIT
microsatellite markers that differ in size between FVB and C57BL/6. These
microsatellites were identified using the Center for Inherited Disease Research
website (http://www.cidr.jhmi.edu/mouse/mouse_dif.html). M13-tagged pri-
mers for the D7MIT267 microsatellite marker were used for PCR amplification
and analysis by electrophoresis on LI-COR apparatus (LI-COR Biosciences) as
described above.
Bioinformatics.We analyzed sequences using the Celera Discovery System and
the public mouse and human genome databases. We performed signal sequence
prediction using Signal P3.0 (ref. 46) and TMHMM (version 2.0). Intron splice
sites prediction using NetGene2. We identified conserved sequences between
mouse and human using VISTA47.
Cell transfection, immunohistochemistry and western blotting. CHO1 cells
were grown in DMEM/F10 (Whitaker) medium supplemented with 5% fetal
calf serum, penicillin and streptomycin. We obtained polyclonal cell lines stably
expressing Lgi4, Lgi4clp or Lgi1 after transfection of CHO1 cells with pcDNA3.1
Myc-His– or pcDNA3.1 V5-His–based expression cassettes and selection in
G418 (1 mg ml–1). For immunohistochemistry, the cells were grown in two-
well microchamber slides, washed with phosphate-buffered saline (PBS) and
fixed for 5 min in 4% paraformaldehyde (PFA) followed by 5 min in ice-cold
methanol. Cells were preincubated with blocking solution (0.5% normal goat
serum (DAKO), 0.5% bovine serum albumin (BSA), 0.01% Triton X-100,
0.2 mM glycine in PBS) for 5 min. First antibodies were diluted in blocking
solution (1:200 for the anti-Myc 9E1 (Roche) mouse monoclonal antibody and









































1:100 for the GRP-94 (DAKO) ER marker rabbit serum), applied to the cells
and incubated for 2 h. Cells were washed extensively with PBS–0.001% Triton
X-100 before addition of dilutions of secondary antibodies in blocking buffer
(1:100 of Alexa 594–conjugated goat anti–mouse antibody and 1:100 Alexa
488–conjugated goat anti–rabbit antibody (Molecular Probes)). After 1 h, cells
were extensively washed with PBS–0.01% Triton X-100, PBS and demineralized
water; and mounted. We examined the cells using a Leica Aristoplan epifluo-
rescence microscope and collected images using a Sony video camera.
We purified proteins from cell extracts and medium using Ni2+-NTA beads
(Qiagen) and separated them on a 12% SDS-PAGE gel. Proteins were
transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore) and
detected with primary antibodies to Myc (Lgi4), V5 (Lgi1) or Oct6. We
visualized proteins using an ECL western blot detection kit (Pierce).
Neuron–Schwann cell cocultures and lentiviral infection. Dissociated mouse
DRG cultures: DRGs were dissected from E13 clp/clp, clp/+ and wild-type
embryos, and collected in Leibovitz’s L-15 medium (Invitrogen). DRGs from
individual embryos were dispersed using trypsin and plated in a small drop of
MEM (Invitrogen) supplemented with 10% FBS (HyClone) and 100 ng ml–1 7S
NGF (Promega) on collagen-coated coverslips. We cultured and induced
myelination by the addition of 50 mg ml–1 ascorbic acid (Sigma) as described
in ref. 8. We visualized myelin figures by staining PFA-fixed cultures with
antibodies to the major myelin proteins Mpz (ref. 48) or Mbp. Lgi4-Myc-His–
expressing CHO cells (polyclonal) or non-recombinant CHO cells were grown
in MEM supplemented with 10% FBS for 5 d. The conditioned medium was
harvested, filtered and used to supplement medium for dissociated clp/clp DRG
cultures. The conditioned medium was added the day after plating and was
present during the whole time period of the experiment. For rat DRG–Schwann
cell cultures, primary DRG neuron cultures were established using DRGs
harvested from E16 rat pups. DRGs were disassociated, and approximately
two DRG were plated per well in four-well Nunc plates coated with Matrigel
(BD Biosciences). Neurons were grown in supplemented neural basal medium
(Invitrogen) (B27 supplement, Invitrogen; 4 g l–1 D-glucose, 2 mM glutamine
and 50 ng ml–1 NGF, Harlan) with or without a mixture of 10 mM 5-fluoro-2¢-
deoxyuridine and uridine (Sigma) for two or three 48-h cycles to eliminate
fibroblast growth. Primary rat Schwann cells were harvested from sciatic nerves
of P1 and P2 rat pups according to Brockes’ method and cultured as
described17. For myelination, 100,000 lentiviral-infected Schwann cells were
seeded onto DRG cultures in DMEM/F12 medium (Invitrogen) supplemented
with 15% FBS (Sigma), 2 mM glutamine and 50 ng ml–1 NGF. After 48–96 h,
the medium was switched to myelin-promoting medium consisting of DMEM/
F12, 15% FBS, 2 mM glutamine, 50 ng ml–1 NGF and 50 mg ml–1 ascorbic acid
(Sigma). Myelination medium was changed three times every week, and the
cultures were allowed to myelinate for up to 2 weeks.
The Lgi4 siRNA vector was produced by cloning annealed oligos, which
encoded a hairpin loop and the targeting sequence 5¢-CTGTCACT
CTCTCTCGTCA-3¢ into a lentiviral vector containing the U6 promoter and
a puromycin resistance cassette. Non-recombinant lentivirus without a hairpin
oligo insertion was used as the control. Lentivirus production and infection was
performed as described16. Infected Schwann cells were selected for by treating
with 1 mg/ml puromycin for 48 h.
Immunohistochemistry of rat DRG–Schwann cell cocultures. Cultures were
fixed for 10 min in 4% paraformaldehyde and then permeabilized for 20 min in
cold methanol at –201 C. Incubation with primary antibody was performed
overnight at 41 C with monoclonal antibodies to Mbp (1:200; Sternberger
Monoclonals) in blocking buffer (5% BSA (Sigma), 1% goat serum (Zymed),
0.2% Triton in PBS). Goat anti–mouse IgG–Cy3 (Jackson Immunoresearch)
was used at 1:200 dilution for 1 h at room temperature. Percent myelination
was calculated by counting the total number of Mbp-positive internodes in five
random fields per culture viewed at 10� magnification and setting the control
to 100%. Each condition was performed in triplicate or quadruplicate, and the
data presented is the average ± s.e.m. of three independent experiments.
Quantitative RT-PCR. For cDNA synthesis, 1 mg of total RNA isolated from
lentiviral-infected cultured Schwann cells (Trizol reagent, Invitrogen) was used.
Gene expression was quantified as previously described17 and normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. Each sample was
quantified in triplicate, and the results shown are the averages ± s.e.m. of a
representative experiment.
Note: Supplementary information is available on the Nature Neuroscience website.
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Schwann cells are derived from the neural crest. It is thought that migrating crest cells 
associate with the outgrowing axonal fibers and adopt a Schwann cell precursor identity. 
Schwann cell precursors proliferate and invade the axonal bundles with cytoplasmic exten-
sions, sorting the fibers into smaller groups. This process of radial sorting continues until 
the larger calibre axons are singled out by Schwann cells that will go on to produce the 
myelin sheath. Smaller (diameter < 1 µm) axons will not be myelinated but will instead be 
ensheathed by a Schwann cell that will accommodate several of the small calibre axons 
in cytoplasmic cuffs forming so-called Remak bundles (see introduction). Classic experi-
ments have indicated that the binary choice to become a myelin forming or non-myelin 
forming Schwann cell is determined by the axon1. The nature of the axonal signal that 
dictates Schwann cell identity and that triggers the intracellular cascade of cell differentia-
tion has long remained elusive. Several molecules have been proposed to play a key role 
in the acquisition of a myelinating fate and in the initiation of myelination. In particular, 
the neuregulins (NRG) and the neurotrophins and their respective receptors have gained 
prominence in recent years2-4.
Figure 1. Model of the different molecules interacting with each other in the developing myelinating Schwann cell.
The NRGs are a group of related membrane-bound or secreted peptides that are generated 
from the NRG-1 gene through differential promoter usage and alternative splicing5,6. These 
proteins can be grouped in three major types (I-III) that differ in their amino-terminal 
sequence7. All forms of NRG bind to the ErbB tyrosine-kinase receptors. Schwann cells 
express ErbB2 and ErbB3, which form a functional heterodimeric receptor. In vitro experi-
ments have demonstrated that soluble NRGs are required for the differentiation of Schwann 
cell precursors from neural crest stem cells and their subsequent survival8,9. In addition, 
genetic experiments indicate that myelin sheath thickness is graded to the strength of the 
NRG signal10. More recently it was demonstrated that the membrane bound type III NRG 
is required for the Schwann cell axon interaction, axonal sorting and initiation of myelin 
formation11. However, type III NRG does not induce myelin gene expression in Schwann 
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cells when expressed on the cell surface of CHO cells, indicating that additional axonal 
membrane associated molecules contribute to NRG function11. Activation of the ErbB2/
ErbB3 receptor on the Schwann cell membrane by axonal type III NRG-1 results in ac-
tivation of the PI3K pathway and activation of Akt/PKB. Pharmacological inhibition of 
PI3K activity in  Schwann cell-sensory neuron co-cultures inhibits Schwann cell sorting 
and myelination, phenocopying the type III NRG mutation12. Thus, the effects of type III 
NRG-1 appears to be mediated through the PI3K-PKB pathway. One major target of PKB 
are the O-class forkhead transcription factors; Foxo1, Foxo3, Foxo4 and Foxo613. It is not 
known whether Foxo proteins are expressed in Schwann cells. Whatever the exact nature 
of these signals, they will converge on the Oct-6 Schwann cell enhancer (SCE)14 to initiate 
myelination. Interestingly, potential forkhead binding sites are present in those parts of the 
Oct-6 SCE found to be essential for enhancer function (unpublished results from our lab). 
Future experiments should address the role of Foxo proteins in SCE activity. 
Another signal that has been thought to be involved in initiation of myelination is nuclear 
factor kappa B (NF-κB). Schwann cells express the p65 and p50 NF-κB proteins that can 
homo- or heterodimerize to form active complexes. At early stages of myelination p65 is 
the major form of NF-κB while at later stages p50 is more prominently expressed15. Both 
forms of NF-κB are bound by IκBα and retained in the cytoplasm. Upon phosphorylation 
of IκBα, NF-κB is translocated to the nucleus where it will activate a set of target genes. 
It was demonstrated that p65 null DRG explant cultures do not myelinate, while wild type 
cultures were myelinated. The transcription of Oct-6 was not activated in p65-/- Schwann 
cells and Nickols et al. concluded that the translocation of NF-κB was an important signal 
for the activation of transcription of Oct-615. However, we have found no evidence for a 
direct role of NF-κB in activation of Oct-6 as no NF-κB binding sites are present in the 
Oct-6 SCE nor does p65 activate the SCE in a co-transfection assay (M. Ghazvini, unpub-
lished observations). 
As mentioned earlier, Schwann cell specific transcription of the Oct-6 gene is controlled 
by a remote enhancer element called the SCE (Schwann cell enhancer). This notion is 
based on two lines of evidence. First, linking the Oct-6 SCE element to a minimal unre-
lated promoter confers temporally correct expression of a reporter gene in Schwann cells 
of transgenic mice16. Second, deletion of the SCE from the Oct-6 locus in mice results in 
the selective loss of Oct-6 gene expression in Schwann cells14. Consequently, mice homo-
zygous for the ∆SCE allele, Oct-6∆SCE/∆SCE, exhibit delayed myelination of their peripheral 
nerves similar to what is observed in Oct-6 knock out mice14,17.  In contrast to full Oct-6 
knock out mice (Oct-6βgeo/βgeo), Oct-6∆SCE/∆SCE mice are viable and allowed us to study later 
stages of nerve development.
The relatively mild peripheral nerve developmental defect in Oct-6∆SCE/∆SCE and 
Oct-6βgeo/βgeo mice suggested the existence of a molecule that could partly substitute for 
Oct-6. It was found that Schwann cells express at least two additional POU proteins; Oct-1 
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and Brn-218-20. Oct-1 is a ubiquitously expressed protein belonging to the class II subfamily. 
Brn-2 is closely related to Oct-6, and is expressed in a similar pattern as Oct-6. Further-
more, Brn-2 expression is not dependent on Oct-6. In chapter 3 we demonstrate that Brn-2 
is indeed functionally redundant to Oct-6 in that deletion of Brn-2 in the Oct-6 mutant 
background results in a severe developmental delay of Schwann cell development while 
moderate transgenic overexpression of Brn-2 in Oct-6∆SCE/∆SCE Schwann cells results in 
amelioration of the phenotype. These findings raise the question why we see a peripheral 
nerve phenotype in Oct-6 mutant mice to begin with, despite high levels of Brn-2 in the 
nuclei of these Schwann cells? Possibly Brn-2 and Oct-6 DNA binding affinities differ, 
requiring higher Brn-2 concentrations to achieve appropriate binding site occupancy. Al-
ternatively, Oct-6 and Brn-2 differ in their affinity for other proteins involved in regulation 
of the target gene repertoire of these POU proteins. Although the DNA binding affinities 
of Oct-6 and Brn-2 have not been determined, the near identity of their respective DNA 
binding domains (the POU domain) suggests that they are not significantly different. Fur-
thermore, replacement through gene knock in of Oct-6 by Brn-1, another member of the 
class III POU domain subfamily, did not result in any obvious alterations in the develop-
ment of the peripheral nerve21. These results strongly suggest that the level of class III 
POU domain protein expression is more important for timely Schwann cell differentiation 
than the identity of the class III POU protein expressed. As the class III POU domain 
proteins are almost identical in their primary amino acid sequence of the POU domain 
it is likely that all the important interactions are mediated through the POU domain. In-
deed, the solvent exposed surface of the helical coils that make up the POU specific and 
POU homeodomains of Oct-1 and Oct-2 have been demonstrated to interact with co-fac-
tors such as HCF/VP16 (in case of Oct-1) and OCAB/Bob1 (in case of Oct-2) and that these 
interactions are functionally important22. 
Two aspects of the primary amino acid sequence of Oct-6 and Brn-2 suggest that they 
contribute to differential interactions with other proteins. First, one distinctive feature 
of the Oct-6 POU domain is the presence of a Histidine residue at position 115 in the 
POU homeodomain and a Threonine at position 68 in the POU-specific domain (residues 
are highlighted in figure 2A). All other class III proteins have a Glutamine and an Alanine 
in these respective positions. When the primary amino acid sequence of Oct-6 and Brn-2 
POU domain is modelled on the structure of the Oct-1 POU domain it is clear that the 
two amino acid side chains are solvent exposed and thus open for protein interactions (see 
figure 2B). The specific amino acids in these positions have been maintained in Oct-6 pro-
teins from vertebrate species that are separated from their common ancestor by hundreds 
of millions of years of evolution. Thus, these amino acids may be involved in functional 
interactions with other molecules, most likely proteins. At present it is unknown what 
these proteins are and we have taken a proteomic approach to identify Oct-6 interacting 
proteins23. The fact that Brn-1 can functionally substitute for Oct-6 in Schwann cells sug-
gests that Oct-6 Thr/His interactions play a more important role in other Oct-6 expressing 
cells such as brainstem or hippocampal neurons. 
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A second interesting difference between Brn-2 and Oct-6 (and Brn-1), is the presence of 
a long (23 aa) stretch of glutamine residues in the amino-terminal half of Brn-2. It has 
been demonstrated that a protein called poly-glutamine binding protein or PQBP-1 can 
bind such glutamine stretches. Binding of PQBP-1 to the polyglutamine stretch of ataxin1 
was demonstrated to affect RNA polymerase activity resulting in motorneuron death24. 
Furthermore, mutations in PQBP-1 are associated with Renpenning syndrome, a form 
of X-linked mental retardation. PQBP-1 was originally identified in a yeast-two-hybrid 
screen using the Brn-2 transcription factor as bait. It was subsequently shown that PQBP-1 
could repress Brn-2 mediated activation of a reporter gene in transfection experiments25. It 
is therefore tempting to speculate that Brn-2/PQBP-1 interactions could attenuate/repress 
Brn-2 function in Schwann cells. Indeed, we found that PQBP-1 is expressed in Schwann 
cells. However, co-immune precipitation experiments have so far failed to confirm a direct 
interaction between PQBP-1 and Brn-2. Future experiments should further clarify the pos-
sible interaction between the two proteins.
Several lines of evidence suggest that the zinc-finger transcription factor Krox-20 is a ma-
jor target of Oct-6/Brn-2 regulation in Schwann cells. First, Krox-20 expression is strongly 
reduced in Schwann cells of newborn Oct-6 mutant animals26. Second, the Krox-20 en-
hancer that directs Krox-20 expression in Schwann cells contains a number of high affinity 
Oct1 EELEQFAKTFKQRRIKLGFTQGDVGLAMGKLYGNDFSQTTISRFEALNLSFKNMCKLKPLLEKWLNDAE NLSSDSSLSSPSALNSPGIEGLS---R RRKKRTSIETNIRVALEKSFLENQKPTSEEITMIADQLNMEKEVIRVWFCNRRQKEKRIN
Oct2 EELEQFARTFKQRRIKLGFTQGDVGLAMGKLYGNDFSQTTISRFEALNLSFKNMCKLKPLLEKWLNDAE TMSVDSSLPSPNQLSSPSLGFDGLPGR RRKKRTSIETNVRFALEKSFLANQKPTSEEILLIAEQLHMEKEVIRVWFCNRRQKEKRIN
Oct6 DDLEQFAKQFKQRRIKLGFTQADVGLALGTLYGNVFSQTTICRFEALQLSFKNMCKLKPLLNKWLEETD SSSG----------SPTNLDKIAAQGR KRKKRTSIEVGVKGALESHFLKCPKPSAHEITGLADSLQLEKEVVRVWFCNRRQKEKRMT
Brn2 DDLEQFAKQFKQRRIKLGFTQADVGLALGTLYGNVFSQTTICRFEALQLSFKNMCKLKPLLNKWLEEAD SSSG----------SPTSIDKIAAQGR KRKKRTSIEVSVKGALESHFLKCPKPSAQEITSLADSLQLEKEVVRVWFCNRRQKEKRMT
Brn4 DELEQFAKQFKQRRIKLGFTQADVGLALGTLYGNVFSQTTICRFEALQLSFKNMCKLKPLLNKWLEEAD SSTG----------SPTSIDKIAAQGR KRKKRTSIEVSVKGVLETHFLKCPKPAAQEISSLADSLQLEKEVVRVWFCNRRQKEKRMT
Brn1 DDLEQFAKQFKQRRIKLGFTQADVGLALGTLYGNVFSQTTICRFEALQLSFKNMCKLKPLLNKWLEEAD SSTG----------SPTSIDKIAAQGR KRKKRTSIEVSVKGALESHFLKCPKPSAQEITNLADSLQLEKEVVRVWFCNRRQKEKRMT








Figure 2. (A) Protein alignment of the POU-specific domain and the POU-homeodomain of several POU proteins. 
The residues that differ between the Oct-6 and the Brn proteins are indicated in white on black. (B) The protein 




binding sites for Oct-6 and Brn-2. Mutation of the binding sites results in loss of Schwann 
cell specific expression of a linked beta-Galactosidase reporter gene in transgenic mice27. 
Sox10 enhances activation of the myelinating Schwann cell element (MSE) by Oct-6 or 
Brn-2 in a co-transfection assay. Multiple potential binding sites for Sox10 exist within this 
enhancer making it likely that Sox10 binds to the MSE. Therefore, Krox-20 activation at 
the onset of myelination results from the activity of at least Oct-6/Brn-2 and Sox1026. 
It is generally accepted that Krox-20 activation in promyelinating Schwann cells is suf-
ficient to initiate the myelin gene expression program. These genes include the classical 
myelin genes such as P0 and PMP22 but also genes that encode enzymes in lipid metabo-
lism and cell adhesion molecules such as Neurofascin and Gliomedin. The evidence that 
Krox-20 directly regulates these genes is however rather sparse. The best-studied myelin 
gene regulatory sequences are those of the MBP gene. A 400bp enhancer fragment 9kb up-
stream of the MBP promoter confers Schwann cell specificity on the promoter. Although 
this fragment contains potential Krox-20 binding sites these sites do not contribute to the 
Schwann cell specificity of the enhancer but do affect the level of expression28. However, 
recent work from Dr. John Svaren’s group has identified a conserved module in the first in-
tron of the P0 gene29. They demonstrate that this element functions as a Krox-20 dependent 
enhancer in co-transfection experiments. It is likely that this element represents a major P0 
enhancer element that contributes to the strong myelination associated expression of the 
gene. 
Another factor that appears to be of great importance for Schwann cell specific expression 
is Sox10. Sox10 binding sites are found in promoters and enhancers of myelin genes such 
as P0 and PMP22 and these promoters are activated by Sox10 in co-transfection experi-
ments29-32. 
Thus, the onset and execution of the myelination gene program is primary controlled by 
a genetic hierarchy in which Oct-6/Brn-2 serves as an integrator of extra and intracellular 
signals and in turn activate Krox-20 and myelination. Sox10 appears to play major roles 
in activating and maintaining expression of myelin genes in cooperation with Krox-20. 
Maintenance of the myelination program does not require Oct-6. 
The experiments discussed above demonstrated that Krox-20 activation largely depends on 
Oct-6. But is Oct-6 also sufficient to activate Krox-20 or are there other factors involved? 
We found that Oct-6 is highly expressed in immature sorting and promyelinating Schwann 
cells of clp mice, that do not express Krox-20 until myelination commences33. This ob-
servation suggested that the clp gene is directly involved in Oct-6 mediated regulation of 
Krox-20 or that clp is involved in a parallel non-redundant pathway. Interestingly, forced 
transgenic expression of Krox-20 under control of the Oct-6 SCE in clp animals failed, 
whereas expression of another non-related protein under the same enhancer was expressed 
in clp Schwann cells at this stage of development  (M. Jaegle; unpublished observations). 
This suggests that Krox-20 expression is under negative feedback control, most likely at 
the co- or posttranslational level. If such a posttranslational mechanism of Krox-20 regula-
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tion indeed exists, it is predicted that a LacZ reporter gene under control of the Krox-20 
MSE is normally active. It will be of interest to investigate Oct-6 and Krox-20 expression 
in other mouse mutants that exhibit promyelin arrest, such as the P0 overexpressing mice 
generated in the Wrabetz and Feltri lab34. 
Our initial interest in the clp mouse was raised because of the similarities in the peripheral 
nerve defect observed in clp and Oct-6 mutant mice. These similarities suggested that 
Oct-6 and clp might be involved in similar pathways. We found that the clp phenotype 
results from homozygosity of a mutation in the Leucine rich glioma inactivated (Lgi)-4 
gene35. Lgi4 is a member of the family of Lgi genes, which also includes Lgi1, Lgi2 and 
Lgi3 that encodes a class of related secreted proteins. Lgi1 was the first member of this 
family to be described as a gene inactivated in a glioma cell line. More recently, it was 
found that Lgi1 is frequently mutated in specific forms of epilepsy. Most mutations af-
fect the proper processing of the protein resulting in decreased levels. Interestingly, these 
forms of epilepsy are inherited in a dominant fashion, consistent with haploinsufficiency or 
dominant negative action of the mutant protein. In contrast, the Lgi4 clp allele is a reces-
sive allele, with no detectable phenotype in heterozygotes.
Lgi4 affects Schwann cell development largely in a cell-autonomous fashion. Lgi4 is ex-
pressed by and secreted from the Schwann cell33. How Lgi4 affects Schwann cell differen-
tiation is not clear yet but several mechanisms can be envisaged (figure 3). First it is possible 
that Lgi4 binds to a receptor on the axonal membrane resulting in an axon-derived signal 
that directs proper sorting and myelination. It is of interest to note that the NRG-1 type III 
expressed on the axonal membrane is also required for sorting and myelination. Perhaps 
Lgi4 interacts with type III NRG-1 and modulates its interaction with the Schwann cell 
expressed ErbB2/3 receptor. Second it is possible that Lgi4 interacts with a factor secreted 
by the axon or with a receptor for that molecule. For example, it has been demonstrated 
that neuronal activity results in the release of adenosine from the axo-lemma and release 
of intracellular calcium in Schwann cells that express purinergic receptors36. This activity 
is important in regulating several aspects of Schwann cell proliferation and differentiation 
in Schwann cell-neuronal co-cultures. A third possibility is that Lgi4 acts in an autocrine 
fashion, directly binding to a Schwann cell receptor or extracellular matrix component. 
Such autocrine interactions operate in basal lamina interactions such as between the extra-
cellular laminins and their integrin receptors. These interactions are important for axonal 
sorting. Engineered mutations in laminin or the integrin or dystroglycan receptor result 
in severe axonal sorting defects. It is possible that Lgi4 modulates these interactions. To 
determine through which mechanism Lgi4 works, it is of prime importance to identify the 
interacting partners of Lgi4 in nerve development. Using human Fc-Lgi4 fusion molecules 
or otherwise tagged Lgi4 molecules it should be possible to determine whether Lgi4 binds 
to axons or Schwann cells and its basal lamina or both. Preliminary experiments in our 
laboratory have provided some evidence for the existence of a Lgi4 binding activity on the 
axonal surface, while no such binding could be detected on cultured Schwann cells. Sev-
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eral approaches can be taken to identify the putative Lgi4 receptor or interacting partner. 
One approach is expression cloning. However, this will only work when the Lgi4 receptor 
is a monomeric or homo-multimeric protein. We have therefore chosen a more direct ap-
proach, using the biotinylation strategy described in chapter 6. To this end we have gener-
ated a transgene that carries an avi-tagged Lgi4 gene. This transgene will be crossed into 
the clp background to test whether it will rescue the clp phenotype. If so, we will establish 
DRG explants of these mice and directly purify cross-linked Lgi4 interacting molecules 
using the avi tag and identify these partners by mass spectrometry. 
One recent development suggests that Lgi4 could interact with potassium (K+) channels. 
This suggestion is based on the work of Schulte and co-workers who sought to identify 
molecules associated with rapidly inactivating potassium channels in the hippocampus. 
Gene knock out studies had already demonstrated that loss of potassium channel α-subunit 
Kv1.1 results in severe epileptic seizures37,38. Using a proteomic approach Schulte et al. 
demonstrated a tight interaction between Lgi1 and potassium channels in membrane prepa-
rations of hippocampal neurons. They further demonstrate through expression in Xenopus 
oocytes that Lgi1 modulates the kinetics of K+ channel inactivation. K+ channels consist of 
4 α-subunits and a variable number of β-subunits. These Kv1 channels are rapidly inacti-
vating: following membrane depolarisation the potassium current declines rapidly (low τ 










values). This rapid inactivation is caused by a cytoplasmic domain of the channel (Kv1.4) 
or by a β-subunit (Kv1.1). It was demonstrated that Lgi1 specifically increases the length 
of the inactivation time constant (t) of K+ channels that consist of Kv1.1/Kvβ1 subunits39. 
It is believed that these properties of the potassium channels are important in regenerating 
the action potential and dampening excitability of a synapse. It is therefore no surprise that 
mutations in Lgi1 can cause epilepsy. In analogy with Lgi1 it is conceivable that Lgi4 inter-
acts with axonal potassium channels. The major potassium channels at the juxtaparanodes 
are the Kv1.1 and Kv1.2 α-subunits and Kvβ1 and Kvβ2 subunits. We found that these 
channels are already expressed, together with Lgi4, in embryonic nerves at E13. It is pos-
sible that Lgi4 K+ channel interaction represents a paracrine or cell adhesion interaction 
that affects axonal sorting at these early stages of nerve development. One intriguing, but 
highly speculative, possibility is that Lgi4 K+ channel interactions affect the spontaneous 
excitability of late gestation neurons providing a tentative explanation for the limb posture 
abnormality observed in claw paw neonates. 
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De Schwann cellen die de perifere zenuwen bevolken ontstaan, evenals de rest van het 
perifere zenuwstelsel, uit de neurale lijst. De neurale lijst is een tijdelijke embryologische 
structuur die zich aan de dorsale randen van de zich sluitende neuraalbuis vormt.  Schwann 
cel voorloper cellen vermenigvuldigen zich en migreren langs de axonen van de embry-
onale zenuwen. Uiteindelijk zullen deze cellen differentiëren in de twee typen Schwann 
cellen die kunnen worden onderscheiden; Schwann cellen die een myelineschede vormen 
rondom de dikkere axonen en de niet-myeline vormende Schwann cellen die meerdere 
dunne axonen omgeven. 
De myelineschede wordt gevormd door de spiraalsgewijze omwikkeling van het axon door 
het celmembraan van de Schwann cel. Het myeline membraan is verrijkt in bepaalde lipi-
den zoals cholesterol en eiwitten zoals ‘myelin protein zero’ en ‘myelin basic protein’. De 
myelineschede verdeelt het axonale membraan in domeinen waarbij de natrium en kalium 
kanalen geclusterd worden in respectievelijk het nodale (knoop van Ranvier) en juxtapara-
nodale domein. Deze specifieke organisatie resulteert in een zeer grote geleidingssnelheid 
van de actiepotentiaal. Afbraak van de myelineschede leidt tot neurologische problemen 
welke levensbedreigend kunnen zijn zoals bijvoorbeeld in multiple sclerose. Het doel van 
het in dit proefschrift beschreven onderzoek is inzicht te verkrijgen in de basale mecha-
nismen van Schwann cel differentiatie en myelinisatie en met name de transcriptionele 
netwerken die deze processen beheersen. 
De ontwikkeling van de perifere zenuw komt tot stand door directe cellulaire interacties 
tussen de Schwann cel en het axon. Een belangrijke component in deze interacties wordt 
gevormd door het neureguline1 signaal molecuul, welke gegenereerd wordt op het axon, 
en de ErbB2/3 receptoren op de Schwann cel. Deze interactie speelt een essentiële rol ge-
durende alle stadia van ontwikkeling inclusief de aanzet en uitvoering van het myelinisatie 
proces. De initiatie van het myelinisatie proces leidt tot de activiteit van een specifieke 
set genen welke beheerst wordt door een netwerk van transcriptie factoren. Genetische 
studies van onder andere ons laboratorium hebben laten zien dat de transcriptie factoren 
Oct-6 en Krox-20 een essentiële rol spelen in de initiatie en uitvoering van het myelini-
satie programma. Oct-6 en Krox-20 functioneren in een simpele hiërarchie waarbij Oct-6 
functie vereist is voor de juiste temporele activering van Krox-20 en myeline vorming. 
Dus in Oct-6 muismutanten is de activering van Krox-20 en myelinisatie vertraagd. Oct-6 
genexpressie neemt sterk toe in Schwann cellen die zich opmaken om myeline te vormen, 
hetgeen suggereert dat Oct-6 expressie direct aangestuurd wordt door signaal routes die 
beheerst worden door neureguline-1. Hoewel de identiteit van de signaal routes nog niet ge-
heel opgehelderd is, is duidelijk dat ze uiteindelijk aangrijpen op de Oct-6 enhancer. Deze 
enhancer bevindt zich in een gebied van zo’n 4kb dat ongeveer 10kb achter het Oct-6 gen 
ligt. Onze genetische proeven hebben laten zien dat dit DNA element voldoende is voor 
de juiste temporele expressie van het Oct-6 gen in Schwann cellen. Verder laten we in dit 
proefschrift zien (hoofdstuk 2) dat de Oct-6 Schwann cell enhancer (SCE) ook essentieel 
is voor Schwann cel specifieke expressie van Oct-6. Deletie van de SCE resulteert in een 
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selectief verlies van Oct-6 expressie in Schwann cellen terwijl de expressie van Oct-6 in 
bijvoorbeeld CA1 neuronen van de hippocampus niet is veranderd. Het is dus waarschijn-
lijk dat het complete expressie patroon van Oct-6 tot stand komt door de activiteit van 
verschillende enhancer modules waarvan wij er dus nu een hebben geïdentificeerd.
Hoewel onze genetische studies hebben uitgewezen dat Krox-20 activatie afhanke-
lijk is van Oct-6 activiteit is de ontwikkeling van de perifere zenuwen ernstiger ver-
stoord in Krox-20 muismutanten dan in Oct-6 mutanten. Dus, terwijl in afwezigheid van 
Oct-6 myeline vorming vertraagd is, blijkt het proces geheel te stagneren in afwezigheid 
van Krox-20. Inderdaad, in afwezigheid van Oct-6 wordt Krox-20 vertraagd geactiveerd. 
Deze observaties suggereerden dat een eiwit met een aan Oct-6 verwante functie tot ex-
pressie komt in Schwann cellen dat in staat is Krox-20 te activeren. In hoofdstuk 3 van dit 
proefschrift laten we zien dat Brn-2, nauw verwant aan Oct-6, tot expressie komt en dat 
Schwann cel specifieke deletie van dit gen en Oct-6 een zeer ernstige vertraging van my-
eline vorming veroorzaakt. Deletie van alleen Brn-2 in Schwann cellen, dus Oct-6 komt 
normaal tot expressie, heeft geen merkbaar effect op de ontwikkeling en myelinisatie van 
de perifere zenuwen. Dus, Oct-6 is de belangrijkste factor voor Krox-20 regulatie maar in 
afwezigheid van Oct-6 kan Brn-2 die taak gedeeltelijk overnemen. Het feit dat Brn-2 niet 
volledig compenseert voor verlies van Oct-6 hangt hoogstwaarschijnlijk samen met het 
niveau van Brn-2 expressie. Overexpressie van Brn-2 in een Oct-6 mutant, door middel van 
een transgen, leidt tot een gedeeltelijk herstel van het verloop van myelinisatie. 
Het is echter onwaarschijnlijk dat Oct-6 en Brn-2 geheel functioneel equivalent zijn. Een 
aantal structurele verschillen tussen Oct-6 en Brn-2 (en de andere verwante eiwitten Brn-1 
en Brn-4) suggereren dat deze eiwitten met verschillende eiwitten interacties aangaan. 
Om dergelijke eiwitten te identificeren hebben we een muizen lijn gegenereerd die Oct-6 
met een zeer sterke affiniteit voor avidine expresseert. Dit maakt het mogelijk om Oct-6 
complexen uit weefsel extracten te isoleren en de eiwitten die met Oct-6 mee zuiveren 
te identificeren door middel van massaspectroscopie. Deze methode is ontwikkeld in het 
laboratorium van prof. Frank Grosveld en is succesvol aangewend om eiwitten die een 
complex met Gata-1 in rode bloedcellen vormen te identificeren. De ontwikkeling van deze 
muizen lijn is beschreven in hoofdstuk 4. 
Natuurlijke muismutanten zijn van onschatbare waarde voor ons onderzoek naar de ont-
wikkeling en functioneren van het zenuwstelsel. Een natuurlijke muismutant, genaamd 
claw paw (clp), had onze aandacht getrokken omdat de aandoening, vertraagde ontwikke-
ling en hypomyelinatie van de perifere zenuwen, erg leek op wat we waarnamen in Oct-6 
mutanten. Dit suggereerde dat het clp gen of door Oct-6 gereguleerd wordt, of dat clp 
Oct-6 reguleert, of dat clp functioneert in een route parallel met Oct-6. Een bijzonder in-
teressante mogelijkheid was dat clp een directe regulator van Oct-6 is die of in het neuron 
of in de Schwann cel actief is. Om nu in eerste instantie het defect in deze mutanten beter 
te karakteriseren en te bepalen in welk celtype clp tot expressie komt, hebben we een serie 
experimenten uitgevoerd welke beschreven staan in hoofdstuk 5. Deze experimenten sug-
gereerden dat clp in Schwann cellen tot expressie komt. Verder lieten onze experimenten 
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zien dat Schwann cel differentiatie in clp muizen al verstoord is in een stadium voor dat 
Oct-6 geactiveerd wordt. 
Het genetische defect dat ten grondslag ligt aan het clp fenotype hebben we in samenwer-
king met de onderzoeksgroep van dr. John Bermingham bepaald door middel van ‘positio-
nal cloning’. De clp mutatie bleek een allel te zijn van het Lgi4 gen. Lgi4 behoort tot een 
kleine familie van vier genen (Lgi1-4) welke voornamelijk in het zenuwstelsel tot expressie 
komen maar waarvan verder nog zeer weinig bekend is.  Het clp allel van Lgi4 bevat een 
kleine insertie in intron 3 van het gen wat leidt tot exclusie van exon 4 gedurende splicing 
van het Lgi4 mRNA. We toonden aan dat Lgi4 normaliter in Schwann cellen geëxpres-
seerd wordt en dat het eiwit wordt uitgescheiden door de cel. Exon 4 is 72 nucleotiden lang 
en exclusie van dit exon in processing van het clp gen resulteert in een in-frame deletie 
van 24 aminozuren in het LRR domein van Lgi4. In tegenstelling tot Lgi4 wordt Lgi4clp 
helemaal niet door de cel uitgescheiden. Verder hebben we laten zien dat toevoeging van 
Lgi4 bevattend medium aan Schwann cel/neuron co-cultures die afgeleid waren van claw 
paw embryo’s het myelinatie proces in deze cultures herstelt. Op grond van deze gegevens 
is het dus zeer waarschijnlijk dat Lgi4 een cruciale rol speelt in de communicatie tussen 
het axon en de Schwann cel. Wat deze rol precies is en met welke andere moleculen Lgi4 




ATP  Adenosine Tri Phosphate
BDNF  Brain Derived Neurotrophic Factor
Caspr  Contactin-associated protein
CH  Congenital Hypomyelination 
clp  claw paw
CMT  Charcot Marie Tooth
CNS  Central Nervous System
Cx32  Connexin32
Dhh  Desert Hedgehog
DNA  Deoxy Ribonucleic Acid
DRG  Dorsal Root Ganglion
DSS  Dejerine-Sottas Syndrome
eGFP  enhanced Green Fluorescent Protein
ER  Endoplasmatic Reticulum
GDNF  Glial Derived Neurotrophic Factor
HMSN  Hereditary Motor and Sensory Neuropathies
HNPP  Hereditary Neuropathy with liability to Pressure Palsies
Lgi  Leucine-rich, glioma activated
MSE  Myelinating Schwann cell Element
MTMR-2 Myotubularin-related protein 2
NGF  Nerve Growth Factor
NRG-1  Neuregulin 1
NT-3  Neurotrophin 3
PNS  Peripheral Nervous System
P0  Myelin Protein Zero
PMP22  Peripheral Myelin Protein-22
PQBP-1  Poly-glutamine tract Binding Protein
POU  Pit-1, Oct1/2, Unc-86
SCE  Schwann cell specific enhancer
Sp  Splotch
Spd  Splotch delayed
Tr  Trembler
TrJ  Trembler J
Trk  Tyrosine receptor kinase
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Na veel tijd in het schrijven te hebben gestoken van dit boekje, ben ik nu bij het laatste (en 
belangrijkste) hoofdstuk aangekomen. Dit gedeelte geeft mij de kans om mijn dank uit te 
laten gaan naar de mensen die naar mijn inzicht een (grote) bijdrage hebben geleverd aan 
het tot stand komen van dit boekje.
Allereerst wil ik Dies bedanken voor alles wat hij heeft gedaan om het  mogelijk te maken 
dat ik zo ver ben gekomen. Mijn AIO-schap is niet zo standaard verlopen als bij anderen 
(wel de normale ups en downs van het onderzoek) maar mede doordat jij mij bent blijven 
stimuleren om het toch af te maken sta ik vandaag hier. Ik heb tot nu toe heel veel geleerd: 
Hoe een goed experiment uit te voeren, maar ook hoe in de keuken van een recept iets 
eetsbaars te maken. Ook probeer je ons al jaren te overtuigen dat Bob Dylan hele goede 
muziek heeft en de laatste cd lijkt inderdaad ook binnen je lab aan te slaan. Daarnaast heb 
ik ook heel veel plezier gehad in je lab, maar ook daarbuiten: lunchen op Oct-6 dag of het 
uitzwaaien van een stagiaire. En het Bob-Rossen van het huisje zal ik zeker niet vergeten.
Frank jij hebt als promotor wat meer een bijdrage geleverd op de achtergrond en dan met 
name in de eerste paar jaar. De werkbesprekingen bij jou zal ik niet vergeten, maar wat ik 
niet mis zijn de vragen die je stelde, op de een of andere manier kreeg jij me altijd wel stil 
en kon ik niet zo goed een antwoord bedenken.
Joan jij was met name op de achtergrond aanwezig; ik wil je bedanken voor wat ik heb 
mogen leren van je in de afgelopen jaren.
Natuurlijk zou ik nergens zijn gekomen zonder de hulp van mijn labgenoten. Martine, tu 
m’as appris beaucoup de choses, techniques bien sûr, mais tu aussi appris à me taire quand 
il le faut...bien que ce dernier point soit encore ‘a work-in-progress’. Arend, dankjewel bij 
alle hulp nu aan het einde van het boekje. Die laatste loodjes blijken toch inderdaad wel 
wat te wegen. Matthijs je werkt niet meer op dit lab, maar ik ben absoluut niet al je hulp 
vergeten en soms is het bepaald lastig dat ik niet even je hulp kan vragen als ik een paar 
handen meer nodig hebt. Dorota you came into our lab with your own research because 
labspace was needed. I enjoyed your company and hope you will be able to finish quickly 
too. Ekim you showed me that there are more movies except the ones that come in the cine-
mas. I definitely watched some movies I would otherwise never have checked out. Noorie 
you were the last one to come in and you have a few more years to convince me that certain 
Indian food is not spicy and that I should try it.
Naast de mensen van mijn eigen lab zijn er natuurlijk ook andere mensen op de afdeling te 
bedanken die belangrijk zijn geweest voor hulp bij experimenten of gewoon dat beetje steun 
dat zo belangrijk is als je bezig bent met je AIO-schap. Allereerst Sjaak en de mensen van 
zijn lab Nynke, Roy, Rita, Harald, Thamar (we missen jullie eigenlijk nog steeds stiekem 
wel een beetje). Ook Elaine en de mensen van haar lab Esther, Marianne, German-Katrin, 
French-Catherine, Sandra, Claudia, Karin, Karine, Chris and Fredrik (het was heel gezel-
lig met zijn allen op één lab).
De dames van de keuken (Jopie, Fatima, Chenelva, Prema en Joke) dank jullie wel voor 
jullie hulp. Jullie hebben er een aantal malen voor gezorgd dat geplande experimenten toch 
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door konden gaan door op het laatste moment nog even iets voor ons te autoclaveren of 
anderszins schoon te maken. Jullie zijn gezellige buren, jullie maken altijd geluid.
Melle, Petra en Mieke en Koos jullie staan altijd klaar om te helpen bij bestellingen die we 
snel nodig hebben of die veel te lang op zich laten wachten. Wat natuurlijk erg sjiek is dat 
we onze eigen afdelingsbezorgdienst hebben. 
De jongens van de computers Sjozef, Ton, Pim, Leo en Mario, dankjewel voor de hulp en 
waarom die computers toch altijd kapot gaan op het moment dat je vlak voor een deadline 
zit is mij nog steeds een raadsel.
Elize, Mandy en Erika, ik denk dat als ze een decibel test zouden doen als jullie alledrie 
op het lab aanwezig zijn, dat iedereen wordt verplicht met gehoorbescherming te lopen, 
maar het is wel gezellig hoor. Hartelijk bedankt voor jullie praktische hulp of af en toe 
gewoon een praatje. 
Nynke (leuk hè? jullie krijgen je eigen stukje) en Ton jullie wil ik hartelijk bedanken voor 
de gezellige avondjes en Nynke ik weet niet of het zo verstandig is om hier neer te zetten 
dat als ze mij zoeken op het lab ze misschien eens even bij jou op het lab navraag moeten 
doen. Dank jullie wel voor alle steun die jullie me vaak boden met nuchter commentaar 
om deze stresskip tot rust te brengen.
Marike en Jasperina, ik weet niet of jullie mij ooit nog mee willen nemen naar een kerst-
nachtdienst, want ik kan mij niet stil houden. Ik vind de avondjes met jullie heel gezellig 
en hoop dat we dat nog een poosje vol houden.
De mooie lay-out van dit boekje is tot stand gekomen met de inzet van Tom. Dankjewel 
voor je hulp, want zonder die hulp was het maar een gewoon boekje geweest. Met deze 
vormgeving is het ook leuk om naar het boekje te kijken als het niet hoeft te worden inge-
keken voor de tekstuele inhoud.
Basketbal is een hele leuke sport om te doen en een nog veel leukere sport om aan kinderen 
te leren. Kees dankjewel dat ik de kans heb gekregen om van jou te leren hoe een goede 
en ook leuke (want dat is nog veel belangrijker) training te geven. Wedstrijden zijn nog 
veel gaver, want dat is proberen de kinderen de goede kant op te sturen en ook ze leren dat 
verliezen niet erg is zo lang je maar volle inzet toont en je best doet ook als het een keertje 
niet zo goed lukt. En als je dan wel een keer wint is het ook dubbel feest.
Ik wil mijn beide paranimfen heel hartelijk bedanken voor alle hulp en steun die ze mij 
geven. 
Merhnaz jij bent al door de promotie heen geweest en weet dus wat er moet gebeuren, dat 
is erg handig. Ook toen je nog bij ons op het lab zat heb ik van je geleerd en plezier met je 
gehad. Je pizza’s zijn goed, maar je hamburgers kunnen er ook wat van. Ik wens je nu alle 
tijd toe om te genieten met Saeed en Arian.
Laetitia, met jou heb ik samen een fantastische stage gelopen in Ann Arbor, Michigan, 
waar we samen bij Jeanette in huis hebben gewoond. We hebben gave dingen gedaan daar 
en veel geleerd, positieve en negatieve dingen. Rollercoasters zijn gaaf, maar je wordt er 
ook onwijs misselijk van als je vervolgens een chocolade-ijsje eet. Vorig jaar terug geweest 
naar Amerika op vakantie naar Cape Cod om Jeanette te zien en ik heb het erg leuk gevon-
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den dat je spontaan zei dat je meeging. Jij bent ook bijna zover en ik wens je succes met 
jouw afronding. Het komt allemaal goed! Jullie beide dankjewel dat jullie naast me staan 
op het moment suprème.
Jeanette you gave me and Laetitia an incredible cheap place to stay (only mowing the lawn 
now and then) during our intern. Thank you for all your help and love. You gave us a place 
to feel at home away from home.
Pap en mam zonder jullie steun had ik nooit deze vier jaar kunnen volbrengen. Lekker 
thuis uitrusten of gezellig op vakantie. Vaak hebben jullie geslikt dat ik wat vroeger weg 
moest van huis omdat ik nog ‘s avonds even wat moest doen als voorbereiding voor de 
volgende dag of simpel weg mijn cellen verzorgen. Georg, Lara, Marit en Meike, bij jullie 
was het af en toe even heerlijk ontspannen en even lekker nergens aan denken. Dat is goed 
anders ben je alleen maar met wetenschap bezig maar af en toe zijn er ook andere dingen. 
Paul en Petra jullie zaten in eerste instantie wat verder weg in Frankrijk, maar het was 
leuk om daar een keer langs te gaan en nu jullie weer terug zijn is het leuk dat jullie lekker 
dichtbij zitten. Dan kun je af en toe een gezellig avondje doen of ik kan jullie ‘s morgens 
om 5 uur van de bus halen.
Ome Niek en tante Jacqueline, gezellig kletsen aan de telefoon of een weekendje of dagje 
bij jullie langs. Het is altijd gezellig en veel te snel weer voorbij.
Paul nog bedankt voor de foto van je golf, ik hoop dat je vindt dat hij er mooi op staat. 
Ik wil jullie allemaal (ook oma en tante Willy) bedanken voor jullie inzet om een mooie 
tekening te maken van de figuur die ik jullie heb gegeven. Mede daardoor is dit denk ik een 
heel speciaal boekje geworden dat een leerzame periode van mijn leven afsluit om door te 
gaan met de volgende. 
 

